| 1 |
Li W, Shao L, Liu J, Sheng J, Zheng Q, Wang M. Intracellular delivery of bacterial effectors for cancer therapy using biodegradable lipid nanoparticles. Biomater Sci 2023. [PMID: 36919841 DOI: 10.1039/d3bm00008g] [Reference Citation Analysis]
|
| 2 |
Liu S, Pan Y, Li T, Zou M, Liu W, Li Q, Wan H, Peng J, Hao L. The Role of Regulated Programmed Cell Death in Osteoarthritis: From Pathogenesis to Therapy. IJMS 2023;24:5364. [DOI: 10.3390/ijms24065364] [Reference Citation Analysis]
|
| 3 |
Ahmadi Y, Fard JK, Ghafoor D, Eid AH, Sahebkar A. Paradoxical effects of statins on endothelial and cancer cells: the impact of concentrations. Cancer Cell Int 2023;23:43. [PMID: 36899388 DOI: 10.1186/s12935-023-02890-1] [Reference Citation Analysis]
|
| 4 |
Bertaglia V, Morelli AM, Solinas C, Aiello MM, Manunta S, Denaro N, Tampellini M, Scartozzi M, Novello S. Infections in lung cancer patients undergoing immunotherapy and targeted therapy: An overview on the current scenario. Crit Rev Oncol Hematol 2023;184:103954. [PMID: 36878396 DOI: 10.1016/j.critrevonc.2023.103954] [Reference Citation Analysis]
|
| 5 |
Watterson A, Coelho MA. Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions. Cell Commun Signal 2023;21:45. [PMID: 36864508 DOI: 10.1186/s12964-023-01063-x] [Reference Citation Analysis]
|
| 6 |
Lin L, Zhang W, Chen Y, Ren W, Zhao J, Ouyang W, He Z, Su W, Yao H, Yu Y. Immune gene patterns and characterization of the tumor immune microenvironment associated with cancer immunotherapy efficacy. Heliyon 2023;9:e14450. [PMID: 36950600 DOI: 10.1016/j.heliyon.2023.e14450] [Reference Citation Analysis]
|
| 7 |
Zhao Z, Bohidar N, Bourne PE. Analysis of KRAS-Ligand Interaction Modes and Flexibilities Reveals the Binding Characteristics. J Chem Inf Model 2023;63:1362-70. [PMID: 36780612 DOI: 10.1021/acs.jcim.3c00097] [Reference Citation Analysis]
|
| 8 |
Yang W, Ge J, Yuan M, Li J, Pan L, Ren J, Dou G, Yang L, Zhou Y, Xie H, Wang X, Hu H. Computational study of novel natural inhibitors targeting Kirsten rat sarcoma viral oncogene homolog G12C. Anticancer Drugs 2023:e001428. [PMID: 36847041 DOI: 10.1097/CAD.0000000000001428] [Reference Citation Analysis]
|
| 9 |
Jung YH, Choi Y, Seo HD, Seo MH, Kim HS. A conformation-selective protein binder for a KRAS mutant inhibits the interaction between RAS and RAF. Biochem Biophys Res Commun 2023;645:110-7. [PMID: 36682330 DOI: 10.1016/j.bbrc.2023.01.019] [Reference Citation Analysis]
|
| 10 |
Xiao H, Wang G, Zhao M, Shuai W, Ouyang L, Sun Q. Ras superfamily GTPase activating proteins in cancer: Potential therapeutic targets? Eur J Med Chem 2023;248:115104. [PMID: 36641861 DOI: 10.1016/j.ejmech.2023.115104] [Reference Citation Analysis]
|
| 11 |
Müller F, Lim JKM, Bebber CM, Seidel E, Tishina S, Dahlhaus A, Stroh J, Beck J, Yapici FI, Nakayama K, Torres Fernández L, Brägelmann J, Leprivier G, von Karstedt S. Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation. Cell Death Differ 2023;30:442-56. [PMID: 36443441 DOI: 10.1038/s41418-022-01096-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 12 |
Wang X, Xie Q, Ji Y, Yang J, Shen J, Peng F, Zhang Y, Jiang F, Kong X, Ma W, Liu D, Zheng L, Qing C, Lang JY. Targeting KRAS-mutant stomach/colorectal tumors by disrupting the ERK2-p53 complex. Cell Rep 2023;42:111972. [PMID: 36641751 DOI: 10.1016/j.celrep.2022.111972] [Reference Citation Analysis]
|
| 13 |
Akhlaghipour I, Taghehchian N, Zangouei AS, Maharati A, Mahmoudian RA, Saburi E, Moghbeli M. MicroRNA-377: A therapeutic and diagnostic tumor marker. Int J Biol Macromol 2023;226:1226-35. [PMID: 36442575 DOI: 10.1016/j.ijbiomac.2022.11.236] [Reference Citation Analysis]
|
| 14 |
Ugwah-Oguejiofor CJ, Chukwuka EP, Onifade OF, Agu ST, Adegboyega AE, Johnson GI, Ogunsuyi OI, Johnson TO. Computational assessment of chemicals from Morinda citrifolia as potential inhibitors of B-Raf kinase in hepatocellular carcinoma treatment. J Biomol Struct Dyn 2023;:1-16. [PMID: 36709454 DOI: 10.1080/07391102.2023.2172459] [Reference Citation Analysis]
|
| 15 |
Zhang X, Zhao T, Sun M, Li P, Lai M, Xie L, Chen J, Ding J, Xie H, Zhou J, Zhang H. Design, synthesis and biological evaluation of KRAS(G12C)-PROTACs. Bioorg Med Chem 2023;78:117153. [PMID: 36621179 DOI: 10.1016/j.bmc.2023.117153] [Reference Citation Analysis]
|
| 16 |
Yokoyama N, Nakayama H, Iwabuchi K. Novel Insights into the Role of Kras in Myeloid Differentiation: Engaging with Wnt/β-Catenin Signaling. Cells 2023;12. [PMID: 36672256 DOI: 10.3390/cells12020322] [Reference Citation Analysis]
|
| 17 |
Schanknecht E, Bachari A, Nassar N, Piva T, Mantri N. Phytochemical Constituents and Derivatives of Cannabis sativa; Bridging the Gap in Melanoma Treatment. Int J Mol Sci 2023;24. [PMID: 36614303 DOI: 10.3390/ijms24010859] [Reference Citation Analysis]
|
| 18 |
Calaf GM. Breast carcinogenesis induced by organophosphorous pesticides. Adv Pharmacol 2023;96:71-117. [PMID: 36858780 DOI: 10.1016/bs.apha.2022.10.003] [Reference Citation Analysis]
|
| 19 |
Jayaraman S, Ponnusamy B, Rajagopal P, Gowtham Kumar S, Chandrasekar K. Experimental Model for Pancreatic Cancer and Its Therapeutic Implications in Clinical Research. Handbook of Animal Models and its Uses in Cancer Research 2023. [DOI: 10.1007/978-981-19-3824-5_39] [Reference Citation Analysis]
|
| 20 |
Li G, Lei C, Hu S. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS-mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies 2023. [DOI: 10.1016/b978-0-12-821584-5.00024-9] [Reference Citation Analysis]
|
| 21 |
Pirzada M, Altintas Z. Biosensors for cancer biomarker detection. Advanced Sensor Technology 2023. [DOI: 10.1016/b978-0-323-90222-9.00009-1] [Reference Citation Analysis]
|
| 22 |
Han D, Zhu S, Li X, Li Z, Huang H, Gao W, Liu Y, Zhu H, Yu X. The NF-κB/miR-488/ERBB2 axis modulates pancreatic cancer cell malignancy and tumor growth through cell cycle signaling. Cancer Biol Ther 2022;23:294-309. [PMID: 35343383 DOI: 10.1080/15384047.2022.2054257] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 23 |
He H, Zhang S, Yang H, Xu P, Kutschick I, Pfeffer S, Britzen-Laurent N, Grützmann R, Fu D, Pilarsky C. Identification of Genes Associated with Liver Metastasis in Pancreatic Cancer Reveals PCSK6 as a Crucial Mediator. Cancers (Basel) 2022;15. [PMID: 36612240 DOI: 10.3390/cancers15010241] [Reference Citation Analysis]
|
| 24 |
Jang G, Kweon J, Kim Y. CRISPR prime editing for unconstrained correction of oncogenicKRASvariants.. [DOI: 10.1101/2022.12.21.521522] [Reference Citation Analysis]
|
| 25 |
Qingfang Li, Zhihui Li, Ting Luo, Huashan Shi. Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy. Mol Biomed 2022;3:47. [PMID: 36539659 DOI: 10.1186/s43556-022-00110-2] [Reference Citation Analysis]
|
| 26 |
Li J, Wang Y, Luo Y, Liu Y, Yi Y, Li J, Pan Y, Li W, You W, Hu Q, Zhao Z, Zhang Y, Cao Y, Zhang L, Yuan J, Xiao ZJ. USP5-Beclin 1 axis overrides p53-dependent senescence and drives Kras-induced tumorigenicity. Nat Commun 2022;13:7799. [PMID: 36528652 DOI: 10.1038/s41467-022-35557-y] [Reference Citation Analysis]
|
| 27 |
Li C, Kuai L, Cui R, Miao X. Melanogenesis and the Targeted Therapy of Melanoma. Biomolecules 2022;12. [PMID: 36551302 DOI: 10.3390/biom12121874] [Reference Citation Analysis]
|
| 28 |
yuan Q, tang B, Wan C, Xie Y, Xie Y, zhu Y, Su H, Zhang C. PRDM16 deficiency triggered by TGF-β signaling aggravated renal fibrosis by promoting tubular mitochondrial dysfunction.. [DOI: 10.21203/rs.3.rs-2323212/v1] [Reference Citation Analysis]
|
| 29 |
Murphy BM, Jensen DM, Arnold TE, Aguilar-valenzuela R, Hughes J, Posada V, Nguyen KT, Chu VT, Tsai KY, Burd CJ, Burd CE. The OSUMMER lines: a series of ultraviolet-accelerated NRAS-mutant mouse melanoma cell lines syngeneic to C57BL/6.. [DOI: 10.1101/2022.12.09.519766] [Reference Citation Analysis]
|
| 30 |
Roet S, Hooft F, Bolhuis PG, Swenson DWH, Vreede J. Path Sampling Simulations Reveal How the Q61L Mutation Alters the Dynamics of KRas. J Phys Chem B 2022;126:10034-44. [PMID: 36427204 DOI: 10.1021/acs.jpcb.2c06235] [Reference Citation Analysis]
|
| 31 |
Enomoto M, Igaki T. Cell-cell interactions that drive tumorigenesis in Drosophila. Fly (Austin) 2022;16:367-81. [PMID: 36413374 DOI: 10.1080/19336934.2022.2148828] [Reference Citation Analysis]
|
| 32 |
Ni QZ, Zhu B, Ji Y, Zheng QW, Liang X, Ma N, Jiang H, Zhang FK, Shang YR, Wang YK, Xu S, Zhang EB, Yuan YM, Chen TW, Yin FF, Cao HJ, Huang JY, Xia J, Ding XF, Qiu XS, Ding K, Song C, Zhou WT, Wu M, Wang K, Lui R, Lin Q, Chen W, Li ZG, Cheng SQ, Wang XF, Xie D, Li JJ. PPDPF Promotes the Development of Mutant KRAS-Driven Pancreatic Ductal Adenocarcinoma by Regulating the GEF Activity of SOS1. Adv Sci (Weinh) 2023;10:e2202448. [PMID: 36453576 DOI: 10.1002/advs.202202448] [Reference Citation Analysis]
|
| 33 |
Kim Y, Kang MH, Cho YH. API-2-Induced Cell Migration Is Overcome by Small Molecular Approaches Inhibiting β-Catenin. Curr Issues Mol Biol 2022;44:6006-14. [PMID: 36547070 DOI: 10.3390/cimb44120409] [Reference Citation Analysis]
|
| 34 |
Manley LJ, Lin MM. Kinetic and thermodynamic allostery in the Ras protein family.. [DOI: 10.1101/2022.11.29.518294] [Reference Citation Analysis]
|
| 35 |
Henriques SN, Oliveira L, Santos RF, Carmo AM. CD6-mediated inhibition of T cell activation via modulation of Ras. Cell Commun Signal 2022;20:184. [PMID: 36414966 DOI: 10.1186/s12964-022-00998-x] [Reference Citation Analysis]
|
| 36 |
Molika P, Leetanaporn K, Rungkamoltip P, Roytrakul S, Hanpresertpong J, Navakanitworakul R. Proteomic analysis of circulating small extracellular vesicles unique to cervical cancer.. [DOI: 10.21203/rs.3.rs-2245744/v1] [Reference Citation Analysis]
|
| 37 |
Badheeb M, Abdelrahim A, Esmail A, Umoru G, Abboud K, Al-Najjar E, Rasheed G, Alkhulaifawi M, Abudayyeh A, Abdelrahim M. Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening. Curr Oncol 2022;29:8693-719. [PMID: 36421339 DOI: 10.3390/curroncol29110686] [Reference Citation Analysis]
|
| 38 |
Damaskos C, Garmpis N, Dimitroulis D, Garmpi A, Psilopatis I, Sarantis P, Koustas E, Kanavidis P, Prevezanos D, Kouraklis G, Karamouzis MV, Marinos G, Kontzoglou K, Antoniou EA. Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead-A Systematic Review. Int J Mol Sci 2022;23. [PMID: 36430594 DOI: 10.3390/ijms232214117] [Reference Citation Analysis]
|
| 39 |
Iraqi M, Bolel P, Sarkar R, Bhattacharya B, Abu Ahmad M, Edri A, Roisman LC, Elkabets M, Shalata W, Peled N, Porgador A. NKp44-Derived Peptide Used in Combination Stimulates Antineoplastic Efficacy of Targeted Therapeutic Drugs. Int J Mol Sci 2022;23. [PMID: 36430528 DOI: 10.3390/ijms232214054] [Reference Citation Analysis]
|
| 40 |
Tian Y, Tsujisaka Y, Li VY, Tani K, Lucena-cacace A, Yoshida Y. Immunosuppressants Tacrolimus and Sirolimus revert the cardiac antifibrotic properties of p38-MAPK inhibition in 3D-multicellular human iPSC-heart organoids. Front Cell Dev Biol 2022;10. [DOI: 10.3389/fcell.2022.1001453] [Reference Citation Analysis]
|
| 41 |
Therachiyil L, Anand A, Azmi A, Bhat A, Korashy HM, Uddin S. Role of RAS signaling in ovarian cancer. F1000Res 2022;11:1253. [PMID: 36451660 DOI: 10.12688/f1000research.126337.1] [Reference Citation Analysis]
|
| 42 |
Kamath A, Kamanna K. Prenylated Proteins: Structural Diversity and Functions. Modifications of Biomolecules [Working Title] 2022. [DOI: 10.5772/intechopen.104689] [Reference Citation Analysis]
|
| 43 |
Schubert OT, Bloom JS, Sadhu MJ, Kruglyak L. Genome-wide base editor screen identifies regulators of protein abundance in yeast. Elife 2022;11:e79525. [PMID: 36326816 DOI: 10.7554/eLife.79525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 44 |
Raut H, Jadhav C, Shetty K, Laxane N, Nijhawan HP, Rao GK, Alavala RR, Joshi G, Patro CN, Soni G, Yadav KS. Sorafenib tosylate novel drug delivery systems: implications of nanotechnology in both approved and unapproved indications. OpenNano 2022. [DOI: 10.1016/j.onano.2022.100103] [Reference Citation Analysis]
|
| 45 |
Song Z, Lou L, Fan G, Liu L, Ge Y, Liu H, Chan AS, Zhang X, Xiong X. Identification of novel Pyrrolo[2,3-d]Pyrimidine-based KRAS G12C inhibitors with anticancer effects. European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114907] [Reference Citation Analysis]
|
| 46 |
Poad H, Khan S, Wheaton L, Thomas A, Sweeting M, Bujkiewicz S. The Validity of Surrogate Endpoints in Sub Groups of Metastatic Colorectal Cancer Patients Defined by Treatment Class and KRAS Status. Cancers (Basel) 2022;14. [PMID: 36358810 DOI: 10.3390/cancers14215391] [Reference Citation Analysis]
|
| 47 |
Qi Y, Zou H, Zhao X, Kapeleris J, Monteiro M, Li F, Xu ZP, Deng Y, Wu Y, Tang Y, Gu W. Inhibition of colon cancer K-RasG13D mutation reduces cancer cell proliferation but promotes stemness and inflammation via RAS/ERK pathway. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.996053] [Reference Citation Analysis]
|
| 48 |
Wen X, Sun X, Ou Z, Jiang J, Chen Q, He X, Hu Z, Qiao H, Zhou K, Li X, Deng Y, Wen J. Phosphorylation-mediated interaction between human E26 transcription factor 1 and specific protein 1 is required for tumor cell migration. Acta Biochim Biophys Sin (Shanghai) 2022;54:1441-52. [PMID: 36305724 DOI: 10.3724/abbs.2022148] [Reference Citation Analysis]
|
| 49 |
Issahaku AR, Mukelabai N, Agoni C, Rudrapal M, Aldosari SM, Almalki SG, Khan J. Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRAS(G12D) inhibitors for cancer therapy. Sci Rep 2022;12:17796. [PMID: 36273239 DOI: 10.1038/s41598-022-22668-1] [Reference Citation Analysis]
|
| 50 |
Kontandreopoulou C, Kalopisis K, Viniou N, Diamantopoulos P. The genetics of myelodysplastic syndromes and the opportunities for tailored treatments. Front Oncol 2022;12:989483. [DOI: 10.3389/fonc.2022.989483] [Reference Citation Analysis]
|
| 51 |
Moss DY, McCann C, Kerr EM. Rerouting the drug response: Overcoming metabolic adaptation in KRAS-mutant cancers. Sci Signal 2022;15:eabj3490. [PMID: 36256706 DOI: 10.1126/scisignal.abj3490] [Reference Citation Analysis]
|
| 52 |
Fang H, Li H, Zhang H, Wang S, Xu S, Chang L, Yang Y, Cui R. Short-chain L-3-hydroxyacyl-CoA dehydrogenase: A novel vital oncogene or tumor suppressor gene in cancers. Front Pharmacol 2022;13:1019312. [DOI: 10.3389/fphar.2022.1019312] [Reference Citation Analysis]
|
| 53 |
Chatzigoulas A, Andreadelis I, Doerr S, Lamprakis C, Theodoropoulou A, Manchester J, Velez-vega C, Duca J, Cournia Z. Evaluation of K-Ras4B dimer interfaces and the role of Raf effectors.. [DOI: 10.1101/2022.10.04.510804] [Reference Citation Analysis]
|
| 54 |
Cao Q, Huang L, Koo S, He Y, Jangili P, Kim JS. Self-assemble nanostructured ensembles for detection of guanosine triphosphate based on receptor structure modulated sensitivity and selectivity. Sensors and Actuators B: Chemical 2022;368:132091. [DOI: 10.1016/j.snb.2022.132091] [Reference Citation Analysis]
|
| 55 |
Kennedy JJ, Woodcock A, Ivey RG, Lin C, Corral G, Hooper E, Martin G, Longman G, Stancik B, Cromwell EA, Whiteaker JR, Zhao L, Lorentzen TD, Thielman S, Paulovich AG. Preserving the Phosphoproteome of Clinical Biopsies Using a Quick-Freeze Collection Device. Biopreserv Biobank 2022;20:436-45. [PMID: 36301140 DOI: 10.1089/bio.2022.0068] [Reference Citation Analysis]
|
| 56 |
Likonen D, Pinchasi M, Beery E, Sarsor Z, Signorini LF, Gervits A, Sharan R, Lahav M, Raanani P, Uziel O. Exosomal telomerase transcripts reprogram the microRNA transcriptome profile of fibroblasts and partially contribute to CAF formation. Sci Rep 2022;12:16415. [PMID: 36180493 DOI: 10.1038/s41598-022-20186-8] [Reference Citation Analysis]
|
| 57 |
Sarni D, Barroso S, Shtrikman A, Irony-Tur Sinai M, Oren YS, Aguilera A, Kerem B. Topoisomerase 1-dependent R-loop deficiency drives accelerated replication and genomic instability. Cell Rep 2022;40:111397. [PMID: 36170822 DOI: 10.1016/j.celrep.2022.111397] [Reference Citation Analysis]
|
| 58 |
East P, Kelly GP, Biswas D, Marani M, Hancock DC, Creasy T, Sachsenmeier K, Swanton C, Downward J, de Carné Trécesson S; TRACERx consortium. RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma. Nat Commun 2022;13:5632. [PMID: 36163168 DOI: 10.1038/s41467-022-33290-0] [Reference Citation Analysis]
|
| 59 |
Ouyang X, Xu C. Targeting the (pro)renin receptor in cancers: from signaling to pathophysiological effects. J Cancer Res Clin Oncol. [DOI: 10.1007/s00432-022-04373-8] [Reference Citation Analysis]
|
| 60 |
meigui Z, Li J, Xi J, Xi L, Ma R, Zhou R, Zhang B, Li Y, Bai Z. (2E)-1-(2,4,6-trimethoxyphenyl)-3-(3-nitrophenyl)-2-propen-1-one Promotes Apoptosis By Regulating ERK/MAPK Pathway In Hepatocellular Carcinoma Cells.. [DOI: 10.21203/rs.3.rs-2058947/v1] [Reference Citation Analysis]
|
| 61 |
Poole A, Karuppiah V, Hartt A, Haidar JN, Moureau S, Dobrzycki T, Hayes C, Rowley C, Dias J, Harper S, Barnbrook K, Hock M, Coles C, Yang W, Aleksic M, Lin AB, Robinson R, Dukes JD, Liddy N, Van der Kamp M, Plowman GD, Vuidepot A, Cole DK, Whale AD, Chillakuri C. Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen. Nat Commun 2022;13. [DOI: 10.1038/s41467-022-32811-1] [Reference Citation Analysis]
|
| 62 |
Li M, Li X, Chen S, Zhang T, Song L, Pei J, Sun G, Guo L, Hussain T. IPO5 Mediates EMT and Promotes Esophageal Cancer Development through the RAS-ERK Pathway. Oxidative Medicine and Cellular Longevity 2022;2022:1-17. [DOI: 10.1155/2022/6570879] [Reference Citation Analysis]
|
| 63 |
Wang G, Bai Y, Cui J, Zong Z, Gao Y, Zheng Z. Computer-Aided Drug Design Boosts RAS Inhibitor Discovery. Molecules 2022;27:5710. [PMID: 36080477 DOI: 10.3390/molecules27175710] [Reference Citation Analysis]
|
| 64 |
Kidoguchi S, Sugano N, Yokoo T, Kaneko H, Akazawa H, Mukai M, Node K, Yano Y, Nishiyama A. Antihypertensive Drugs and Cancer Risk. Am J Hypertens 2022;35:767-83. [PMID: 35595533 DOI: 10.1093/ajh/hpac066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 65 |
Uddin MH, Al-Hallak N, Philip PA, Chen H, El-Rayes B, Azmi AS. Aberrant transcription factors in the cancers of the pancreas. Semin Cancer Biol 2022:S1044-579X(22)00197-3. [PMID: 36058426 DOI: 10.1016/j.semcancer.2022.08.011] [Reference Citation Analysis]
|
| 66 |
Huo Y, Cao K, Kou B, Chai M, Dou S, Chen D, Shi Y, Liu X. TP53BP2: Roles in suppressing tumorigenesis and therapeutic opportunities. Genes & Diseases 2022. [DOI: 10.1016/j.gendis.2022.08.014] [Reference Citation Analysis]
|
| 67 |
Raimondi V, Iannozzi NT, Burroughs-garcìa J, Toscani D, Storti P, Giuliani N. A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors. Exploration of Targeted Anti-tumor Therapy 2022. [DOI: 10.37349/etat.2022.00095] [Reference Citation Analysis]
|
| 68 |
Cronin SJF, Rao S, Tejada MA, Turnes BL, Licht-Mayer S, Omura T, Brenneis C, Jacobs E, Barrett L, Latremoliere A, Andrews N, Channon KM, Latini A, Arvanites AC, Davidow LS, Costigan M, Rubin LL, Penninger JM, Woolf CJ. Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key regulator of EGFR/KRAS-mediated neuropathic pain and lung cancer. Sci Transl Med 2022;14:eabj1531. [PMID: 36044597 DOI: 10.1126/scitranslmed.abj1531] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 69 |
Cuddy LK, Alia AO, Salvo MA, Chandra S, Grammatopoulos TN, Justman CJ, Lansbury PT Jr, Mazzulli JR, Vassar R. Farnesyltransferase inhibitor LNK-754 attenuates axonal dystrophy and reduces amyloid pathology in mice. Mol Neurodegener 2022;17:54. [PMID: 35987691 DOI: 10.1186/s13024-022-00561-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 70 |
Barzaman K, Vafaei R, Samadi M, Kazemi MH, Hosseinzadeh A, Merikhian P, Moradi-kalbolandi S, Eisavand MR, Dinvari H, Farahmand L. Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk. Cancer Cell Int 2022;22. [DOI: 10.1186/s12935-022-02658-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 71 |
Firnau M, Brieger A. CK2 and the Hallmarks of Cancer. Biomedicines 2022;10:1987. [DOI: 10.3390/biomedicines10081987] [Reference Citation Analysis]
|
| 72 |
Zhang M, Yang B, Zhang J, Song Y, Wang W, Li N, Wang Y, Li W, Wang J. Monitoring the Dynamic Regulation of the Mitochondrial GTP‐to‐GDP Ratio with a Genetically Encoded Fluorescent Biosensor. Angew Chem Int Ed 2022;61. [DOI: 10.1002/anie.202201266] [Reference Citation Analysis]
|
| 73 |
Nazir LA, Shahid NH, Amit K, Umar SA, Rajni S, Bharate S, Sangwan PL, Tasduq SA. Synthesis and anti-melanoma effect of 3-O-prenyl glycyrrhetinic acid against B16F10 cells via induction of endoplasmic reticulum stress-mediated autophagy through ERK/AKT signaling pathway. Front Oncol 2022;12:890299. [DOI: 10.3389/fonc.2022.890299] [Reference Citation Analysis]
|
| 74 |
Lee M, Chang C, Lin J, Wu Y. Piper betle stem extract induces apoptosis through mitochondria inactivation, p38MAPK activation and ErB2/ErbB3 suppression on oral squamous cell carcinoma cells. Phytomedicine Plus 2022;2:100295. [DOI: 10.1016/j.phyplu.2022.100295] [Reference Citation Analysis]
|
| 75 |
Ueda M, Matsuda K, Kurohama H, Mussazhanova Z, Sailaubekova Y, Kondo H, Shimizu T, Takada N, Matsuoka Y, Otsubo C, Sato S, Yamashita H, Kawakami A, Nakashima M. Molecular Pathological Characteristics of Thyroid Follicular-Patterned Tumors Showing Nodule-in-Nodule Appearance with Poorly Differentiated Component. Cancers 2022;14:3577. [DOI: 10.3390/cancers14153577] [Reference Citation Analysis]
|
| 76 |
Morshneva AV, Gnedina OO, Kindt DN, Igotti MV. Ras Participates in the Regulation of the Stability of Adenoviral Protein E1A via MAP-kinase ERK. Acta Naturae 2022;14:78-84. [DOI: 10.32607/actanaturae.11675] [Reference Citation Analysis]
|
| 77 |
Ognerubov NA, Ezhova EN. Somatic mutations in colorectal cancer: regional experience. Consilium Medicum 2022;24:291-296. [DOI: 10.26442/20751753.2022.5.201796] [Reference Citation Analysis]
|
| 78 |
Ferreira A, Pereira F, Reis C, Oliveira MJ, Sousa MJ, Preto A. Crucial Role of Oncogenic KRAS Mutations in Apoptosis and Autophagy Regulation: Therapeutic Implications. Cells 2022;11:2183. [DOI: 10.3390/cells11142183] [Reference Citation Analysis]
|
| 79 |
Dricu A. Oncogenic Signalling of Growth Factor Receptors in Cancer: Mechanisms and Therapeutic Opportunities. IJMS 2022;23:7376. [DOI: 10.3390/ijms23137376] [Reference Citation Analysis]
|
| 80 |
Alewine G, Knight J, Ghantae A, Mamrega C, Attiah B, Coover RA, Fahrenholtz CD. Silver Nanoparticles Selectively Treat Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors in a Neurofibromin-Dependent Manner. JPM 2022;12:1080. [DOI: 10.3390/jpm12071080] [Reference Citation Analysis]
|
| 81 |
Cacace F, Iula R, De Novellis D, Caprioli V, D’amico MR, De Simone G, Cuccurullo R, Wierda WG, Mahadeo KM, Menna G, Tambaro FP. High-Risk Acute Myeloid Leukemia: A Pediatric Prospective. Biomedicines 2022;10:1405. [DOI: 10.3390/biomedicines10061405] [Reference Citation Analysis]
|
| 82 |
Wang L, Lin S, Yang C, Cai S, Li W. Effect of KRAS mutations and p53 expression on the postoperative prognosis of patients with colorectal cancer. Mol Genet Genomic Med 2022;:e1905. [PMID: 35686701 DOI: 10.1002/mgg3.1905] [Reference Citation Analysis]
|
| 83 |
Makrooni MA, O’shea D, Geeleher P, Seoighe C. Random-effects meta-analysis of effect sizes as a unified framework for gene set analysis.. [DOI: 10.1101/2022.06.06.494956] [Reference Citation Analysis]
|
| 84 |
Kim J, Chang IY, You HJ. Interactions between EGFR and EphA2 promote tumorigenesis through the action of Ephexin1. Cell Death Dis 2022;13:528. [PMID: 35668076 DOI: 10.1038/s41419-022-04984-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 85 |
Li M, Keshavarz-rahaghi F, Ladua G, Swanson L, Speers C, Renouf DJ, Lim HJ, Davies JM, Gill S, Stuart HC, Yip S, Loree JM. Characterizing the KRAS G12C mutation in metastatic colorectal cancer: a population-based cohort and assessment of expression differences in The Cancer Genome Atlas. Ther Adv Med Oncol 2022;14:175883592210979. [DOI: 10.1177/17588359221097940] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 86 |
Scarpi-luttenauer M, Galentino K, Orvain C, Cecchini M, Gaiddon C, Mobian P. TiO4N2 complexes formed with 1,10-phenanthroline ligands containing a donor-acceptor hydrogen bond site: synthesis, cytotoxicity and docking experiments. Inorganica Chimica Acta 2022. [DOI: 10.1016/j.ica.2022.121036] [Reference Citation Analysis]
|
| 87 |
Tao R, Liu Q, Huang R, Wang K, Sun Z, Yang P, Wang J. A Novel TNFSF-Based Signature Predicts the Prognosis and Immunosuppressive Status of Lower-Grade Glioma. Biomed Res Int 2022;2022:3194996. [PMID: 35592520 DOI: 10.1155/2022/3194996] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 88 |
Huang R, Dai Q, Yang R, Duan Y, Zhao Q, Haybaeck J, Yang Z. A Review: PI3K/AKT/mTOR Signaling Pathway and Its Regulated Eukaryotic Translation Initiation Factors May Be a Potential Therapeutic Target in Esophageal Squamous Cell Carcinoma. Front Oncol 2022;12:817916. [PMID: 35574327 DOI: 10.3389/fonc.2022.817916] [Reference Citation Analysis]
|
| 89 |
Rokni M, Sadeghi Shaker M, Kavosi H, Shokoofi S, Mahmoudi M, Farhadi E. The role of endothelin and RAS/ERK signaling in immunopathogenesis-related fibrosis in patients with systemic sclerosis: an updated review with therapeutic implications. Arthritis Res Ther 2022;24:108. [PMID: 35562771 DOI: 10.1186/s13075-022-02787-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 90 |
Wang Z, Zhou X, Han J, Xie G, Liu J. DNA coated CoZn-ZIF metal-organic frameworks for fluorescent sensing guanosine triphosphate and discrimination of nucleoside triphosphates. Analytica Chimica Acta 2022;1207:339806. [DOI: 10.1016/j.aca.2022.339806] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 91 |
Göbel A, Riffel RM, Hofbauer LC, Rachner TD. The mevalonate pathway in breast cancer biology. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215761] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 92 |
Kettle JG, Bagal SK, Bickerton S, Bodnarchuk MS, Boyd S, Breed J, Carbajo RJ, Cassar DJ, Chakraborty A, Cosulich S, Cumming I, Davies M, Davies NL, Eatherton A, Evans L, Feron L, Fillery S, Gleave ES, Goldberg FW, Hanson L, Harlfinger S, Howard M, Howells R, Jackson A, Kemmitt P, Lamont G, Lamont S, Lewis HJ, Liu L, Niedbala MJ, Phillips C, Polanski R, Raubo P, Robb G, Robinson DM, Ross S, Sanders MG, Tonge M, Whiteley R, Wilkinson S, Yang J, Zhang W. Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRASG12C. J Med Chem 2022. [PMID: 35471939 DOI: 10.1021/acs.jmedchem.2c00369] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 93 |
Danel A, Gondek E, Kucharek M, Szlachcic P, Gut A. 1H-Pyrazolo[3,4-b]quinolines: Synthesis and Properties over 100 Years of Research. Molecules 2022;27:2775. [PMID: 35566124 DOI: 10.3390/molecules27092775] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 94 |
Poorebrahim M, Abazari MF, Moradi L, Shahbazi B, Mahmoudi R, Kalhor H, Askari H, Teimoori-toolabi L. Multi-targeting of K-Ras domains and mutations by peptide and small molecule inhibitors. PLoS Comput Biol 2022;18:e1009962. [DOI: 10.1371/journal.pcbi.1009962] [Reference Citation Analysis]
|
| 95 |
McGowan R, Sally Á, McCabe A, Moran BM, Finn K. Circulating Nucleic Acids as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2022;14:2027. [PMID: 35454933 DOI: 10.3390/cancers14082027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 96 |
Wang T, Gong M, Cao Y, Zhao C, Lu Y, Zhou Y, Yao S, Chen J, Zhao C, Ju R. Persistent ferroptosis promotes cervical squamous intraepithelial lesion development and oncogenesis by regulating KRAS expression in patients with high risk-HPV infection. Cell Death Discov 2022;8. [DOI: 10.1038/s41420-022-01013-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 97 |
Zhou Y, Zou Y, Yang M, Mei S, Liu X, Han H, Zhang CD, Niu MM. Highly Potent, Selective, Biostable, and Cell-Permeable Cyclic d-Peptide for Dual-Targeting Therapy of Lung Cancer. J Am Chem Soc 2022. [PMID: 35417174 DOI: 10.1021/jacs.1c12075] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 98 |
Alam M, Alam S, Shamsi A, Adnan M, Elasbali AM, Al-Soud WA, Alreshidi M, Hawsawi YM, Tippana A, Pasupuleti VR, Hassan MI. Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer. Front Oncol 2022;12:869672. [PMID: 35402265 DOI: 10.3389/fonc.2022.869672] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 99 |
Ostrem JM, Shokat KM. Targeting KRAS G12C with Covalent Inhibitors. Annu Rev Cancer Biol 2022;6:49-64. [DOI: 10.1146/annurev-cancerbio-041621-012549] [Reference Citation Analysis]
|
| 100 |
Yang F, Xuan G, Chen Y, Cao L, Zhao M, Wang C, Chen E. MicroRNAs Are Key Molecules Involved in the Gene Regulation Network of Colorectal Cancer. Front Cell Dev Biol 2022;10:828128. [DOI: 10.3389/fcell.2022.828128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 101 |
Seguin L. KRAS Addiction Promotes Cancer Cell Adaptation in Harsh Microenvironment Through Macropinocytosis. Subcell Biochem 2022;98:189-204. [PMID: 35378709 DOI: 10.1007/978-3-030-94004-1_10] [Reference Citation Analysis]
|
| 102 |
Su W, Tsai Y, Tsai H, Chang T, Yin T, Huang C, Chen Y, Li C, Chen P, Liu Y, Hsieh T, Wang J. Comparison of Next-Generation Sequencing and Polymerase Chain Reaction for Personalized Treatment-Related Genomic Status in Patients with Metastatic Colorectal Cancer. CIMB 2022;44:1552-63. [DOI: 10.3390/cimb44040106] [Reference Citation Analysis]
|
| 103 |
Issahaku AR, Aljoundi A, Soliman ME. Establishing the mutational effect on the binding susceptibility of AMG510 to KRAS switch II binding pocket: Computational insights. Informatics in Medicine Unlocked 2022. [DOI: 10.1016/j.imu.2022.100952] [Reference Citation Analysis]
|
| 104 |
Bitto A, Lui M, Giosa D, Romeo O. Computational Pathways Analysis and Personalized Medicine in HER2-Positive Breast Cancer. CPPM 2022;19:40-52. [DOI: 10.2174/1875692119666220407114044] [Reference Citation Analysis]
|
| 105 |
Hamidi-sofiani V, Rakhshi R, Moradi N, Zeynali P, Nakhaie M, Behboudi E. Oncolytic viruses and pancreatic cancer. Cancer Treatment and Research Communications 2022. [DOI: 10.1016/j.ctarc.2022.100563] [Reference Citation Analysis]
|
| 106 |
Ravichandran R, PriyaDharshini LC, Sakthivel KM, Rasmi RR. Role and regulation of autophagy in cancer. Biochim Biophys Acta Mol Basis Dis 2022;:166400. [PMID: 35341960 DOI: 10.1016/j.bbadis.2022.166400] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 107 |
Salem ME, El-Refai SM, Sha W, Puccini A, Grothey A, George TJ, Hwang JJ, O'Neil B, Barrett AS, Kadakia KC, Musselwhite LW, Raghavan D, Van Cutsem E, Tabernero J, Tie J. Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers. JCO Precis Oncol 2022;6:e2100245. [PMID: 35319967 DOI: 10.1200/PO.21.00245] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 108 |
Caratti B, Fidan M, Caratti G, Breitenecker K, Engler M, Kazemitash N, Traut R, Wittig R, Casanova E, Ahmadian MR, Tuckermann JP, Moll HP, Cirstea IC. The glucocorticoid receptor associates with RAS complexes to inhibit cell proliferation and tumor growth. Sci Signal 2022;15:eabm4452. [PMID: 35316097 DOI: 10.1126/scisignal.abm4452] [Reference Citation Analysis]
|
| 109 |
Dong XD, Zhang M, Cai CY, Teng QX, Wang JQ, Fu YG, Cui Q, Patel K, Wang DT, Chen ZS. Overexpression of ABCB1 Associated With the Resistance to the KRAS-G12C Specific Inhibitor ARS-1620 in Cancer Cells. Front Pharmacol 2022;13:843829. [PMID: 35281897 DOI: 10.3389/fphar.2022.843829] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 110 |
Arendt KAM, Ntaliarda G, Armenis V, Kati D, Henning C, Giotopoulou GA, Pepe MAA, Klotz LV, Lamort AS, Hatz RA, Kobold S, Schamberger AC, Stathopoulos GT. An In Vivo Inflammatory Loop Potentiates KRAS Blockade. Biomedicines 2022;10. [PMID: 35327394 DOI: 10.3390/biomedicines10030592] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 111 |
Ufuk A, Garner T, Stevens A, Latif A. Monocarboxylate Transporters Are Involved in Extracellular Matrix Remodelling in Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2022;14. [PMID: 35267606 DOI: 10.3390/cancers14051298] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 112 |
Rohatgi A, Govindan R. Targeting KRAS G12C mutation in lung adenocarcinoma. Lung Cancer 2022;165:28-33. [DOI: 10.1016/j.lungcan.2021.12.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 113 |
Qian J, Li Z, Pei K, Li Z, Li C, Yan M, Qian M, Song Y, Zhang H, He Y. Effects of NRAS Mutations on Leukemogenesis and Targeting of Children With Acute Lymphoblastic Leukemia. Front Cell Dev Biol 2022;10:712484. [PMID: 35211470 DOI: 10.3389/fcell.2022.712484] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 114 |
Wang K, Zhang M, Zhao S, Xie Z, Zhang Y, Liu J, Zhang Y, Yang X, Wu N. Mutational spectrum of syndromic genes in sporadic brain arteriovenous malformation. Chin Neurosurg J 2022;8:4. [PMID: 35209959 DOI: 10.1186/s41016-022-00270-8] [Reference Citation Analysis]
|
| 115 |
Vlahos AE, Kang J, Aldrete CA, Zhu R, Chong LS, Elowitz MB, Gao XJ. Protease-controlled secretion and display of intercellular signals. Nat Commun 2022;13:912. [PMID: 35177637 DOI: 10.1038/s41467-022-28623-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 116 |
Jafari Nivlouei S, Soltani M, Shirani E, Salimpour MR, Travasso R, Carvalho J. A multiscale cell-based model of tumor growth for chemotherapy assessment and tumor-targeted therapy through a 3D computational approach. Cell Prolif 2022;:e13187. [PMID: 35132721 DOI: 10.1111/cpr.13187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 117 |
Rhaiem R, Rached L, Tashkandi A, Bouché O, Kianmanesh R. Implications of RAS Mutations on Oncological Outcomes of Surgical Resection and Thermal Ablation Techniques in the Treatment of Colorectal Liver Metastases. Cancers (Basel) 2022;14:816. [PMID: 35159083 DOI: 10.3390/cancers14030816] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 118 |
Brown MA, Ried T. Shifting the Focus of Signaling Abnormalities in Colon Cancer. Cancers 2022;14:784. [DOI: 10.3390/cancers14030784] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 119 |
Dong G, Ye X, Wang S, Li W, Cai R, Du L, Shi X, Li M. Au-24 as a Potential Thioredoxin Reductase Inhibitor in Hepatocellular Carcinoma Cells. Pharmacol Res 2022;:106113. [PMID: 35124208 DOI: 10.1016/j.phrs.2022.106113] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 120 |
Zhu JY, Huang X, Fu Y, Wang Y, Zheng P, Liu Y, Han Z. Pharmacological or genetic inhibition of hypoxia signaling attenuates oncogenic RAS-induced cancer phenotypes. Dis Model Mech 2022;15:dmm048953. [PMID: 34580712 DOI: 10.1242/dmm.048953] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 121 |
Li Y, Han L, Zhang Z. Understanding the influence of AMG 510 on the structure of KRASG12C empowered by molecular dynamics simulation. Computational and Structural Biotechnology Journal 2022. [DOI: 10.1016/j.csbj.2022.02.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 122 |
Wang P, Liu H, Pan X, Feng Q, Yang J. A method of delivering an anti-p21Ras single-chain antibody fragment to tumor sites in vivo. Journal of Drug Delivery Science and Technology 2022;68:103024. [DOI: 10.1016/j.jddst.2021.103024] [Reference Citation Analysis]
|
| 123 |
Conrad D, Kehl A, Beitzinger C, Metzler T, Steiger K, Pfarr N, Fischer K, Klopfleisch R, Aupperle-lellbach H. Molecular Genetic Investigation of Digital Melanoma in Dogs. Veterinary Sciences 2022;9:56. [DOI: 10.3390/vetsci9020056] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 124 |
Lang L, Loveless R, Dou J, Lam T, Chen A, Wang F, Sun L, Juarez J, Qin ZS, Saba NF, Shay C, Teng Y. ATAD3A mediates activation of RAS-independent mitochondrial ERK1/2 signaling, favoring head and neck cancer development. J Exp Clin Cancer Res 2022;41. [DOI: 10.1186/s13046-022-02274-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 125 |
Corral de la Fuente E, Olmedo Garcia ME, Gomez Rueda A, Lage Y, Garrido P. Targeting KRAS in Non-Small Cell Lung Cancer. Front Oncol 2021;11:792635. [PMID: 35083149 DOI: 10.3389/fonc.2021.792635] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 126 |
Karagiannakos A, Adamaki M, Tsintarakis A, Vojtesek B, Fåhraeus R, Zoumpourlis V, Karakostis K. Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets. Cancers 2022;14:664. [DOI: 10.3390/cancers14030664] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 127 |
Lu L, Cole A, Huang D, Wang Q, Guo Z, Yang W, Lu J. Clinical Significance of Hepsin and Underlying Signaling Pathways in Prostate Cancer. Biomolecules 2022;12:203. [DOI: 10.3390/biom12020203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 128 |
Wang Y, Ma LY, Yin XP, Gao BL. Radiomics and Radiogenomics in Evaluation of Colorectal Cancer Liver Metastasis. Front Oncol 2021;11:689509. [PMID: 35070948 DOI: 10.3389/fonc.2021.689509] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 129 |
Kwan AK, Piazza GA, Keeton AB, Leite CA. The path to the clinic: a comprehensive review on direct KRASG12C inhibitors. J Exp Clin Cancer Res 2022;41. [DOI: 10.1186/s13046-021-02225-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 130 |
Abeysinghe P, Turner N, Peiris H, Vaswani K, Cameron N, McGhee N, Logan J, Mitchell MD. Differentially Expressed Extracellular Vesicle, Exosome and Non-Exosome miRNA Profile in High and Low Tick-Resistant Beef Cattle. Front Cell Infect Microbiol 2021;11:780424. [PMID: 34976862 DOI: 10.3389/fcimb.2021.780424] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 131 |
Yang X, Jones K, Chen G. Pathology of Pancreatic Ductal Adenocarcinoma. Hepato-Pancreato-Biliary Malignancies 2022. [DOI: 10.1007/978-3-030-41683-6_30] [Reference Citation Analysis]
|
| 132 |
Rasool F, Kumar B, Sharma D, Jayadev Magani SK. Molecular signaling and its role in drug resistance in hepatocellular carcinomas. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 2 2022. [DOI: 10.1016/b978-0-323-98807-0.00006-5] [Reference Citation Analysis]
|
| 133 |
Suzuki T, Kishikawa T, Sato T, Takeda N, Sugiura Y, Seimiya T, Sekiba K, Ohno M, Iwata T, Ishibashi R, Otsuka M, Koike K. Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells. Cancer Gene Ther 2022;29:505-18. [PMID: 33833413 DOI: 10.1038/s41417-021-00326-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 134 |
Fountoulakis KN. Neurotrophic Factors. The Human Connectome 2022. [DOI: 10.1007/978-3-031-10351-3_9] [Reference Citation Analysis]
|
| 135 |
Herreros E, Janssens X, Pepe D, Keersmaecker KD. SNPs Ability to Influence Disease Risk: Breaking the Silence on Synonymous Mutations in Cancer. Single Nucleotide Polymorphisms 2022. [DOI: 10.1007/978-3-031-05616-1_5] [Reference Citation Analysis]
|
| 136 |
Tran TM, Philipp J, Bassi JS, Nibber N, Draper JM, Lin TL, Palanichamy JK, Jaiswal AK, Silva O, Paing M, King J, Katzman S, Sanford JR, Rao DS. The RNA-binding protein IGF2BP3 is critical for MLL-AF4-mediated leukemogenesis. Leukemia 2022;36:68-79. [PMID: 34321607 DOI: 10.1038/s41375-021-01346-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 137 |
Khan I, Marelia-Bennet C, Lefler J, Zuberi M, Denbaum E, Koide A, Connor DM, Broome AM, Pécot T, Timmers C, Ostrowski MC, Koide S, O'Bryan JP. Targeting the KRAS α4-α5 allosteric interface inhibits pancreatic cancer tumorigenesis. Small GTPases 2022;13:114-27. [PMID: 33949915 DOI: 10.1080/21541248.2021.1906621] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 138 |
Periyasamy L, Krishnan A, Palanichami MK, Ramachandran I, Kumaran RI, Behlen J, Stanley JA, Muthusami S. Reactive Oxygen Species: Induced Epigenetic Modification in the Expression Pattern of Oncogenic Proteins. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects 2022. [DOI: 10.1007/978-981-16-5422-0_68] [Reference Citation Analysis]
|
| 139 |
Sexton R, Al-hallak N, Al-share B, Tesfaye A, Azmi AS. Noncoding ribonucleic acids in gastric cancer patients. Clinical Applications of Non-Coding RNAs in Cancer 2022. [DOI: 10.1016/b978-0-12-824550-7.00012-6] [Reference Citation Analysis]
|
| 140 |
Hsu J, Annunziata JF, Burns E, Bernicker EH, Olsen RJ, Thomas JS. Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status. Clin Pathol 2022;15:2632010X221102054. [PMID: 35634237 DOI: 10.1177/2632010X221102054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 141 |
Viviano-posadas AO, Romero-mendoza U, Bazany-rodríguez IJ, Velázquez-castillo RV, Martínez-otero D, Bautista-renedo JM, González-rivas N, Galindo-murillo R, Salomón-flores MK, Dorazco-gonzález A. Efficient fluorescent recognition of ATP/GTP by a water-soluble bisquinolinium pyridine-2,6-dicarboxamide compound. Crystal structures, spectroscopic studies and interaction mode with DNA. RSC Adv 2022;12:27826-38. [DOI: 10.1039/d2ra05040d] [Reference Citation Analysis]
|
| 142 |
Hamidi AA, Zangoue M, Kashani D, Zangouei AS, Rahimi HR, Abbaszadegan MR, Moghbeli M. MicroRNA-217: a therapeutic and diagnostic tumor marker. Expert Rev Mol Diagn 2021;:1-16. [PMID: 34883033 DOI: 10.1080/14737159.2022.2017284] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 143 |
Wang R, Zhang Y, Shan F. PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer? Int Immunopharmacol 2021;103:108484. [PMID: 34954558 DOI: 10.1016/j.intimp.2021.108484] [Reference Citation Analysis]
|
| 144 |
Tailor K, Paul J, Ghosh S, Kumari N, Kwabi-Addo B. RASAL2 suppresses the proliferative and invasive ability of PC3 prostate cancer cells. Oncotarget 2021;12:2489-99. [PMID: 34966481 DOI: 10.18632/oncotarget.28158] [Reference Citation Analysis]
|
| 145 |
Wang Y, Stevens M, Mandigo T, Bouley S, Sharma A, Sengupta S, Housden A, Perrimon N, Walker J, Housden B. Synthetic lethal screening identifies existing autophagy drugs with selective viability effects on Neurofibromatosis type-1 model systems.. [DOI: 10.1101/2021.12.20.473481] [Reference Citation Analysis]
|
| 146 |
Jacobs F, Cani M, Malapelle U, Novello S, Napoli VM, Bironzo P. Targeting KRAS in NSCLC: Old Failures and New Options for "Non-G12c" Patients. Cancers (Basel) 2021;13:6332. [PMID: 34944952 DOI: 10.3390/cancers13246332] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 147 |
Sutton MN, Gammon ST, Muzzioli R, Pisaneschi F, Radaram B, Yang P, Piwnica-Worms D. RAS-Driven Macropinocytosis of Albumin or Dextran Reveals Mutation-Specific Target Engagement of RAS p.G12C Inhibitor ARS-1620 by NIR-Fluorescence Imaging. Mol Imaging Biol 2021. [PMID: 34905147 DOI: 10.1007/s11307-021-01689-8] [Reference Citation Analysis]
|
| 148 |
Wu PS, Wang CY, Chen PS, Hung JH, Yen JH, Wu MJ. 8-Hydroxydaidzein Downregulates JAK/STAT, MMP, Oxidative Phosphorylation, and PI3K/AKT Pathways in K562 Cells. Biomedicines 2021;9:1907. [PMID: 34944720 DOI: 10.3390/biomedicines9121907] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 149 |
Adamopoulos PG, Tsiakanikas P, Boti MA, Scorilas A. Targeted Long-Read Sequencing Decodes the Transcriptional Atlas of the Founding RAS Gene Family Members. Int J Mol Sci 2021;22:13298. [PMID: 34948093 DOI: 10.3390/ijms222413298] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 150 |
Fumagalli G, Carbajo RJ, Nissink JWM, Tart J, Dou R, Thomas AP, Spring DR. Targeting a Novel KRAS Binding Site: Application of One-Component Stapling of Small (5-6-mer) Peptides. J Med Chem 2021;64:17287-303. [PMID: 34787423 DOI: 10.1021/acs.jmedchem.1c01334] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 151 |
Opitz FV, Haeberle L, Daum A, Esposito I. Tumor Microenvironment in Pancreatic Intraepithelial Neoplasia. Cancers 2021;13:6188. [DOI: 10.3390/cancers13246188] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 152 |
Wang XD, Kim C, Zhang Y, Rindhe S, Cobb MH, Yu Y. Cholesterol Regulates the Tumor Adaptive Resistance to MAPK Pathway Inhibition. J Proteome Res 2021;20:5379-91. [PMID: 34751028 DOI: 10.1021/acs.jproteome.1c00550] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 153 |
Schmukler E, Pinkas-kramarski R. The interplay between Ras, Autophagy and cancer. Advances in Cancer Biology - Metastasis 2021;3:100014. [DOI: 10.1016/j.adcanc.2021.100014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 154 |
Sunaga N, Miura Y, Kasahara N, Sakurai R. Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer. Cancers (Basel) 2021;13:5956. [PMID: 34885068 DOI: 10.3390/cancers13235956] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 155 |
Saito S, Cao DY, Victor AR, Peng Z, Wu HY, Okwan-Duodu D. RASAL3 Is a Putative RasGAP Modulating Inflammatory Response by Neutrophils. Front Immunol 2021;12:744300. [PMID: 34777356 DOI: 10.3389/fimmu.2021.744300] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 156 |
Foo BJ, Eu JQ, Hirpara JL, Pervaiz S. Interplay between Mitochondrial Metabolism and Cellular Redox State Dictates Cancer Cell Survival. Oxid Med Cell Longev 2021;2021:1341604. [PMID: 34777681 DOI: 10.1155/2021/1341604] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 157 |
Chen B, Deng T, Deng L, Yu H, He B, Chen K, Zheng C, Wang D, Wang Y, Chen G. Identification of tumour immune microenvironment-related alternative splicing events for the prognostication of pancreatic adenocarcinoma. BMC Cancer 2021;21:1211. [PMID: 34772375 DOI: 10.1186/s12885-021-08962-7] [Reference Citation Analysis]
|
| 158 |
Hyun S, Shin D. Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers. Int J Mol Sci 2021;22:12142. [PMID: 34830024 DOI: 10.3390/ijms222212142] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 159 |
Yan Y, Gao Z, Han H, Zhao Y, Zhang Y, Ma X, Chen H. NRAS expression is associated with prognosis and tumor immune microenvironment in lung adenocarcinoma. J Cancer Res Clin Oncol 2021. [PMID: 34746975 DOI: 10.1007/s00432-021-03842-w] [Reference Citation Analysis]
|
| 160 |
Huang H, Xie L, Feng X, Zheng Z, Ouyang J, Li Y, Yu J. An integrated analysis of DNA promoter methylation, microRNA regulation, and gene expression in gastric adenocarcinoma. Ann Transl Med 2021;9:1414. [PMID: 34733966 DOI: 10.21037/atm-21-3211] [Reference Citation Analysis]
|
| 161 |
Mongre RK, Mishra CB, Shukla AK, Prakash A, Jung S, Ashraf-Uz-Zaman M, Lee MS. Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure? Int J Mol Sci 2021;22:11659. [PMID: 34769090 DOI: 10.3390/ijms222111659] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 162 |
Guo Y, Wang S, Zhao ZY, Li JN, Shang A, Li DL, Wang M. Skeletal muscle metastasis with bone metaplasia from colon cancer: A case report and review of the literature. World J Clin Cases 2021; 9(30): 9285-9294 [PMID: 34786415 DOI: 10.12998/wjcc.v9.i30.9285] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 163 |
Chaudhary P, Guragain D, Chang JH, Kim JA. TPH1 and 5-HT7 Receptor Overexpression Leading to Gemcitabine-Resistance Requires Non-Canonical Permissive Action of EZH2 in Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021;13:5305. [PMID: 34771469 DOI: 10.3390/cancers13215305] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 164 |
Vlahos AE, Kang J, Aldrete CA, Zhu R, Chong LS, Elowitz MB, Gao XJ. Protease-controlled secretion and display of intercellular signals.. [DOI: 10.1101/2021.10.18.464444] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 165 |
Feng B, Wang K, Herpel E, Plath M, Weichert W, Freier K, Zaoui K, Hess J. Prognostic Gene Signature for Squamous Cell Carcinoma with a Higher Risk for Treatment Failure and Accelerated MEK-ERK Pathway Activity. Cancers (Basel) 2021;13:5182. [PMID: 34680330 DOI: 10.3390/cancers13205182] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 166 |
Kim J, Xu Z, Marignani PA. Single-cell RNA sequencing for the identification of early-stage lung cancer biomarkers from circulating blood. NPJ Genom Med 2021;6:87. [PMID: 34654834 DOI: 10.1038/s41525-021-00248-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 167 |
Kumar N, Mandal CC. Cholesterol-Lowering Drugs on Akt Signaling for Prevention of Tumorigenesis. Front Genet 2021;12:724149. [PMID: 34603386 DOI: 10.3389/fgene.2021.724149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 168 |
Plangger A, Rath B, Hochmair M, Funovics M, Hamilton G. Cytotoxicity of combinations of the pan-KRAS inhibitor BAY-293 against primary non-small lung cancer cells. Transl Oncol 2021;14:101230. [PMID: 34598083 DOI: 10.1016/j.tranon.2021.101230] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 169 |
Safavi A, Ghodousi ES, Ghavamizadeh M, Sabaghan M, Azadbakht O, veisi A, Babaei H, Nazeri Z, Darabi MK, Zarezade V. Computational investigation of novel farnesyltransferase inhibitors using 3D-QSAR pharmacophore modeling, virtual screening, molecular docking and molecular dynamics simulation studies: A new insight into cancer treatment. Journal of Molecular Structure 2021;1241:130667. [DOI: 10.1016/j.molstruc.2021.130667] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 170 |
Herrero A, Crespo P. RAS Dimers: The Novice Couple at the RAS-ERK Pathway Ball. Genes (Basel) 2021;12:1556. [PMID: 34680951 DOI: 10.3390/genes12101556] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 171 |
Zhou Y, Hancock JF. Lipid Profiles of RAS Nanoclusters Regulate RAS Function. Biomolecules 2021;11. [PMID: 34680072 DOI: 10.3390/biom11101439] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 172 |
Hu Q, Masuda T, Koike K, Sato K, Tobo T, Kuramitsu S, Kitagawa A, Fujii A, Noda M, Tsuruda Y, Otsu H, Kuroda Y, Ito S, Oki E, Mimori K. Oxysterol binding protein-like 3 (OSBPL3) is a novel driver gene that promotes tumor growth in part through R-Ras/Akt signaling in gastric cancer. Sci Rep 2021;11:19178. [PMID: 34584127 DOI: 10.1038/s41598-021-98485-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 173 |
Park J, Park H, Byun JM, Hong J, Shin DY, Koh Y, Yoon SS. Pan-RAF inhibitor LY3009120 is highly synergistic with low-dose cytarabine, but not azacitidine, in acute myeloid leukemia with RAS mutations. Oncol Lett 2021;22:745. [PMID: 34539849 DOI: 10.3892/ol.2021.13006] [Reference Citation Analysis]
|
| 174 |
Rodak O, Peris-Díaz MD, Olbromski M, Podhorska-Okołów M, Dzięgiel P. Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy. Cancers (Basel) 2021;13:4705. [PMID: 34572931 DOI: 10.3390/cancers13184705] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 175 |
Chekmarev J, Azad MG, Richardson DR. The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity. Cells 2021;10. [PMID: 34572031 DOI: 10.3390/cells10092382] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 176 |
Stubbs CK, Biancucci M, Vidimar V, Satchell KJF. RAS specific protease induces irreversible growth arrest via p27 in several KRAS mutant colorectal cancer cell lines. Sci Rep 2021;11:17925. [PMID: 34504197 DOI: 10.1038/s41598-021-97422-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 177 |
Applications of Constrained Helices. Cyclized Helical Peptides 2021. [DOI: 10.1002/9783527343430.ch4] [Reference Citation Analysis]
|
| 178 |
Zhang Z, Wang X, Ye J, Liu H, Fang J, Zhang M, Li Y, Huang J, Zhang D, Wang J, Zhang X. Development and Preclinical Evaluation of Radiolabeled Covalent G12C-Specific Inhibitors for Direct Imaging of the Oncogenic KRAS Mutant. Mol Pharm 2021;18:3509-18. [PMID: 34410132 DOI: 10.1021/acs.molpharmaceut.1c00426] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 179 |
Harms M, Habib MMW, Nemska S, Nicolò A, Gilg A, Preising N, Sokkar P, Carmignani S, Raasholm M, Weidinger G, Kizilsavas G, Wagner M, Ständker L, Abadi AH, Jumaa H, Kirchhoff F, Frossard N, Sanchez-Garcia E, Münch J. An optimized derivative of an endogenous CXCR4 antagonist prevents atopic dermatitis and airway inflammation. Acta Pharm Sin B 2021;11:2694-708. [PMID: 34589390 DOI: 10.1016/j.apsb.2020.12.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 180 |
Zhu J, Liu C, Wang D, Cao X, Wang S, Liu Y, Wang J, Li P, He Q. The Emerging Landscapes of Long Noncoding RNA in Thyroid Carcinoma: Biological Functions and Clinical Significance. Front Oncol 2021;11:706011. [PMID: 34447696 DOI: 10.3389/fonc.2021.706011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 181 |
de Castro CPM, Cadefau M, Cuartero S. The Mutational Landscape of Myeloid Leukaemia in Down Syndrome. Cancers (Basel) 2021;13:4144. [PMID: 34439298 DOI: 10.3390/cancers13164144] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 182 |
Hamilton G, Plangger A. Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics. Expert Opin Drug Metab Toxicol 2021;:1-9. [PMID: 34347509 DOI: 10.1080/17425255.2021.1965123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 183 |
Zuberi M, Khan I, O'Bryan JP. Inhibition of RAS: proven and potential vulnerabilities. Biochem Soc Trans 2020;48:1831-41. [PMID: 32869838 DOI: 10.1042/BST20190023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 184 |
Thompson SK, Buckl A, Dossetter AG, Griffen E, Gill A. Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature. Expert Opin Ther Pat 2021;:1-16. [PMID: 34253125 DOI: 10.1080/13543776.2021.1952984] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 185 |
Mir MA, Qayoom H, Mehraj U, Nisar S, Bhat B, Wani NA. Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer. Curr Cancer Drug Targets 2020;20:586-602. [PMID: 32418525 DOI: 10.2174/1570163817666200518081955] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 15.5] [Reference Citation Analysis]
|
| 186 |
Shaikh M, Shinde Y, Pawara R, Noolvi M, Surana S, Ahmad I, Patel H. Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer. J Med Chem 2021. [PMID: 34323489 DOI: 10.1021/acs.jmedchem.1c00876] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 187 |
Enomoto M, Takemoto D, Igaki T. Interaction between Ras and Src clones causes interdependent tumor malignancy via Notch signaling in Drosophila. Dev Cell 2021;56:2223-2236.e5. [PMID: 34324859 DOI: 10.1016/j.devcel.2021.07.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 188 |
Whiteaker JR, Sharma K, Hoffman MA, Kuhn E, Zhao L, Cocco AR, Schoenherr RM, Kennedy JJ, Voytovich U, Lin C, Fang B, Bowers K, Whiteley G, Colantonio S, Bocik W, Roberts R, Hiltke T, Boja E, Rodriguez H, McCormick F, Holderfield M, Carr SA, Koomen JM, Paulovich AG. Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling. Cell Rep Methods 2021;1:100015. [PMID: 34671754 DOI: 10.1016/j.crmeth.2021.100015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 189 |
Wang S, Qian H, Zhang L, Liu P, Zhuang D, Zhang Q, Bai F, Wang Z, Yan Y, Guo J, Huang J, Wu X. Inhibition of Calcineurin/NFAT Signaling Blocks Oncogenic H-Ras Induced Autophagy in Primary Human Keratinocytes. Front Cell Dev Biol 2021;9:720111. [PMID: 34350189 DOI: 10.3389/fcell.2021.720111] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 190 |
Bear AS, Blanchard T, Cesare J, Ford MJ, Richman LP, Xu C, Baroja ML, McCuaig S, Costeas C, Gabunia K, Scholler J, Posey AD Jr, O'Hara MH, Smole A, Powell DJ Jr, Garcia BA, Vonderheide RH, Linette GP, Carreno BM. Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting. Nat Commun 2021;12:4365. [PMID: 34272369 DOI: 10.1038/s41467-021-24562-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 191 |
Orgován Z, Keserű GM. Small molecule inhibitors of RAS proteins with oncogenic mutations. Cancer Metastasis Rev 2020;39:1107-26. [PMID: 32770300 DOI: 10.1007/s10555-020-09911-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 192 |
Osaka N, Hirota Y, Ito D, Ikeda Y, Kamata R, Fujii Y, Chirasani VR, Campbell SL, Takeuchi K, Senda T, Sasaki AT. Divergent Mechanisms Activating RAS and Small GTPases Through Post-translational Modification. Front Mol Biosci 2021;8:707439. [PMID: 34307463 DOI: 10.3389/fmolb.2021.707439] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 193 |
Ruiz EJ, Lan L, Diefenbacher ME, Riising EM, Da Costa C, Chakraborty A, Hoeck JD, Spencer-Dene B, Kelly G, David JP, Nye E, Downward J, Behrens A. JunD, not c-Jun, is the AP-1 transcription factor required for Ras-induced lung cancer. JCI Insight 2021;6:124985. [PMID: 34236045 DOI: 10.1172/jci.insight.124985] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 194 |
Van Thillo Q, De Bie J, Seneviratne JA, Demeyer S, Omari S, Balachandran A, Zhai V, Tam WL, Sweron B, Geerdens E, Gielen O, Provost S, Segers H, Boeckx N, Marshall GM, Cheung BB, Isobe K, Kato I, Takita J, Amos TG, Deveson IW, McCalmont H, Lock RB, Oxley EP, Garwood MM, Dickins RA, Uyttebroeck A, Carter DR, Cools J, de Bock CE. Oncogenic cooperation between TCF7-SPI1 and NRAS(G12D) requires β-catenin activity to drive T-cell acute lymphoblastic leukemia. Nat Commun 2021;12:4164. [PMID: 34230493 DOI: 10.1038/s41467-021-24442-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 195 |
Kane RA, Christodoulides N, Jensen IM, Becker DJ, Mansfield KL, Savage AE. Gene expression changes with tumor disease and leech parasitism in the juvenile green sea turtle skin transcriptome. Gene 2021;800:145800. [PMID: 34175400 DOI: 10.1016/j.gene.2021.145800] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 196 |
Zhou Y, Prakash PS, Liang H, Gorfe AA, Hancock JF. The KRAS and other prenylated polybasic domain membrane anchors recognize phosphatidylserine acyl chain structure. Proc Natl Acad Sci U S A 2021;118:e2014605118. [PMID: 33526670 DOI: 10.1073/pnas.2014605118] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 197 |
Kumar SU, Priya Doss CG. Residue interaction networks of K-Ras protein with water molecules identifies the potential role of switch II and P-loop. Comput Biol Med 2021;135:104597. [PMID: 34237589 DOI: 10.1016/j.compbiomed.2021.104597] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 198 |
Jafari Nivlouei S, Soltani M, Carvalho J, Travasso R, Salimpour MR, Shirani E. Multiscale modeling of tumor growth and angiogenesis: Evaluation of tumor-targeted therapy. PLoS Comput Biol 2021;17:e1009081. [PMID: 34161319 DOI: 10.1371/journal.pcbi.1009081] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 199 |
Giotopoulou GA, Ntaliarda G, Marazioti A, Lilis I, Kalogianni F, Tourkochristou E, Spiropoulou N, Giopanou I, Spella M, Iliopoulou M, Korfiati A, Mantamadiotis T, Rosero C, Goldmann T, Marwitz S, Stathopoulos GT. Immune-evasion of KRAS-mutant lung adenocarcinoma mediated by cAMP response element-binding protein.. [DOI: 10.1101/2021.06.19.449094] [Reference Citation Analysis]
|
| 200 |
He P, Zou Y, Qiu J, Yang T, Peng L, Zhang X. Pretreatment 18F-FDG PET/CT Imaging Predicts the KRAS/NRAS/BRAF Gene Mutational Status in Colorectal Cancer. J Oncol 2021;2021:6687291. [PMID: 34239564 DOI: 10.1155/2021/6687291] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 201 |
Zhou Y, Gorfe AA, Hancock JF. RAS Nanoclusters Selectively Sort Distinct Lipid Headgroups and Acyl Chains. Front Mol Biosci 2021;8:686338. [PMID: 34222339 DOI: 10.3389/fmolb.2021.686338] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 202 |
Pepi C, de Palma L, Trivisano M, Pietrafusa N, Lepri FR, Diociaiuti A, Camassei FD, Carfi-Pavia G, De Benedictis A, Rossi-Espagnet C, Vigevano F, Marras CE, Novelli A, Bluemcke I, Specchio N. The Role of KRAS Mutations in Cortical Malformation and Epilepsy Surgery: A Novel Report of Nevus Sebaceous Syndrome and Review of the Literature. Brain Sci 2021;11:793. [PMID: 34208656 DOI: 10.3390/brainsci11060793] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 203 |
Henkels KM, Rehl KM, Cho KJ. Blocking K-Ras Interaction With the Plasma Membrane Is a Tractable Therapeutic Approach to Inhibit Oncogenic K-Ras Activity. Front Mol Biosci 2021;8:673096. [PMID: 34222333 DOI: 10.3389/fmolb.2021.673096] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 204 |
Yan L, Tu B, Yao J, Gong J, Carugo A, Bristow CA, Wang Q, Zhu C, Dai B, Kang Y, Han L, Feng N, Jin Y, Fleming J, Heffernan TP, Yao W, Ying H. Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition. Cancer Res 2021;81:4054-65. [PMID: 34117030 DOI: 10.1158/0008-5472.CAN-20-3792] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 205 |
Friedrich C, Schallenberg S, Kirchner M, Ziehm M, Niquet S, Haji M, Beier C, Neudecker J, Klauschen F, Mertins P. Comprehensive micro-scaled proteome and phosphoproteome characterization of archived retrospective cancer repositories. Nat Commun 2021;12:3576. [PMID: 34117251 DOI: 10.1038/s41467-021-23855-w] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 206 |
Zhao Q, Fujimiya R, Kubo S, Marshall CB, Ikura M, Shimada I, Nishida N. Real-Time In-Cell NMR Reveals the Intracellular Modulation of GTP-Bound Levels of RAS. Cell Rep 2020;32:108074. [PMID: 32846131 DOI: 10.1016/j.celrep.2020.108074] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 207 |
Li L, Wang X. Identification of gastric cancer subtypes based on pathway clustering. NPJ Precis Oncol 2021;5:46. [PMID: 34079012 DOI: 10.1038/s41698-021-00186-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 208 |
Lizcano Sanz I, Guzmán Bernardo FJ, Castañeda Peñalvo G, Rodríguez Flores J. Determination of dabrafenib and trametinib in serum by dispersive solid phase extraction with multi-walled carbon nanotubes and capillary electrophoresis coupled to ultraviolet/visible detection. Microchemical Journal 2021;165:106180. [DOI: 10.1016/j.microc.2021.106180] [Reference Citation Analysis]
|
| 209 |
Ford KM, Panwala R, Chen DH, Portell A, Palmer N, Mali P. Peptide-tiling screens of cancer drivers reveal oncogenic protein domains and associated peptide inhibitors. Cell Syst 2021;12:716-732.e7. [PMID: 34051140 DOI: 10.1016/j.cels.2021.05.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 210 |
Kong Y, Tian X, He R, Li C, Xu H, Tian L, Liu Z. The accumulation of exosome-associated microRNA-1246 and microRNA-150-3p in human red blood cell suspensions. J Transl Med 2021;19:225. [PMID: 34044888 DOI: 10.1186/s12967-021-02887-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 211 |
Park JK, Coffey NJ, Limoges A, Le A. The Heterogeneity of Lipid Metabolism in Cancer. Adv Exp Med Biol 2021;1311:39-56. [PMID: 34014533 DOI: 10.1007/978-3-030-65768-0_3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 2] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 212 |
Wang X, Kim C, Zhang Y, Rindhe S, Cobb MH, Yu Y. Quantitative Tyr Phosphoproteomic Analyses Identify Cholesterol as a Master Regulator of the Tumor Adaptive Resistance to MAPK Inhibition.. [DOI: 10.1101/2021.05.20.444617] [Reference Citation Analysis]
|
| 213 |
Tsuji G, Takai-Yumine A, Kato T, Furue M. Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine. Cell Death Dis 2021;12:513. [PMID: 34011935 DOI: 10.1038/s41419-021-03802-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 214 |
Henley MJ, Koehler AN. Advances in targeting 'undruggable' transcription factors with small molecules. Nat Rev Drug Discov 2021;20:669-88. [PMID: 34006959 DOI: 10.1038/s41573-021-00199-0] [Cited by in Crossref: 50] [Cited by in F6Publishing: 55] [Article Influence: 25.0] [Reference Citation Analysis]
|
| 215 |
Tayama H, Karasawa H, Yamamura A, Okamura Y, Katsuoka F, Suzuki H, Kajiwara T, Kobayashi M, Hatsuzawa Y, Shiihara M, Bin L, Gazi MY, Sato M, Kumada K, Ito S, Shimada M, Furukawa T, Kamei T, Ohnuma S, Unno M. The association between ERK inhibitor sensitivity and molecular characteristics in colorectal cancer. Biochem Biophys Res Commun 2021;560:59-65. [PMID: 33989908 DOI: 10.1016/j.bbrc.2021.04.130] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 216 |
Marca JEL, Somers WG. The Drosophila gonads: models for stem cell proliferation, self-renewal, and differentiation. AIMS Genetics 2021;01:055-80. [DOI: 10.3934/genet.2014.1.55] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 217 |
Lelliott EJ, McArthur GA, Oliaro J, Sheppard KE. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma. Front Immunol 2021;12:661737. [PMID: 34025662 DOI: 10.3389/fimmu.2021.661737] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 218 |
Belakhoua SM, Rodriguez FJ. Diagnostic Pathology of Tumors of Peripheral Nerve. Neurosurgery 2021;88:443-56. [PMID: 33588442 DOI: 10.1093/neuros/nyab021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 219 |
Fang S, Peng W, Xiong Y, Nie X, Huang J. Crystal structure of 3-(2-chloro-benzyl)-7-[4-(2-chloro-benzyl)-piperazin-1-yl]-5,6,8-trifluoro-3 H -quinazolin-4-one, C 26 H 21 Cl 2 F 3 N 4 O. Zeitschrift für Kristallographie - New Crystal Structures 2021;236:815-7. [DOI: 10.1515/ncrs-2021-0085] [Reference Citation Analysis]
|
| 220 |
Fernández-Medarde A, De Las Rivas J, Santos E. 40 Years of RAS-A Historic Overview. Genes (Basel) 2021;12:681. [PMID: 34062774 DOI: 10.3390/genes12050681] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 221 |
Hong SH, Yoo DY, Conway L, Richards-Corke KC, Parker CG, Arora PS. A Sos proteomimetic as a pan-Ras inhibitor. Proc Natl Acad Sci U S A 2021;118:e2101027118. [PMID: 33926964 DOI: 10.1073/pnas.2101027118] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 222 |
Jurado M, Castaño Ó, Zorzano A. Stochastic modulation evidences a transitory EGF-Ras-ERK MAPK activity induced by PRMT5. Comput Biol Med 2021;133:104339. [PMID: 33910125 DOI: 10.1016/j.compbiomed.2021.104339] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 223 |
Ahmed A, Naidu A. Towards better understanding of giant cell granulomas of the oral cavity. J Clin Pathol 2021;74:483-90. [PMID: 33858937 DOI: 10.1136/jclinpath-2020-206858] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 224 |
Wen L, Zhang G, Ren C, Li X, Mok H, Jia M, Wang Y, Chen B, Li K, Cao L, Li C, Xiao W, Lai J, Lin J, Wei G, Li Y, Zhang Y, Chen X, Liao N. Characterization of AKT Somatic Mutations in Chinese Breast Cancer Patients. Cancer Manag Res 2021;13:3055-65. [PMID: 33854375 DOI: 10.2147/CMAR.S299624] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 225 |
Chaudhary S, Singh A, Kumar P, Kaushik M. Strategic targeting of non-small-cell lung cancer utilizing genetic material-based delivery platforms of nanotechnology. J Biochem Mol Toxicol 2021;35:e22784. [PMID: 33826765 DOI: 10.1002/jbt.22784] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 226 |
East P, Kelly GP, Biswas D, Marani M, Hancock DC, Creasy T, Sachsenmeier K, Swanton C, de Carné Trécesson S, Downward J. Oncogenic RAS activity predicts response to chemotherapy and outcome in lung adenocarcinoma.. [DOI: 10.1101/2021.04.02.437896] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 227 |
Javadrashid D, Baghbanzadeh A, Derakhshani A, Leone P, Silvestris N, Racanelli V, Solimando AG, Baradaran B. Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment. Biomedicines 2021;9:373. [PMID: 33918146 DOI: 10.3390/biomedicines9040373] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 228 |
Beckers P, Berzenji L, Yogeswaran SK, Lauwers P, Bilotta G, Shkarpa N, Hendriks J, Van Schil PE. Pulmonary metastasectomy in colorectal carcinoma. J Thorac Dis 2021;13:2628-35. [PMID: 34012611 DOI: 10.21037/jtd-2019-pm-14] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 229 |
John L, Krauth MT, Podar K, Raab MS. Pathway-Directed Therapy in Multiple Myeloma. Cancers (Basel) 2021;13:1668. [PMID: 33916289 DOI: 10.3390/cancers13071668] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 230 |
Pedreira-García WM, Pérez-Morales J, Chardón-Colón C, Cabán-Rivera J, Santiago-Cardona PG. Immunoblot Validation of Phospho-Specific Antibodies Using Lung Cancer Cell Lines. Methods Mol Biol 2021;2279:75-90. [PMID: 33683687 DOI: 10.1007/978-1-0716-1278-1_7] [Reference Citation Analysis]
|
| 231 |
Wu L, Wen Y, Yang X, Yan B, He S, Bo X. Synthetic Lethal Interactions Prediction Based on Multiple Similarity Measures Fusion. J Comput Sci Technol 2021;36:261-75. [DOI: 10.1007/s11390-021-0866-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 232 |
Muscarella P, Bekaii-Saab T, McIntyre K, Rosemurgy A, Ross SB, Richards DA, Fisher WE, Flynn PJ, Mattson A, Coeshott C, Roder H, Roder J, Harrell FE, Cohn A, Rodell TC, Apelian D. A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer. J Pancreat Cancer 2021;7:8-19. [PMID: 33786412 DOI: 10.1089/pancan.2020.0021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 233 |
Moghadamchargari Z, Shirzadeh M, Liu C, Schrecke S, Packianathan C, Russell DH, Zhao M, Laganowsky A. Molecular assemblies of the catalytic domain of SOS with KRas and oncogenic mutants. Proc Natl Acad Sci U S A 2021;118:e2022403118. [PMID: 33723061 DOI: 10.1073/pnas.2022403118] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 234 |
Chen J, Zhang S, Wang W, Pang L, Zhang Q, Liu X. Mutation-Induced Impacts on the Switch Transformations of the GDP- and GTP-Bound K-Ras: Insights from Multiple Replica Gaussian Accelerated Molecular Dynamics and Free Energy Analysis. J Chem Inf Model 2021;61:1954-69. [PMID: 33739090 DOI: 10.1021/acs.jcim.0c01470] [Cited by in Crossref: 33] [Cited by in F6Publishing: 41] [Article Influence: 16.5] [Reference Citation Analysis]
|
| 235 |
Zhang Q, Cheng S, Cao L, Yang J, Wang Y, Chen Y. LINC00978 promotes hepatocellular carcinoma carcinogenesis partly via activating the MAPK/ERK pathway. Biosci Rep 2020;40:BSR20192790. [PMID: 32077915 DOI: 10.1042/BSR20192790] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 236 |
Zhou Y, Hill C, Yao L, Li J, Hancock D, Downward J, Jones MG, Davies DE, Ewing RM, Skipp P, Wang Y. Quantitative Proteomic Analysis in Alveolar Type II Cells Reveals the Different Capacities of RAS and TGF-β to Induce Epithelial-Mesenchymal Transition. Front Mol Biosci 2021;8:595712. [PMID: 33869273 DOI: 10.3389/fmolb.2021.595712] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 237 |
du Plessis M, Davis T, Loos B, Pretorius E, de Villiers WJS, Engelbrecht AM. Molecular regulation of autophagy in a pro-inflammatory tumour microenvironment: New insight into the role of serum amyloid A. Cytokine Growth Factor Rev 2021;59:71-83. [PMID: 33727011 DOI: 10.1016/j.cytogfr.2021.01.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 238 |
Hammers MD, Hodny MH, Bader TK, Mahmoodi MM, Fang S, Fenton AD, Nurie K, Trial HO, Xu F, Healy AT, Ball ZT, Blank DA, Distefano MD. Two-photon uncaging of bioactive thiols in live cells at wavelengths above 800 nm. Org Biomol Chem 2021;19:2213-23. [PMID: 33349821 DOI: 10.1039/d0ob01986k] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 239 |
Bellier J, Nokin MJ, Caprasse M, Tiamiou A, Blomme A, Scheijen JL, Koopmansch B, MacKay GM, Chiavarina B, Costanza B, Rademaker G, Durieux F, Agirman F, Maloujahmoum N, Cusumano PG, Lovinfosse P, Leung HY, Lambert F, Bours V, Schalkwijk CG, Hustinx R, Peulen O, Castronovo V, Bellahcène A. Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab. Cell Rep 2020;30:1400-1416.e6. [PMID: 32023458 DOI: 10.1016/j.celrep.2020.01.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 240 |
Wang P, van der Hoeven D, Ye N, Chen H, Liu Z, Ma X, Montufar-Solis D, Rehl KM, Cho KJ, Thapa S, Chen W, van der Hoeven R, Frost JA, Hancock JF, Zhou J. Scaffold repurposing of fendiline: Identification of potent KRAS plasma membrane localization inhibitors. Eur J Med Chem 2021;217:113381. [PMID: 33756124 DOI: 10.1016/j.ejmech.2021.113381] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 241 |
Sakai H, Shiina I, Shinomiya T, Nagahara Y. BRAP2 inhibits the Ras/Raf/MEK and PI3K/Akt pathways in leukemia cells, thereby inducing apoptosis and inhibiting cell growth. Exp Ther Med 2021;21:463. [PMID: 33747195 DOI: 10.3892/etm.2021.9894] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 242 |
Patel M, Eckburg A, Gantiwala S, Hart Z, Dein J, Lam K, Puri N. Resistance to Molecularly Targeted Therapies in Melanoma. Cancers (Basel) 2021;13:1115. [PMID: 33807778 DOI: 10.3390/cancers13051115] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 243 |
Wang C, Fang H, Zhang J, Gu Y. Targeting "undruggable" c-Myc protein by synthetic lethality. Front Med 2021;15:541-50. [PMID: 33660217 DOI: 10.1007/s11684-020-0780-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 244 |
Bielski CM, Taylor BS. Mutant Allele Imbalance in Cancer. Annu Rev Cancer Biol 2021;5:221-234. [DOI: 10.1146/annurev-cancerbio-051320-124252] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 245 |
Veluswamy R, Mack PC, Houldsworth J, Elkhouly E, Hirsch FR. KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing. J Mol Diagn 2021;23:507-20. [PMID: 33618059 DOI: 10.1016/j.jmoldx.2021.02.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 246 |
Kattan WE, Hancock JF. RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics. Biochem J 2020;477:2893-919. [PMID: 32797215 DOI: 10.1042/BCJ20190839] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 247 |
Fouad S, Hauton D, D'Angiolella V. E2F1: Cause and Consequence of DNA Replication Stress. Front Mol Biosci 2020;7:599332. [PMID: 33665206 DOI: 10.3389/fmolb.2020.599332] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 248 |
Wang C, Fakih M. Targeting KRAS in Colorectal Cancer. Curr Oncol Rep 2021;23:28. [PMID: 33582927 DOI: 10.1007/s11912-021-01022-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 249 |
Malapelle U, Passiglia F, Cremolini C, Reale ML, Pepe F, Pisapia P, Avallone A, Cortinovis D, De Stefano A, Fassan M, Fontanini G, Galetta D, Lauricella C, Listì A, Loupakis F, Pagni F, Pietrantonio F, Pilotto S, Righi L, Bianchi AS, Parra HS, Tiseo M, Verzè M, Troncone G, Novello S. RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. Eur J Cancer 2021;146:74-83. [PMID: 33588147 DOI: 10.1016/j.ejca.2021.01.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 250 |
Wang Y, Ji D, Lei C, Chen Y, Qiu Y, Li X, Li M, Ni D, Pu J, Zhang J, Fu Q, Liu Y, Lu S. Mechanistic insights into the effect of phosphorylation on Ras conformational dynamics and its interactions with cell signaling proteins. Comput Struct Biotechnol J 2021;19:1184-99. [PMID: 33680360 DOI: 10.1016/j.csbj.2021.01.044] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 251 |
Yildiz A, Kaya Y. Post-Translational Regulation of the Activity of ERK/MAPK and PI3K/AKT Signaling Pathways in Neuroblastoma Cancer. Post-Translational Modifications in Cellular Functions and Diseases [Working Title] 2021. [DOI: 10.5772/intechopen.96176] [Reference Citation Analysis]
|
| 252 |
Lee CI, Liao CB, Chen CS, Cheng FY, Chung YH, Wang YC, Ciou SY, Hsueh WY, Lo TH, Huang GR, Huang HY, Tsai CS, Lu YJ, Chuang SH, Huang JJ. Design and synthesis of 4-anilinoquinazolines as Raf kinase inhibitors. Part 1. Selective B-Raf/B-RafV600E and potent EGFR/VEGFR2 inhibitory 4-(3-hydroxyanilino)-6-(1H-1,2,3-triazol-4-yl)quinazolines. Bioorg Chem 2021;109:104715. [PMID: 33647741 DOI: 10.1016/j.bioorg.2021.104715] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 253 |
Aydin E, Faehling S, Saleh M, Llaó Cid L, Seiffert M, Roessner PM. Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors? Front Immunol 2020;11:595818. [PMID: 33552053 DOI: 10.3389/fimmu.2020.595818] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 254 |
Tanaka T, Thomas J, Van Montfort R, Miller A, Rabbitts T. Pan RAS-binding compounds selected from a chemical library by inhibiting interaction between RAS and a reduced affinity intracellular antibody. Sci Rep 2021;11:1712. [PMID: 33462327 DOI: 10.1038/s41598-021-81262-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 255 |
Chen J, Wang W, Pang L, Zhu W. Unveiling conformational dynamics changes of H-Ras induced by mutations based on accelerated molecular dynamics. Phys Chem Chem Phys 2020;22:21238-50. [PMID: 32930679 DOI: 10.1039/d0cp03766d] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 256 |
Luo X, Peng S, Ding S, Zeng Q, Wang R, Ma Y, Chen S, Wang Y, Wang W. Prognostic values, ceRNA network, and immune regulation function of SDPR in KRAS-mutant lung cancer. Cancer Cell Int 2021;21:49. [PMID: 33435990 DOI: 10.1186/s12935-021-01756-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 257 |
Yan L, Tu B, Yao J, Gong J, Carugo A, Bristow CA, Wang Q, Zhu C, Dai B, Kang Y, Han L, Feng N, Jin Y, Fleming J, Heffernan TP, Yao W, Ying H. Targeting glucose metabolism sensitizes pancreatic cancer to MEK inhibition.. [DOI: 10.1101/2021.01.09.425923] [Reference Citation Analysis]
|
| 258 |
Han J, Liu Y, Yang S, Wu X, Li H, Wang Q. MEK inhibitors for the treatment of non-small cell lung cancer. J Hematol Oncol 2021;14:1. [PMID: 33402199 DOI: 10.1186/s13045-020-01025-7] [Cited by in Crossref: 52] [Cited by in F6Publishing: 61] [Article Influence: 26.0] [Reference Citation Analysis]
|
| 259 |
Bhalerao U, Bhalerao A, Bhalerao S, Srivastava M, Singh M, Lavuri ST, Barman MK, Burada AP, Sonkar SC, Bhukya PL. Diagnosis of Colorectal Cancer Using Molecular Techniques. Colon Cancer Diagnosis and Therapy 2021. [DOI: 10.1007/978-3-030-64668-4_7] [Reference Citation Analysis]
|
| 260 |
Donninger H, Harrell-stewart D, Clark GJ. Detection of Endogenous RASSF1A Interacting Proteins. Methods in Molecular Biology 2021. [DOI: 10.1007/978-1-0716-1190-6_18] [Reference Citation Analysis]
|
| 261 |
Tomiyama A. Understanding signal transduction pathways to overcome targeted therapy resistance in glioblastoma. Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies 2021. [DOI: 10.1016/b978-0-12-821567-8.00015-4] [Reference Citation Analysis]
|
| 262 |
Zhang J, Jiang X, Yin J, Dou S, Xie X, Liu T, Wang Y, Wang S, Zhou X, Zhang D, Jiang H. RNF141 interacts with KRAS to promote colorectal cancer progression. Oncogene 2021;40:5829-42. [PMID: 34345014 DOI: 10.1038/s41388-021-01877-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 263 |
Yang X, Jones K, Chen G. Pathology of Pancreatic Ductal Adenocarcinoma. Hepato-Pancreato-Biliary Malignancies 2021. [DOI: 10.1007/978-3-030-37482-2_30-1] [Reference Citation Analysis]
|
| 264 |
Zhou Y, Hancock JF. Super-Resolution Imaging and Spatial Analysis of RAS on Intact Plasma Membrane Sheets. Methods Mol Biol 2021;2262:217-32. [PMID: 33977479 DOI: 10.1007/978-1-0716-1190-6_12] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 265 |
Khan MS, Mudassar S. Thyroid Cancer and SNPs. Genetic Polymorphism and cancer susceptibility 2021. [DOI: 10.1007/978-981-33-6699-2_8] [Reference Citation Analysis]
|
| 266 |
Literatur. ELSEVIER ESSENTIALS Onkologie 2021. [DOI: 10.1016/b978-3-437-21432-5.00020-0] [Reference Citation Analysis]
|
| 267 |
Zambetti NA, Firestone AJ, Remsberg JR, Huang BJ, Wong JC, Long AM, Predovic M, Suciu RM, Inguva A, Kogan SC, Haigis KM, Cravatt BF, Shannon K. Genetic disruption of N-RasG12D palmitoylation perturbs hematopoiesis and prevents myeloid transformation in mice. Blood 2020;135:1772-82. [PMID: 32219446 DOI: 10.1182/blood.2019003530] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 268 |
Tran TM, Philipp J, Bassi J, Nibber N, Draper J, Lin T, Palanichamy JK, Jaiswal AK, Silva O, Paing M, King J, Katzman S, Sanford JR, Rao DS. Post-transcriptional gene regulation by the RNA binding protein IGF2BP3 is critical for MLL-AF4 mediated leukemogenesis.. [DOI: 10.1101/2020.12.20.423624] [Reference Citation Analysis]
|
| 269 |
Kun E, Tsang YTM, Ng CW, Gershenson DM, Wong KK. MEK inhibitor resistance mechanisms and recent developments in combination trials. Cancer Treat Rev 2021;92:102137. [PMID: 33340965 DOI: 10.1016/j.ctrv.2020.102137] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 12.7] [Reference Citation Analysis]
|
| 270 |
Day EK, Campbell A, Pandolf A, Rogerson T, Zhong Q, Xiao A, Purow B, Lazzara MJ. ERK-dependent suicide gene therapy for selective targeting of RTK/RAS-driven cancers. Mol Ther 2021;29:1585-601. [PMID: 33333291 DOI: 10.1016/j.ymthe.2020.12.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 271 |
Stubbs CK, Biancucci M, Vidimar V, Satchell KJF. RAS specific protease Induces Irreversible Growth Arrest via p27 in several KRAS Mutant Colorectal Cancer cell lines.. [DOI: 10.1101/2020.12.08.416578] [Reference Citation Analysis]
|
| 272 |
De Vita E. 10 years into the resurgence of covalent drugs. Future Med Chem 2021;13:193-210. [PMID: 33275063 DOI: 10.4155/fmc-2020-0236] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 273 |
Kobayashi T, Miyazaki M, Sasaki N, Yamamuro S, Uchida E, Kawauchi D, Takahashi M, Otsuka Y, Kumagai K, Takeuchi S, Toyooka T, Otani N, Wada K, Narita Y, Yamaguchi H, Muragaki Y, Kawamata T, Mori K, Ichimura K, Tomiyama A. Enhanced Malignant Phenotypes of Glioblastoma Cells Surviving NPe6-Mediated Photodynamic Therapy are Regulated via ERK1/2 Activation. Cancers (Basel) 2020;12:E3641. [PMID: 33291680 DOI: 10.3390/cancers12123641] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 274 |
Sarwar A, Wang B, Su Q, Zhang Y. MiRNAs directly targeting the key intermediates of biological pathways in pancreatic cancer. Biochem Pharmacol 2021;189:114357. [PMID: 33279497 DOI: 10.1016/j.bcp.2020.114357] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 275 |
Gemma C, Singh AK, Belfiore A, Lai C, Periyasamy M, Abuelmaaty S, Davies CM, Wang X, Simmons GM, Nguyen VTM, Magnani L, Rakha E, Martin L, Coombes RC, Pruneri G, Buluwela L, Ali S. VGLL1-directed TEAD activation drives endocrine therapy resistance in estrogen receptor positive breast cancer.. [DOI: 10.1101/2020.11.29.402842] [Reference Citation Analysis]
|
| 276 |
Cui J, Shen HM, Lim LHK. The Role of Autophagy in Liver Cancer: Crosstalk in Signaling Pathways and Potential Therapeutic Targets. Pharmaceuticals (Basel) 2020;13:E432. [PMID: 33260729 DOI: 10.3390/ph13120432] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 277 |
Ratti S, Lonetti A, Follo MY, Paganelli F, Martelli AM, Chiarini F, Evangelisti C. B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients? Cancers (Basel) 2020;12:E3498. [PMID: 33255367 DOI: 10.3390/cancers12123498] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 278 |
Scheiblecker L, Kollmann K, Sexl V. CDK4/6 and MAPK-Crosstalk as Opportunity for Cancer Treatment. Pharmaceuticals (Basel) 2020;13:E418. [PMID: 33255177 DOI: 10.3390/ph13120418] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 279 |
Chen H, Smaill JB, Liu T, Ding K, Lu X. Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics. J Med Chem 2020;63:14404-24. [PMID: 33225706 DOI: 10.1021/acs.jmedchem.0c01312] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 8.7] [Reference Citation Analysis]
|
| 280 |
Hurd CA, Brear P, Revell J, Ross S, Mott HR, Owen D. Affinity maturation of the RLIP76 Ral binding domain to inform the design of stapled peptides targeting the Ral GTPases. J Biol Chem 2021;296:100101. [PMID: 33214225 DOI: 10.1074/jbc.RA120.015735] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 281 |
Clerici S, Boletta A. Role of the KEAP1-NRF2 Axis in Renal Cell Carcinoma. Cancers (Basel) 2020;12:E3458. [PMID: 33233657 DOI: 10.3390/cancers12113458] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 282 |
Maeda S, Yoshitake R, Chambers JK, Uchida K, Eto S, Ikeda N, Nakagawa T, Nishimura R, Goto-Koshino Y, Yonezawa T, Momoi Y. BRAFV595E Mutation Associates CCL17 Expression and Regulatory T Cell Recruitment in Urothelial Carcinoma of Dogs. Vet Pathol 2021;58:971-80. [PMID: 33205710 DOI: 10.1177/0300985820967449] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 283 |
Kawauchi K, Urano R, Kinoshita N, Kuwamoto S, Torii T, Hashimoto Y, Taniguchi S, Tsuruta M, Miyoshi D. Photosensitizers Based on G-Quadruplex Ligand for Cancer Photodynamic Therapy. Genes (Basel) 2020;11:E1340. [PMID: 33198362 DOI: 10.3390/genes11111340] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 284 |
Mund JA, Park S, Smith AE, He Y, Jiang L, Hawley E, Roberson MJ, Mitchell DK, Abu-Sultanah M, Yuan J, Bessler WK, Sandusky G, Chen S, Zhang C, Rhodes SD, Clapp DW. Genetic disruption of the small GTPase RAC1 prevents plexiform neurofibroma formation in mice with neurofibromatosis type 17. J Biol Chem 2020;295:9948-58. [PMID: 33685622 DOI: 10.1074/jbc.RA119.010981] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 285 |
Béganton B, Coyaud E, Laurent EMN, Mangé A, Jacquemetton J, Le Romancer M, Raught B, Solassol J. Proximal Protein Interaction Landscape of RAS Paralogs. Cancers (Basel) 2020;12:E3326. [PMID: 33187149 DOI: 10.3390/cancers12113326] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 286 |
Zamame Ramirez JA, Romagnoli GG, Kaneno R. Inhibiting autophagy to prevent drug resistance and improve anti-tumor therapy. Life Sci 2021;265:118745. [PMID: 33186569 DOI: 10.1016/j.lfs.2020.118745] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 287 |
Mai Y, Peng S, Li H, Gao Y, Lai Z. NOD-like receptor signaling pathway activation: A potential mechanism underlying negative effects of benzo(α)pyrene on zebrafish. Comp Biochem Physiol C Toxicol Pharmacol 2021;240:108935. [PMID: 33161151 DOI: 10.1016/j.cbpc.2020.108935] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 288 |
McDonald AF, Goh YW, White JM, Scott AM, Ackermann U. Automated synthesis of 18F radiolabelled indole containing Oncrasin-like molecules; a comparison of iodonium salts and boronic ester chemistry. EJNMMI Radiopharm Chem 2020;5:23. [PMID: 33169204 DOI: 10.1186/s41181-020-00104-x] [Reference Citation Analysis]
|
| 289 |
Klimpel A, Stillger K, Wiederstein JL, Krüger M, Neundorf I. Cell-permeable CaaX-peptides affect K-Ras downstream signaling and promote cell death in cancer cells. FEBS J 2021;288:2911-29. [PMID: 33112492 DOI: 10.1111/febs.15612] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 290 |
Martín-Acosta P, Xiao X. PROTACs to address the challenges facing small molecule inhibitors. Eur J Med Chem 2021;210:112993. [PMID: 33189436 DOI: 10.1016/j.ejmech.2020.112993] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 291 |
Hao P, Yu J, Ward R, Liu Y, Hao Q, An S, Xu T. Eukaryotic translation initiation factors as promising targets in cancer therapy. Cell Commun Signal 2020;18:175. [PMID: 33148274 DOI: 10.1186/s12964-020-00607-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 292 |
Tran KB, Buchanan CM, Shepherd PR. Evolution of Molecular Targets in Melanoma Treatment. Curr Pharm Des 2020;26:396-414. [PMID: 32000640 DOI: 10.2174/1381612826666200130091318] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 293 |
Iaccarino A, Pisapia P, De Felice M, Pepe F, Gragnano G, De Luca C, Ianniello G, Malapelle U. Concomitant Rare KRAS and BRAF Mutations in Lung Adenocarcinoma: A Case Report. JMP 2020;1:36-42. [DOI: 10.3390/jmp1010006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 294 |
Ou-yang L, Zhang X, Yan H. Sparse regularized low-rank tensor regression with applications in genomic data analysis. Pattern Recognition 2020;107:107516. [DOI: 10.1016/j.patcog.2020.107516] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 295 |
Raufi AG, Wong W, Chen K, Iuga A, Ahmed F, Manji GA. Sustained Partial Response to Inhibition of the Mitogen-Activated Protein Kinase and Autophagy Pathways in Combination With Immune Checkpoint Blockade in KRAS-Mutated Adenocarcinoma of the Small Bowel. JCO Precision Oncology 2020. [DOI: 10.1200/po.20.00134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 296 |
Keino D, Yokosuka T, Hirose A, Sakurai Y, Nakamura W, Fujita S, Hayashi A, Miyagawa N, Iwasaki F, Hamanoue S, Yanagimachi M, Shiomi M, Goto S, Kitagawa N, Tanaka M, Nozawa K, Tanaka Y, Goto H. Pilot study of the combination of sorafenib and fractionated irinotecan in pediatric relapse/refractory hepatic cancer (FINEX pilot study). Pediatr Blood Cancer 2020;67:e28655. [PMID: 32798298 DOI: 10.1002/pbc.28655] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 297 |
Zhao J, Sun H, Wang W, Zhang L, Chen J. Theoretical insights into mutation-mediated conformational changes of the GNP-bound H-RAS. Chemical Physics Letters 2020;759:138042. [DOI: 10.1016/j.cplett.2020.138042] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 298 |
Müller L, Berkeley R, Barr T, Ilett E, Errington-Mais F. Past, Present and Future of Oncolytic Reovirus. Cancers (Basel) 2020;12:E3219. [PMID: 33142841 DOI: 10.3390/cancers12113219] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 11.3] [Reference Citation Analysis]
|
| 299 |
Jang HJ, Lee A, Kang J, Song IH, Lee SH. Prediction of clinically actionable genetic alterations from colorectal cancer histopathology images using deep learning. World J Gastroenterol 2020; 26(40): 6207-6223 [PMID: 33177794 DOI: 10.3748/wjg.v26.i40.6207] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 300 |
Zhang Q, Du X, He Q, Shi W, Mei L, Qv M, Tan D, Wu J, Zeng LH, Wu X. T851I mutation of human large tumor suppressor 1 disrupts its kinase activity and tumor-suppressor functions. Life Sci 2021;264:118655. [PMID: 33141042 DOI: 10.1016/j.lfs.2020.118655] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 301 |
Martin J, Petrillo A, Smyth EC, Shaida N, Khwaja S, Cheow H, Duckworth A, Heister P, Praseedom R, Jah A, Balakrishnan A, Harper S, Liau S, Kosmoliaptsis V, Huguet E. Colorectal liver metastases: Current management and future perspectives. World J Clin Oncol 2020; 11(10): 761-808 [PMID: 33200074 DOI: 10.5306/wjco.v11.i10.761] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 37] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 302 |
Wang J, Tan S, Yan PP, Xiao X, Zhang H, Zhang SQ, Li W, Cao YX, Wang HY. Irreversible epidermal growth factor receptor inhibitor Z25h exhibits pronounced inhibition on non-small cell lung adenocarcinoma cell line Hcc827. Anticancer Drugs 2021;32:417-26. [PMID: 33079732 DOI: 10.1097/CAD.0000000000001012] [Reference Citation Analysis]
|
| 303 |
Sharma N, Sonavane U, Joshi R. Comparative MD simulations and advanced analytics based studies on wild-type and hot-spot mutant A59G HRas. PLoS One 2020;15:e0234836. [PMID: 33064725 DOI: 10.1371/journal.pone.0234836] [Reference Citation Analysis]
|
| 304 |
Kim D, Xue JY, Lito P. Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients. Cell 2020;183:850-9. [PMID: 33065029 DOI: 10.1016/j.cell.2020.09.044] [Cited by in Crossref: 68] [Cited by in F6Publishing: 76] [Article Influence: 22.7] [Reference Citation Analysis]
|
| 305 |
Todenhöfer T, Lodde M, van Kessel K, Pichler R, Vlahou A, Lotan Y. Urinary-Based Markers for Bladder Cancer Detection. Société Internationale d’Urologie Journal 2020;1:49-61. [DOI: 10.48083/kqgp2151] [Reference Citation Analysis]
|
| 306 |
Krisnawan VE, Stanley JA, Schwarz JK, DeNardo DG. Tumor Microenvironment as a Regulator of Radiation Therapy: New Insights into Stromal-Mediated Radioresistance. Cancers (Basel) 2020;12:E2916. [PMID: 33050580 DOI: 10.3390/cancers12102916] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 307 |
Katoch A, Jamwal VL, Faheem MM, Kumar S, Senapati S, Yadav G, Gandhi SG, Goswami A. Overlapping targets exist between the Par-4 and miR-200c axis which regulate EMT and proliferation of pancreatic cancer cells. Transl Oncol 2021;14:100879. [PMID: 33045679 DOI: 10.1016/j.tranon.2020.100879] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 308 |
Méndez-Martínez S, Calvo P, Ruiz-Moreno O, Pardiñas Barón N, Leciñena Bueno J, Gil Ruiz MDR, Pablo L. OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS. Retina 2019;39:1435-50. [PMID: 30681641 DOI: 10.1097/IAE.0000000000002451] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 309 |
Dai C, Shen L, Jin W, Lv B, Liu P, Wang X, Yin Y, Fu Y, Liang L, Ma Z, Zhang X, Wang Y, Xu D, Chen Z. Physapubescin B enhances the sensitivity of gastric cancer cells to trametinib by inhibiting the STAT3 signaling pathway. Toxicol Appl Pharmacol 2020;408:115273. [PMID: 33035574 DOI: 10.1016/j.taap.2020.115273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 310 |
Lv T, Lv H, Fei J, Xie Y, Lian D, Hu J, Tang L, Shi X, Wang J, Zhang S, Li F, Jiang X, Yi Y. p53-R273H promotes cancer cell migration via upregulation of neuraminidase-1. J Cancer 2020;11:6874-82. [PMID: 33123278 DOI: 10.7150/jca.44718] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 311 |
Rackley B, Seong C, Kiely E, Parker RE, Rupji M, Dwivedi B, Heddleston JM, Giang W, Anthony N, Chew T, Gilbert-ross M. The level of oncogenic Ras controls the malignant transformation of Lkb1 mutant tissue in vivo.. [DOI: 10.1101/2020.09.25.308080] [Reference Citation Analysis]
|
| 312 |
Hoang T, Kim J. Combining Correlated Outcomes and Surrogate Endpoints in a Network Meta-Analysis of Colorectal Cancer Treatments. Cancers (Basel) 2020;12:E2663. [PMID: 32961943 DOI: 10.3390/cancers12092663] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 313 |
Libertini M, Oneda E, Di Biasi B, Savelli G, Zaniboni A. Cutaneous Adnexal Carcinoma with Apocrine Differentiation: A Challenging Diagnosis and Personalized Treatment with mTOR Inhibitor in a Very Rare Disease. Case Rep Oncol 2020;13:1091-6. [PMID: 33082753 DOI: 10.1159/000510097] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 314 |
Vaidya GN, Rana P, Venkatesh A, Chatterjee DR, Contractor D, Satpute DP, Nagpure M, Jain A, Kumar D. Paradigm shift of "classical" HDAC inhibitors to "hybrid" HDAC inhibitors in therapeutic interventions. Eur J Med Chem 2021;209:112844. [PMID: 33143937 DOI: 10.1016/j.ejmech.2020.112844] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 315 |
Meng B, Folaron MR, Strawbridge RR, Sadeghipour N, Samkoe KS, Tichauer K, Davis SC. Noninvasive quantification of target availability during therapy using paired-agent fluorescence tomography. Theranostics 2020;10:11230-43. [PMID: 33042280 DOI: 10.7150/thno.45273] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 316 |
Sirait-Fischer E, Olesch C, Fink AF, Berkefeld M, Huard A, Schmid T, Takeda K, Brüne B, Weigert A. Immune Checkpoint Blockade Improves Chemotherapy in the PyMT Mammary Carcinoma Mouse Model. Front Oncol 2020;10:1771. [PMID: 33014872 DOI: 10.3389/fonc.2020.01771] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 317 |
Na Y, Huang G, Wu J. The Role of RUNX1 in NF1-Related Tumors and Blood Disorders. Mol Cells 2020;43:153-9. [PMID: 31940719 DOI: 10.14348/molcells.2019.0295] [Reference Citation Analysis]
|
| 318 |
Shi H, Zhao J, Han L, Xu M, Wang K, Shi J, Dong Z. Retrospective study of gene signatures and prognostic value of m6A regulatory factor in non-small cell lung cancer using TCGA database and the verification of FTO. Aging (Albany NY) 2020;12:17022-37. [PMID: 32903217 DOI: 10.18632/aging.103622] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 319 |
Ayaz Z, Zainab B, Khan S, Abbasi AM, Elshikh MS, Munir A, Al-Ghamdi AA, Alajmi AH, Alsubaie QD, Mustafa AEMA. In silico authentication of amygdalin as a potent anticancer compound in the bitter kernels of family Rosaceae. Saudi J Biol Sci 2020;27:2444-51. [PMID: 32884428 DOI: 10.1016/j.sjbs.2020.06.041] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 320 |
Molina-Arcas M, Moore C, Rana S, van Maldegem F, Mugarza E, Romero-Clavijo P, Herbert E, Horswell S, Li LS, Janes MR, Hancock DC, Downward J. Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer. Sci Transl Med 2019;11:eaaw7999. [PMID: 31534020 DOI: 10.1126/scitranslmed.aaw7999] [Cited by in Crossref: 98] [Cited by in F6Publishing: 102] [Article Influence: 32.7] [Reference Citation Analysis]
|
| 321 |
Gupta GK, Collier AL, Lee D, Hoefer RA, Zheleva V, Siewertsz van Reesema LL, Tang-Tan AM, Guye ML, Chang DZ, Winston JS, Samli B, Jansen RJ, Petricoin EF, Goetz MP, Bear HD, Tang AH. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. Cancers (Basel) 2020;12:E2392. [PMID: 32846967 DOI: 10.3390/cancers12092392] [Cited by in Crossref: 86] [Cited by in F6Publishing: 87] [Article Influence: 28.7] [Reference Citation Analysis]
|
| 322 |
Hadden M, Mittal A, Samra J, Zreiqat H, Sahni S, Ramaswamy Y. Mechanically stressed cancer microenvironment: Role in pancreatic cancer progression.BiochimBiophysActa Rev Cancer. 2020;1874:188418. [PMID: 32827581 DOI: 10.1016/j.bbcan.2020.188418] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 323 |
Yuan J, Dong X, Yap J, Hu J. The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. J Hematol Oncol. 2020;13:113. [PMID: 32807225 DOI: 10.1186/s13045-020-00949-4] [Cited by in Crossref: 90] [Cited by in F6Publishing: 103] [Article Influence: 30.0] [Reference Citation Analysis]
|
| 324 |
Hussain J, Chhabria D, Kirubakaran S. Design, synthesis and biological evaluation of new Myo-inositol derivatives as potential RAS inhibitors. Bioorg Med Chem Lett 2020;30:127290. [PMID: 32631512 DOI: 10.1016/j.bmcl.2020.127290] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 325 |
Wang X, Xie Q, Ji Y, Shen J, Zhang Y, Jiang F, Kong X, Liu D, Zheng L, Qing C, Lang J. Targeting KRAS-mutant stomach/colorectal tumours by disrupting the ERK2-p53 complex.. [DOI: 10.1101/2020.08.12.247460] [Reference Citation Analysis]
|
| 326 |
Xu T, Sun D, Chen Y, Ouyang L. Targeting mTOR for fighting diseases: A revisited review of mTOR inhibitors. European Journal of Medicinal Chemistry 2020;199:112391. [DOI: 10.1016/j.ejmech.2020.112391] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 327 |
Passiglia F, Malapelle U, Del Re M, Righi L, Pagni F, Furlan D, Danesi R, Troncone G, Novello S. KRAS inhibition in non-small cell lung cancer: Past failures, new findings and upcoming challenges. Eur J Cancer 2020;137:57-68. [PMID: 32745965 DOI: 10.1016/j.ejca.2020.06.023] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 328 |
Shapiro GI, LoRusso P, Cho DC, Musib L, Yan Y, Wongchenko M, Chang I, Patel P, Chan IT, Sanabria-Bohorquez S, Meng RD, Bendell JC. A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors. Invest New Drugs 2021;39:163-74. [PMID: 32737717 DOI: 10.1007/s10637-020-00975-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 329 |
Sasaki S, Izumi H, Morimoto Y, Sakurai K, Mochizuki S. Induction of potent cell growth inhibition by schizophyllan/K-ras antisense complex in combination with gemcitabine. Bioorg Med Chem 2020;28:115668. [PMID: 32828430 DOI: 10.1016/j.bmc.2020.115668] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 330 |
Sarni D, Shtrikman A, Oren YS, Kerem B. Topoisomerase 1 dependent R-loop deficiency drives accelerated replication and genomic instability.. [DOI: 10.1101/2020.07.21.214700] [Reference Citation Analysis]
|
| 331 |
Hou HA, Tien HF. Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies. J Biomed Sci 2020;27:81. [PMID: 32690020 DOI: 10.1186/s12929-020-00674-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 332 |
Wang P, Pan X, Feng Q, Zou H, Cui J, He Y, Luo Y, Yang J. The immunoreactivity of the anti-p21Ras single-chain fragment variant KGH-R1 and its predicted binding sites to p21Ras. Immunotherapy 2020;12:879-90. [PMID: 32664770 DOI: 10.2217/imt-2019-0222] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 333 |
Patel KR, Patel HD. p53: An Attractive Therapeutic Target for Cancer. Curr Med Chem 2020;27:3706-34. [PMID: 31223076 DOI: 10.2174/1573406415666190621094704] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 334 |
Dong G, Chen L, Zhang J, Liu T, Du L, Sheng C, Li M. Discovery of Turn-On Fluorescent Probes for Detecting PDEδ Protein in Living Cells and Tumor Slices. Anal Chem 2020;92:9516-22. [PMID: 32571022 DOI: 10.1021/acs.analchem.0c00335] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 335 |
Rhett JM, Khan I, O'Bryan JP. Biology, pathology, and therapeutic targeting of RAS. Adv Cancer Res 2020;148:69-146. [PMID: 32723567 DOI: 10.1016/bs.acr.2020.05.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 336 |
Campos MA, Macedo S, Fernandes MS, Pestana A, Pardal J, Batista R, Vinagre J, Sanches A, Baptista A, Lopes JM, Soares P. Prognostic Significance of RAS Mutations and P53 Expression in Cutaneous Squamous Cell Carcinomas. Genes (Basel) 2020;11:E751. [PMID: 32640663 DOI: 10.3390/genes11070751] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 337 |
Biber G, Ben-Shmuel A, Sabag B, Barda-Saad M. Actin regulators in cancer progression and metastases: From structure and function to cytoskeletal dynamics. Int Rev Cell Mol Biol 2020;356:131-96. [PMID: 33066873 DOI: 10.1016/bs.ircmb.2020.05.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 338 |
Sutanto F, Konstantinidou M, Dömling A. Covalent inhibitors: a rational approach to drug discovery. RSC Med Chem 2020;11:876-84. [PMID: 33479682 DOI: 10.1039/d0md00154f] [Cited by in Crossref: 85] [Cited by in F6Publishing: 94] [Article Influence: 28.3] [Reference Citation Analysis]
|
| 339 |
Vidimar V, Beilhartz GL, Park M, Biancucci M, Kieffer MB, Gius DR, Melnyk RA, Satchell KJF. An engineered chimeric toxin that cleaves activated mutant and wild-type RAS inhibits tumor growth. Proc Natl Acad Sci U S A 2020;117:16938-48. [PMID: 32616570 DOI: 10.1073/pnas.2000312117] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 340 |
Hu Y, Li Y, Huang Y, Jin Z, Wang C, Wang H, Xu J. METTL3 regulates the malignancy of cervical cancer via post-transcriptional regulation of RAB2B. European Journal of Pharmacology 2020;879:173134. [DOI: 10.1016/j.ejphar.2020.173134] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 341 |
Ward AB, Keeton AB, Chen X, Mattox TE, Coley AB, Maxuitenko YY, Buchsbaum DJ, Randall TD, Zhou G, Piazza GA. Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS. MedComm (Beijing) 2020;1:121-8. [PMID: 33073260 DOI: 10.1002/mco2.10] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 342 |
Li D, Sun H, Meng L, Li D. The Overexpression of Kinesin Superfamily Protein 2A (KIF2A) was Associated with the Proliferation and Prognosis of Esophageal Squamous Cell Carcinoma. Cancer Manag Res 2020;12:3731-9. [PMID: 32547209 DOI: 10.2147/CMAR.S248008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 343 |
Lu KH, Lu EW, Lin CW, Yang JS, Yang SF. New insights into molecular and cellular mechanisms of zoledronate in human osteosarcoma. Pharmacol Ther 2020;214:107611. [PMID: 32565177 DOI: 10.1016/j.pharmthera.2020.107611] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 344 |
Liang Z, Zhang Q, Nie Y, Zhang X, Ma Q. Polarized-Electrochemiluminescence Biosensor Based on Surface Plasmon Coupling Strategy and Fluorine-Doped BN Quantum Dots. Anal Chem 2020;92:9223-9. [DOI: 10.1021/acs.analchem.0c01558] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 345 |
Li ZN, Zhao L, Yu LF, Wei MJ. BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy. Gastroenterol Rep (Oxf) 2020;8:192-205. [PMID: 32665851 DOI: 10.1093/gastro/goaa022] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 346 |
Subramanian A, Hall M, Hou H, Mufteev M, Yu B, Yuki KE, Nishimura H, Sathaseevan A, Lant B, Zhai B, Ellis J, Wilson MD, Daugaard M, Derry WB. Alternative polyadenylation is a determinant of oncogenic Ras function.. [DOI: 10.1101/2020.06.08.140145] [Reference Citation Analysis]
|
| 347 |
Sharma N, Sonavane U, Joshi R. Comparative MD simulations and advanced analytics based studies on wild-type and hot-spot mutant A59G HRas.. [DOI: 10.1101/2020.06.04.133967] [Reference Citation Analysis]
|
| 348 |
Domingo-Relloso A, Riffo-Campos AL, Haack K, Rentero-Garrido P, Ladd-Acosta C, Fallin DM, Tang WY, Herreros-Martinez M, Gonzalez JR, Bozack AK, Cole SA, Navas-Acien A, Tellez-Plaza M. Cadmium, Smoking, and Human Blood DNA Methylation Profiles in Adults from the Strong Heart Study. Environ Health Perspect 2020;128:67005. [PMID: 32484362 DOI: 10.1289/EHP6345] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 349 |
Ali ES, Sahu U, Villa E, O'Hara BP, Gao P, Beaudet C, Wood AW, Asara JM, Ben-Sahra I. ERK2 Phosphorylates PFAS to Mediate Posttranslational Control of De Novo Purine Synthesis. Mol Cell 2020;78:1178-1191.e6. [PMID: 32485148 DOI: 10.1016/j.molcel.2020.05.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 350 |
Jiménez-Sánchez A, Cybulska P, Mager KL, Koplev S, Cast O, Couturier DL, Memon D, Selenica P, Nikolovski I, Mazaheri Y, Bykov Y, Geyer FC, Macintyre G, Gavarró LM, Drews RM, Gill MB, Papanastasiou AD, Sosa RE, Soslow RA, Walther T, Shen R, Chi DS, Park KJ, Hollmann T, Reis-Filho JS, Markowetz F, Beltrao P, Vargas HA, Zamarin D, Brenton JD, Snyder A, Weigelt B, Sala E, Miller ML. Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. Nat Genet 2020;52:582-93. [PMID: 32483290 DOI: 10.1038/s41588-020-0630-5] [Cited by in Crossref: 83] [Cited by in F6Publishing: 85] [Article Influence: 27.7] [Reference Citation Analysis]
|
| 351 |
Turdo A, Porcelli G, D'Accardo C, Franco SD, Verona F, Forte S, Giuffrida D, Memeo L, Todaro M, Stassi G. Metabolic Escape Routes of Cancer Stem Cells and Therapeutic Opportunities. Cancers (Basel) 2020;12:E1436. [PMID: 32486505 DOI: 10.3390/cancers12061436] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 352 |
Weekes C, Lockhart A, LoRusso P, Murray E, Park E, Tagen M, Singh J, Sarkar I, Mueller L, Dokainish H, Shapiro G, Burris H. A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors. Oncologist 2020;25:833-e1438. [PMID: 32311798 DOI: 10.1634/theoncologist.2020-0292] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 353 |
Chen K, Shang Z, Dai AL, Dai PL. Novel PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: Strategy for non-small cell lung cancer with mutant RAS gene. Life Sci 2020;255:117816. [PMID: 32454155 DOI: 10.1016/j.lfs.2020.117816] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 354 |
Wang J, Wang C, Li Q, Guo C, Sun W, Zhao D, Jiang S, Hao L, Tian Y, Liu S, Sun MZ. miR-429-CRKL axis regulates clear cell renal cell carcinoma malignant progression through SOS1/MEK/ERK/MMP2/MMP9 pathway. Biomed Pharmacother 2020;127:110215. [PMID: 32413671 DOI: 10.1016/j.biopha.2020.110215] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 355 |
Bazany-Rodríguez IJ, Salomón-Flores MK, Bautista-Renedo JM, González-Rivas N, Dorazco-González A. Chemosensing of Guanosine Triphosphate Based on a Fluorescent Dinuclear Zn(II)-Dipicolylamine Complex in Water. Inorg Chem 2020;59:7739-51. [PMID: 32391691 DOI: 10.1021/acs.inorgchem.0c00777] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 356 |
Zhang X, Chen M, Liu X, Zhang L, Ding X, Guo Y, Li X, Guo H. A novel lncRNA, lnc403, involved in bovine skeletal muscle myogenesis by mediating KRAS/Myf6. Gene 2020;751:144706. [PMID: 32387386 DOI: 10.1016/j.gene.2020.144706] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 357 |
Yaqoob A, Li WM, Liu V, Wang C, Mackedenski S, Tackaberry LE, Massicotte HB, Egger KN, Reimer K, Lee CH. Grifolin, neogrifolin and confluentin from the terricolous polypore Albatrellus flettii suppress KRAS expression in human colon cancer cells. PLoS One 2020;15:e0231948. [PMID: 32369483 DOI: 10.1371/journal.pone.0231948] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 358 |
Gupta G, Lee CD, Guye ML, Van Sciver RE, Lee MP, Lafever AC, Pang A, Tang-Tan AM, Winston JS, Samli B, Jansen RJ, Hoefer RA, Tang AH. Unmet Clinical Need: Developing Prognostic Biomarkers and Precision Medicine to Forecast Early Tumor Relapse, Detect Chemo-Resistance and Improve Overall Survival in High-Risk Breast Cancer. Ann Breast Cancer Ther 2020;4:48-57. [PMID: 32542231 DOI: 10.36959/739/525] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 359 |
Stopa KB, Kusiak AA, Szopa MD, Ferdek PE, Jakubowska MA. Pancreatic Cancer and Its Microenvironment-Recent Advances and Current Controversies. Int J Mol Sci 2020;21:E3218. [PMID: 32370075 DOI: 10.3390/ijms21093218] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 360 |
Van Sciver RE, Cao Y, Tang AH. The phylogenetic functional conservation ofDrosophilaSeven-In-Absentia (SINA) E3 ligase and its two human paralogs, SIAH1 and SIAH2, inDrosophilaeye development.. [DOI: 10.1101/2020.04.28.067074] [Reference Citation Analysis]
|
| 361 |
Dhayat SA, Yang Z. Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas. J Cancer Res Clin Oncol 2020;146:1625-45. [PMID: 32338295 DOI: 10.1007/s00432-020-03219-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 362 |
Konstantinidou G, Rimessi A. Editorial: Oncogenic RAS-Dependent Reprogramming of Cellular Plasticity. Front Oncol 2020;10:588. [PMID: 32391272 DOI: 10.3389/fonc.2020.00588] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 363 |
D'Aria F, D'Amore VM, Di Leva FS, Amato J, Caterino M, Russomanno P, Salerno S, Barresi E, De Leo M, Marini AM, Taliani S, Da Settimo F, Salgado GF, Pompili L, Zizza P, Shirasawa S, Novellino E, Biroccio A, Marinelli L, Giancola C. Targeting the KRAS oncogene: Synthesis, physicochemical and biological evaluation of novel G-Quadruplex DNA binders. Eur J Pharm Sci 2020;149:105337. [PMID: 32311457 DOI: 10.1016/j.ejps.2020.105337] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 364 |
Wang S, Jiang M, Yang Z, Huang X, Li N. The role of distinct co-mutation patterns with TP53 mutation in immunotherapy for NSCLC. Genes Dis 2022;9:245-51. [PMID: 35005121 DOI: 10.1016/j.gendis.2020.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 365 |
Huijberts SCFA, van Geel RMJM, van Brummelen EMJ, Opdam FL, Marchetti S, Steeghs N, Pulleman S, Thijssen B, Rosing H, Monkhorst K, Huitema ADR, Beijnen JH, Bernards R, Schellens JHM. Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer. Cancer Chemother Pharmacol 2020;85:917-30. [PMID: 32274564 DOI: 10.1007/s00280-020-04066-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 366 |
Gauthaman A, Moorthy A. Prevalence of K-ras Codon 12 Mutations in Indian Patients with Head and Neck Cancer. Indian J Clin Biochem 2021;36:370-4. [PMID: 34220014 DOI: 10.1007/s12291-020-00882-w] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 367 |
Yoshino D, Funamoto K, Sato K, Kenry, Sato M, Lim CT. Hydrostatic pressure promotes endothelial tube formation through aquaporin 1 and Ras-ERK signaling. Commun Biol 2020;3:152. [PMID: 32242084 DOI: 10.1038/s42003-020-0881-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 368 |
Nix JS, Blakeley J, Rodriguez FJ. An update on the central nervous system manifestations of neurofibromatosis type 1. Acta Neuropathol 2020;139:625-41. [PMID: 30963251 DOI: 10.1007/s00401-019-02002-2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 11.7] [Reference Citation Analysis]
|
| 369 |
Liu Z, Wang M, Wang H, Fang L, Gou S. Targeting RAS-RAF pathway significantly improves antitumor activity of Rigosertib-derived platinum(IV) complexes and overcomes cisplatin resistance. Eur J Med Chem 2020;194:112269. [PMID: 32248002 DOI: 10.1016/j.ejmech.2020.112269] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 370 |
Senosain MF, Massion PP. Intratumor Heterogeneity in Early Lung Adenocarcinoma. Front Oncol 2020;10:349. [PMID: 32257951 DOI: 10.3389/fonc.2020.00349] [Cited by in Crossref: 24] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 371 |
Liu J, Zheng Y, Gao Y, Quan Z, Qiao B, Li L, Li T, Duan L, Yang J, Luo C, Wu X. Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCε/PKCε Signaling Pathway. Front Oncol 2020;10:75. [PMID: 32158687 DOI: 10.3389/fonc.2020.00075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 372 |
Rao H, Li X, Liu M, Liu J, Li X, Xu J, Li L, Gao WQ. Di-Ras2 promotes renal cell carcinoma formation by activating the mitogen-activated protein kinase pathway in the absence of von Hippel-Lindau protein. Oncogene 2020;39:3853-66. [PMID: 32161311 DOI: 10.1038/s41388-020-1247-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 373 |
Wu X, Li J, Gassa A, Buchner D, Alakus H, Dong Q, Ren N, Liu M, Odenthal M, Stippel D, Bruns C, Zhao Y, Wahba R. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma. Int J Biol Sci 2020;16:1551-62. [PMID: 32226301 DOI: 10.7150/ijbs.44024] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 12.3] [Reference Citation Analysis]
|
| 374 |
Thompson BJ. YAP/TAZ: Drivers of Tumor Growth, Metastasis, and Resistance to Therapy. BioEssays 2020;42:1900162. [DOI: 10.1002/bies.201900162] [Cited by in Crossref: 87] [Cited by in F6Publishing: 94] [Article Influence: 29.0] [Reference Citation Analysis]
|
| 375 |
Roet S, Hooft F, Bolhuis PG, Swenson DW, Vreede J. Path sampling simulations reveal how the Q61L mutation restricts the dynamics of KRas.. [DOI: 10.1101/2020.02.28.969451] [Reference Citation Analysis]
|
| 376 |
Gallyas F Jr, Sumegi B, Szabo C. Role of Akt Activation in PARP Inhibitor Resistance in Cancer. Cancers (Basel). 2020;12:532. [PMID: 32106627 DOI: 10.3390/cancers12030532] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 8.7] [Reference Citation Analysis]
|
| 377 |
Song Y, Wang L, Ran W, Li G, Xiao Y, Wang X, Zhang L, Xing X. Effect of Tumor Location on Clinicopathological and Molecular Markers in Colorectal Cancer in Eastern China Patients: An Analysis of 2,356 Cases. Front Genet 2020;11:96. [PMID: 32161617 DOI: 10.3389/fgene.2020.00096] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 378 |
Chen S, Li F, Xu D, Hou K, Fang W, Li Y. The Function of RAS Mutation in Cancer and Advances in its Drug Research. Curr Pharm Des 2019;25:1105-14. [PMID: 31057104 DOI: 10.2174/1381612825666190506122228] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 379 |
Liang H. Advanced glycation end products induce proliferation, invasion and epithelial-mesenchymal transition of human SW480 colon cancer cells through the PI3K/AKT signaling pathway. Oncol Lett 2020;19:3215-22. [PMID: 32218866 DOI: 10.3892/ol.2020.11413] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 380 |
Xu W, Wang Z, Li K, Jin R. Huai Qi Huang Potentiates Dexamethasone-Mediated Lethality in Acute Lymphoblastic Leukemia Cells by Upregulating Glucocorticoid Receptor α. Med Sci Monit 2020;26:e921649. [PMID: 32065117 DOI: 10.12659/MSM.921649] [Reference Citation Analysis]
|
| 381 |
Woods KN, Pfeffer J. Conformational perturbation, allosteric modulation of cellular signaling pathways, and disease in P23H rhodopsin. Sci Rep 2020;10:2657. [PMID: 32060349 DOI: 10.1038/s41598-020-59583-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 382 |
Lim C, Xu JC, Chen TY, Xu JX, Chen WF, Hu JW, Li QL, Zhang YQ. Ubiquitin-specific peptide 22 acts as an oncogene in gastric cancer in a son of sevenless 1-dependent manner. Cancer Cell Int 2020;20:45. [PMID: 32063746 DOI: 10.1186/s12935-020-1137-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 383 |
Harrell Stewart DR, Clark GJ. Pumping the brakes on RAS - negative regulators and death effectors of RAS. J Cell Sci 2020;133:jcs238865. [PMID: 32041893 DOI: 10.1242/jcs.238865] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 384 |
Ahmad A, Ahsan H. Ras-Mediated Activation of NF-κB and DNA Damage Response in Carcinogenesis. Cancer Invest 2020;38:185-208. [PMID: 31971023 DOI: 10.1080/07357907.2020.1721523] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 385 |
Hisrich BV, Young RB, Sansone AM, Bowens Z, Green LJ, Lessey BA, Blenda AV. Role of Human Galectins in Inflammation and Cancers Associated with Endometriosis. Biomolecules 2020;10:E230. [PMID: 32033052 DOI: 10.3390/biom10020230] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 386 |
Caraffini V, Geiger O, Rosenberger A, Hatzl S, Perfler B, Berg JL, Lim C, Strobl H, Kashofer K, Schauer S, Beham-Schmid C, Hoefler G, Geissler K, Quehenberger F, Kolch W, Athineos D, Blyth K, Wölfler A, Sill H, Zebisch A. Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis. Haematologica 2020;105:375-86. [PMID: 31097632 DOI: 10.3324/haematol.2018.209650] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 387 |
Göbel A, Rauner M, Hofbauer LC, Rachner TD. Cholesterol and beyond - The role of the mevalonate pathway in cancer biology. Biochim Biophys Acta Rev Cancer 2020;1873:188351. [PMID: 32007596 DOI: 10.1016/j.bbcan.2020.188351] [Cited by in Crossref: 43] [Cited by in F6Publishing: 52] [Article Influence: 14.3] [Reference Citation Analysis]
|
| 388 |
Ding J, Yao Y, Huang G, Wang X, Yi J, Zhang N, Liu C, Wang K, Zhang Y, Wang M, Liu P, Ye M, Li M, Cheng H. Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib. Cancer Lett 2020;475:53-64. [PMID: 32006616 DOI: 10.1016/j.canlet.2020.01.032] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 389 |
Feng Z, Yu Q, Zhang T, Tie W, Li J, Zhou X. Updates on mechanistic insights and targeting of tumour metastasis. J Cell Mol Med 2020;24:2076-86. [PMID: 31957271 DOI: 10.1111/jcmm.14931] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 390 |
García-Gutiérrez L, McKenna S, Kolch W, Matallanas D. RASSF1A Tumour Suppressor: Target the Network for Effective Cancer Therapy. Cancers (Basel) 2020;12:E229. [PMID: 31963420 DOI: 10.3390/cancers12010229] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 391 |
Kettle JG, Cassar DJ. Covalent inhibitors of the GTPase KRASG12C: a review of the patent literature. Expert Opin Ther Pat 2020;30:103-20. [PMID: 31913776 DOI: 10.1080/13543776.2020.1709443] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 392 |
Huang P, Qi B, Yao H, Zhang L, Li Y, Li Q. Circular RNA cSMARCA5 regulates the progression of cervical cancer by acting as a microRNA‑432 sponge. Mol Med Rep 2020;21:1217-23. [PMID: 31922210 DOI: 10.3892/mmr.2020.10910] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 393 |
Kim J, Novak D, Sachpekidis C, Utikal J, Larribère L. STAT3 Relays a Differential Response to Melanoma-Associated NRAS Mutations. Cancers (Basel) 2020;12:E119. [PMID: 31906480 DOI: 10.3390/cancers12010119] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 394 |
Hanrahan AJ, Iyer G, Solit DB. Intracellular Signaling. Abeloff's Clinical Oncology 2020. [DOI: 10.1016/b978-0-323-47674-4.00002-5] [Reference Citation Analysis]
|
| 395 |
Yamin M, Raza HG, Fatima I. Overview of Cancer Genomics, Organization, and Variations in the Human Genome. 'Essentials of Cancer Genomic, Computational Approaches and Precision Medicine 2020. [DOI: 10.1007/978-981-15-1067-0_1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 396 |
Blanden MJ, Ashok S, Hougland JL. Mechanisms of CaaX Protein Processing: Protein Prenylation by FTase and GGTase-I. Comprehensive Natural Products III 2020. [DOI: 10.1016/b978-0-12-409547-2.14837-1] [Reference Citation Analysis]
|
| 397 |
Zhang Y, Tighe S, Zhu YT. COX-2 Signaling in the Tumor Microenvironment. Adv Exp Med Biol 2020;1277:87-104. [PMID: 33119867 DOI: 10.1007/978-3-030-50224-9_6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 398 |
Liu Q, Miao Y, Wang X, Lv G, Peng Y, Li K, Li M, Qiu L, Lin J. Structure-based virtual screening and biological evaluation of novel non-bisphosphonate farnesyl pyrophosphate synthase inhibitors. European Journal of Medicinal Chemistry 2020;186:111905. [DOI: 10.1016/j.ejmech.2019.111905] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 399 |
Wu M, Zhang P. EGFR-mediated autophagy in tumourigenesis and therapeutic resistance. Cancer Letters 2020;469:207-16. [DOI: 10.1016/j.canlet.2019.10.030] [Cited by in Crossref: 36] [Cited by in F6Publishing: 44] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 400 |
Abdallah N, Nagasaka M, Sukari A. Mechanisms of Toxicities Associated With Targeted Therapy. Handbook of Cancer Treatment-Related Symptons and Toxicities 2020. [DOI: 10.1016/b978-0-323-67241-2.00012-4] [Reference Citation Analysis]
|
| 401 |
Kench T, Vilar R. Metal complexes as G-quadruplex binders. Annual Reports in Medicinal Chemistry 2020. [DOI: 10.1016/bs.armc.2020.05.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 402 |
Awidi M, Ababneh N, Shomaf M, Al Fararjeh F, Owaidi L, AlKhatib M, Al Tarawneh B, Awidi A. KRAS and NRAS mutational gene profile of metastatic colorectal cancer patients in Jordan. PLoS One 2019;14:e0226473. [PMID: 31881025 DOI: 10.1371/journal.pone.0226473] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 403 |
Mattox TE, Chen X, Maxuitenko YY, Keeton AB, Piazza GA. Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers. Int J Mol Sci 2019;21:E141. [PMID: 31878223 DOI: 10.3390/ijms21010141] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 404 |
Lim JKM, Leprivier G. The impact of oncogenic RAS on redox balance and implications for cancer development. Cell Death Dis 2019;10:955. [PMID: 31852884 DOI: 10.1038/s41419-019-2192-y] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 405 |
Yuan M, Huang LL, Chen JH, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther 2019;4:61. [PMID: 31871778 DOI: 10.1038/s41392-019-0099-9] [Cited by in Crossref: 255] [Cited by in F6Publishing: 280] [Article Influence: 63.8] [Reference Citation Analysis]
|
| 406 |
Geng W, Dong K, Pu Q, Lv Y, Gao H. SHOC2 is associated with the survival of breast cancer cells and has prognostic value for patients with breast cancer. Mol Med Rep 2020;21:867-75. [PMID: 31974612 DOI: 10.3892/mmr.2019.10889] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 407 |
Chamseddin BH, Le LQ. Management of cutaneous neurofibroma: current therapy and future directions. Neurooncol Adv 2020;2:i107-16. [PMID: 32642736 DOI: 10.1093/noajnl/vdz034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 408 |
Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in cancer.Br J Cancer. 2020;122:4-22. [PMID: 31819192 DOI: 10.1038/s41416-019-0650-z] [Cited by in Crossref: 397] [Cited by in F6Publishing: 426] [Article Influence: 99.3] [Reference Citation Analysis]
|
| 409 |
Liu Z, Wang M, Wang H, Fang L, Gou S. Platinum-Based Modification of Styrylbenzylsulfones as Multifunctional Antitumor Agents: Targeting the RAS/RAF Pathway, Enhancing Antitumor Activity, and Overcoming Multidrug Resistance. J Med Chem 2020;63:186-204. [DOI: 10.1021/acs.jmedchem.9b01223] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 410 |
Sztul E, Chen PW, Casanova JE, Cherfils J, Dacks JB, Lambright DG, Lee FS, Randazzo PA, Santy LC, Schürmann A, Wilhelmi I, Yohe ME, Kahn RA. ARF GTPases and their GEFs and GAPs: concepts and challenges. Mol Biol Cell 2019;30:1249-71. [PMID: 31084567 DOI: 10.1091/mbc.E18-12-0820] [Cited by in Crossref: 125] [Cited by in F6Publishing: 127] [Article Influence: 31.3] [Reference Citation Analysis]
|
| 411 |
Wang H, Liu Y, Wang D, Xu Y, Dong R, Yang Y, Lv Q, Chen X, Zhang Z. The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases. Cells. 2019;8. [PMID: 31835352 DOI: 10.3390/cells8121597] [Cited by in Crossref: 80] [Cited by in F6Publishing: 90] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 412 |
Fulciniti M, Lin CY, Samur MK, Lopez MA, Singh I, Lawlor MA, Szalat RE, Ott CJ, Avet-Loiseau H, Anderson KC, Young RA, Bradner JE, Munshi NC. Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma. Cell Rep 2018;25:3693-3705.e6. [PMID: 30590042 DOI: 10.1016/j.celrep.2018.12.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 413 |
He H, Xu C, Cheng Z, Qian X, Zheng L. Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers. Curr Top Med Chem 2019;19:2128-42. [PMID: 31475900 DOI: 10.2174/1568026619666190902150555] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 414 |
Shao YT, Ma L, Zhang TH, Xu TR, Ye YC, Liu Y. The Application of the RNA Interference Technologies for KRAS: Current Status, Future Perspective and Associated Challenges. Curr Top Med Chem 2019;19:2143-57. [PMID: 31456522 DOI: 10.2174/1568026619666190828162217] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 415 |
Perrone M, Caroccia N, Genovese I, Missiroli S, Modesti L, Pedriali G, Vezzani B, Vitto VAM, Antenori M, Lebiedzinska-Arciszewska M, Wieckowski MR, Giorgi C, Pinton P. The role of mitochondria-associated membranes in cellular homeostasis and diseases. Int Rev Cell Mol Biol 2020;350:119-96. [PMID: 32138899 DOI: 10.1016/bs.ircmb.2019.11.002] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 416 |
Ye N, Xu Q, Li W, Wang P, Zhou J. Recent Advances in Developing K-Ras Plasma Membrane Localization Inhibitors. Curr Top Med Chem 2019;19:2114-27. [PMID: 31475899 DOI: 10.2174/1568026619666190902145116] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 417 |
Huang X, Chen J, Cao W, Yang L, Chen Q, He J, Yi Q, Huang H, Zhang E, Cai Z. The many substrates and functions of NEDD4-1. Cell Death Dis 2019;10:904. [PMID: 31787758 DOI: 10.1038/s41419-019-2142-8] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 418 |
Post JB, Hami N, Lohuis J, van de Ven M, de Korte-grimmerink R, Stangl C, Stelloo E, Verlaan I, van Rheenen J, Snippert HJ. Cancer modeling in colorectal organoids reveals intrinsic differences between oncogenic RAS and BRAF variants.. [DOI: 10.1101/860122] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 419 |
Gong B, Kao Y, Zhang C, Zhao H, Sun F, Gong Z. Exploring the Pharmacological Mechanism of the Herb Pair "HuangLian-GanJiang" against Colorectal Cancer Based on Network Pharmacology. Evid Based Complement Alternat Med 2019;2019:2735050. [PMID: 31871473 DOI: 10.1155/2019/2735050] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 420 |
Renard I, Grandmougin M, Roux A, Yang SY, Lejault P, Pirrotta M, Wong JMY, Monchaud D. Small-molecule affinity capture of DNA/RNA quadruplexes and their identification in vitro and in vivo through the G4RP protocol. Nucleic Acids Res 2019;47:5502-10. [PMID: 30949698 DOI: 10.1093/nar/gkz215] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 421 |
Kang M, Lee YS. The impact of RASopathy-associated mutations on CNS development in mice and humans. Mol Brain 2019;12:96. [PMID: 31752929 DOI: 10.1186/s13041-019-0517-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 422 |
Chen F, Alphonse MP, Liu Y, Liu Q. Targeting Mutant KRAS for Anticancer Therapy. CTMC 2019;19:2098-113. [DOI: 10.2174/1568026619666190902151307] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 423 |
Aran V, Omerovic J. Current Approaches in NSCLC Targeting K-RAS and EGFR. Int J Mol Sci 2019;20:E5701. [PMID: 31739412 DOI: 10.3390/ijms20225701] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 424 |
Zhou B, Zhu W, Jiang X, Ren C. RASAL2 Plays Inconsistent Roles in Different Cancers. Front Oncol 2019;9:1235. [PMID: 31799194 DOI: 10.3389/fonc.2019.01235] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 425 |
Wu H, Wang Q, Zhong H, Li L, Zhang Q, Huang Q, Yu Z. Differentially expressed microRNAs in exosomes of patients with breast cancer revealed by next‑generation sequencing. Oncol Rep 2020;43:240-50. [PMID: 31746410 DOI: 10.3892/or.2019.7401] [Cited by in Crossref: 18] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 426 |
Zuo Y, Yang T, Wang X, Zhang Y, Tian M, Gou Z, Lin W. Visualizing the cell ferroptosis via a novel polysiloxane-based fluorescent schiff base. Sensors and Actuators B: Chemical 2019;298:126843. [DOI: 10.1016/j.snb.2019.126843] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 427 |
Denkiewicz M, Saha I, Rakshit S, Sarkar JP, Plewczynski D. Identification of Breast Cancer Subtype Specific MicroRNAs Using Survival Analysis to Find Their Role in Transcriptomic Regulation. Front Genet 2019;10:1047. [PMID: 31798622 DOI: 10.3389/fgene.2019.01047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 428 |
Khan I, Rhett JM, O'Bryan JP. Therapeutic targeting of RAS: New hope for drugging the "undruggable". Biochim Biophys Acta Mol Cell Res 2020;1867:118570. [PMID: 31678118 DOI: 10.1016/j.bbamcr.2019.118570] [Cited by in Crossref: 56] [Cited by in F6Publishing: 61] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 429 |
Georgakopoulou E, Stebbing J, Scully C. Targeted cancer therapies: Oral health care implications. J Am Dent Assoc 2018;149:100-11. [PMID: 29389333 DOI: 10.1016/j.adaj.2017.08.046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 430 |
Banys-Paluchowski M, Milde-Langosch K, Fehm T, Witzel I, Oliveira-Ferrer L, Schmalfeldt B, Müller V. Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients. Breast Cancer Res Treat 2020;179:403-14. [PMID: 31646390 DOI: 10.1007/s10549-019-05474-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 431 |
Cuddy LK, Wani WY, Morella ML, Pitcairn C, Tsutsumi K, Fredriksen K, Justman CJ, Grammatopoulos TN, Belur NR, Zunke F, Subramanian A, Affaneh A, Lansbury PT Jr, Mazzulli JR. Stress-Induced Cellular Clearance Is Mediated by the SNARE Protein ykt6 and Disrupted by α-Synuclein. Neuron 2019;104:869-884.e11. [PMID: 31648898 DOI: 10.1016/j.neuron.2019.09.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 432 |
Fan M, Xia P, Liu B, Zhang L, Wang Y, Gao X, Li L. Tumour heterogeneity revealed by unsupervised decomposition of dynamic contrast-enhanced magnetic resonance imaging is associated with underlying gene expression patterns and poor survival in breast cancer patients. Breast Cancer Res 2019;21:112. [PMID: 31623683 DOI: 10.1186/s13058-019-1199-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 433 |
Cope N, Novak B, Candelora C, Wong K, Cavallo M, Gunderwala A, Liu Z, Li Y, Wang Z. Biochemical Characterization of Full-Length Oncogenic BRAFV600E together with Molecular Dynamics Simulations Provide Insight into the Activation and Inhibition Mechanisms of RAF Kinases. Chembiochem 2019;20:2850-61. [PMID: 31152574 DOI: 10.1002/cbic.201900266] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 434 |
Zhumakayeva AM, Rakhimov KD, Omarova IM, Arystan LI, Adekenov SM. Experimental, Clinical and Morphological Analysis of H-Ras Oncoproteins for Locally Advanced Breast Cancer. Open Access Maced J Med Sci 2019;7:3153-7. [PMID: 31949508 DOI: 10.3889/oamjms.2019.708] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 435 |
Stein A, Strong E, Clark Gamblin T, Clarke C, Tsai S, Thomas J, George B, Mogal H. Molecular and Genetic Markers in Appendiceal Mucinous Tumors: A Systematic Review. Ann Surg Oncol 2020;27:85-97. [PMID: 31583543 DOI: 10.1245/s10434-019-07879-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 436 |
Arthur DE, Uzairu A. Molecular docking studies on the interaction of NCI anticancer analogues with human Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit. Journal of King Saud University - Science 2019;31:1151-66. [DOI: 10.1016/j.jksus.2019.01.011] [Cited by in Crossref: 43] [Cited by in F6Publishing: 15] [Article Influence: 10.8] [Reference Citation Analysis]
|
| 437 |
Begoli E, Kusnezov D. Artificial intelligence's essential role in the process of drug discovery. Future Drug Discovery 2019;1:FDD21. [DOI: 10.4155/fdd-2019-0026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 438 |
Ming Z, Lim SY, Kefford RF, Rizos H. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors. Pigment Cell Melanoma Res 2020;33:345-57. [PMID: 31518489 DOI: 10.1111/pcmr.12824] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 439 |
Kang H, Oh T, Bahk YY, Kim GH, Kan SY, Shin DH, Kim JH, Lim JH. HSF1 Regulates Mevalonate and Cholesterol Biosynthesis Pathways. Cancers (Basel) 2019;11:E1363. [PMID: 31540279 DOI: 10.3390/cancers11091363] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 440 |
Shin Y, Jeong JW, Wurz RP, Achanta P, Arvedson T, Bartberger MD, Campuzano IDG, Fucini R, Hansen SK, Ingersoll J, Iwig JS, Lipford JR, Ma V, Kopecky DJ, McCarter J, San Miguel T, Mohr C, Sabet S, Saiki AY, Sawayama A, Sethofer S, Tegley CM, Volak LP, Yang K, Lanman BA, Erlanson DA, Cee VJ. Discovery of N-(1-Acryloylazetidin-3-yl)-2-(1H-indol-1-yl)acetamides as Covalent Inhibitors of KRASG12C. ACS Med Chem Lett 2019;10:1302-8. [PMID: 31531201 DOI: 10.1021/acsmedchemlett.9b00258] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 9.8] [Reference Citation Analysis]
|
| 441 |
Cohn A, Morse MA, O'Neil B, Whiting S, Coeshott C, Ferraro J, Bellgrau D, Apelian D, Rodell TC. Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial.J Immunother. 2018;41:141-150. [PMID: 29528991 DOI: 10.1097/CJI.0000000000000219] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 442 |
Reagan M. CAUSES OF CANCER. Cancer 2019. [DOI: 10.1002/9781119645214.ch3] [Reference Citation Analysis]
|
| 443 |
Liu R, Chen Z, Wang S, Zhao G, Gu Y, Han Q, Chen B. Screening of key genes associated with R‑CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B‑cell lymphoma. Mol Med Rep 2019;20:3679-90. [PMID: 31485671 DOI: 10.3892/mmr.2019.10627] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 444 |
Lian B, Zhang W, Wang T, Yang Q, Jia Z, Chen H, Wang L, Xu J, Wang W, Cao K, Gao X, Sun Y, Shao C, Liu Z, Li J. Clinical Benefit of Sorafenib Combined with Paclitaxel and Carboplatin to a Patient with Metastatic Chemotherapy-Refractory Testicular Tumors. Oncologist 2019;24:e1437-42. [PMID: 31492770 DOI: 10.1634/theoncologist.2019-0295] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 445 |
Kim SM, Kim EM, Ji KY, Lee HY, Yee SM, Woo SM, Yi JW, Yun CH, Choi H, Kang HS. TREM2 Acts as a Tumor Suppressor in Colorectal Carcinoma through Wnt1/β-catenin and Erk Signaling. Cancers (Basel) 2019;11:E1315. [PMID: 31489935 DOI: 10.3390/cancers11091315] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 446 |
Li Y, Sun W, Sun D, Yin D. Retracted: Ras-ERK1/2 signaling promotes the development of uveal melanoma by downregulating H3K14ac. J Cell Physiol 2019;234:16011-20. [PMID: 30770563 DOI: 10.1002/jcp.28259] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 447 |
Hall A, Maynard S, Wu L, Merchut-maya JM, Strauss R, Moghimi SM, Bartek J. Perturbation of mitochondrial bioenergetics by polycations counteracts resistance to BRAFE600 inhibition in melanoma cells. Journal of Controlled Release 2019;309:158-72. [DOI: 10.1016/j.jconrel.2019.07.032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 448 |
Awasthi N, Kronenberger D, Stefaniak A, Hassan MS, von Holzen U, Schwarz MA, Schwarz RE. Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer. Cancer Letters 2019;459:41-9. [DOI: 10.1016/j.canlet.2019.05.037] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 449 |
Khaled M, Gorfe A, Sayyed-Ahmad A. Conformational and Dynamical Effects of Tyr32 Phosphorylation in K-Ras: Molecular Dynamics Simulation and Markov State Models Analysis. J Phys Chem B 2019;123:7667-75. [PMID: 31419909 DOI: 10.1021/acs.jpcb.9b05768] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 450 |
Kovalski JR, Shanderson RL, Khavari PA. Ras functional proximity proteomics establishes mTORC2 as new direct ras effector. Oncotarget 2019;10:5126-35. [PMID: 31497244 DOI: 10.18632/oncotarget.27025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 451 |
Lisnyansky M, Yariv E, Segal O, Marom M, Loewenstein A, Ben-tal N, Giladi M, Haitin Y. Metal Coordination Is Crucial for Geranylgeranyl Diphosphate Synthase–Bisphosphonate Interactions: A Crystallographic and Computational Analysis. Mol Pharmacol 2019;96:580-8. [DOI: 10.1124/mol.119.117499] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 452 |
Zaman A, Wu W, Bivona TG. Targeting Oncogenic BRAF: Past, Present, and Future. Cancers (Basel). 2019;11. [PMID: 31426419 DOI: 10.3390/cancers11081197] [Cited by in Crossref: 85] [Cited by in F6Publishing: 90] [Article Influence: 21.3] [Reference Citation Analysis]
|
| 453 |
Vatansever S, Erman B, Gümüş ZH. Oncogenic G12D mutation alters local conformations and dynamics of K-Ras. Sci Rep 2019;9:11730. [PMID: 31409810 DOI: 10.1038/s41598-019-48029-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 454 |
Murugan AK. mTOR: Role in cancer, metastasis and drug resistance. Semin Cancer Biol 2019;59:92-111. [PMID: 31408724 DOI: 10.1016/j.semcancer.2019.07.003] [Cited by in Crossref: 138] [Cited by in F6Publishing: 122] [Article Influence: 34.5] [Reference Citation Analysis]
|
| 455 |
Hashimoto S, Furukawa S, Hashimoto A, Tsutaho A, Fukao A, Sakamura Y, Parajuli G, Onodera Y, Otsuka Y, Handa H, Oikawa T, Hata S, Nishikawa Y, Mizukami Y, Kodama Y, Murakami M, Fujiwara T, Hirano S, Sabe H. ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer. Proc Natl Acad Sci U S A 2019;116:17450-9. [PMID: 31399545 DOI: 10.1073/pnas.1901765116] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 12.3] [Reference Citation Analysis]
|
| 456 |
Ogawa F, Walters MS, Shafquat A, O'Beirne SL, Kaner RJ, Mezey JG, Zhang H, Leopold PL, Crystal RG. Role of KRAS in regulating normal human airway basal cell differentiation. Respir Res 2019;20:181. [PMID: 31399087 DOI: 10.1186/s12931-019-1129-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 457 |
Yoshino H, Yin G, Kawaguchi R, Popov KI, Temple B, Sasaki M, Kofuji S, Wolfe K, Kofuji K, Okumura K, Randhawa J, Malhotra A, Majd N, Ikeda Y, Shimada H, Kahoud ER, Haviv S, Iwase S, Asara JM, Campbell SL, Sasaki AT. Identification of lysine methylation in the core GTPase domain by GoMADScan. PLoS One 2019;14:e0219436. [PMID: 31390367 DOI: 10.1371/journal.pone.0219436] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 458 |
Hasan MS, Wu X, Zhang L. Uncovering missed indels by leveraging unmapped reads. Sci Rep 2019;9:11093. [PMID: 31366961 DOI: 10.1038/s41598-019-47405-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 459 |
Sumithra B, Saxena U, Das AB. A comprehensive study on genome-wide coexpression network of KHDRBS1/Sam68 reveals its cancer and patient-specific association. Sci Rep 2019;9:11083. [PMID: 31366900 DOI: 10.1038/s41598-019-47558-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 460 |
Ducray SP, Natarajan K, Garland GD, Turner SD, Egger G. The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis. Cancers (Basel) 2019;11:E1074. [PMID: 31366041 DOI: 10.3390/cancers11081074] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 461 |
Bartel K, Pein H, Popper B, Schmitt S, Janaki-Raman S, Schulze A, Lengauer F, Koeberle A, Werz O, Zischka H, Müller R, Vollmar AM, von Schwarzenberg K. Connecting lysosomes and mitochondria - a novel role for lipid metabolism in cancer cell death. Cell Commun Signal 2019;17:87. [PMID: 31358011 DOI: 10.1186/s12964-019-0399-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 462 |
Zinatizadeh MR, Momeni SA, Zarandi PK, Chalbatani GM, Dana H, Mirzaei HR, Akbari ME, Miri SR. The Role and Function of Ras-association domain family in Cancer: A Review. Genes Dis 2019;6:378-84. [PMID: 31832517 DOI: 10.1016/j.gendis.2019.07.008] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 463 |
Kim HC, Kang YR, Ji W, Kim YJ, Yoon S, Lee JC, Choi CM. Frequency and clinical features of BRAF mutations among patients with stage III/IV lung adenocarcinoma without EGFR/ALK aberrations. Onco Targets Ther 2019;12:6045-52. [PMID: 31440061 DOI: 10.2147/OTT.S213928] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 464 |
Lanfredini S, Thapa A, O'Neill E. RAS in pancreatic cancer. Biochem Soc Trans 2019;47:961-72. [PMID: 31341034 DOI: 10.1042/BST20170521] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 465 |
Iliescu FS, Poenar DP, Yu F, Ni M, Chan KH, Cima I, Taylor HK, Cima I, Iliescu C. Recent advances in microfluidic methods in cancer liquid biopsy. Biomicrofluidics 2019;13:041503. [PMID: 31431816 DOI: 10.1063/1.5087690] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 466 |
Moghadamchargari Z, Huddleston J, Shirzadeh M, Zheng X, Clemmer DE, M Raushel F, Russell DH, Laganowsky A. Intrinsic GTPase Activity of K-RAS Monitored by Native Mass Spectrometry. Biochemistry 2019;58:3396-405. [PMID: 31306575 DOI: 10.1021/acs.biochem.9b00532] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 467 |
Kawaguchi Y, Lillemoe HA, Vauthey JN. Gene mutation and surgical technique: Suggestion or more? Surg Oncol 2020;33:210-5. [PMID: 31351766 DOI: 10.1016/j.suronc.2019.07.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 468 |
Sang B, Sun J, Yang D, Xu Z, Wei Y. Ras-AKT signaling represses the phosphorylation of histone H1.5 at threonine 10 via GSK3 to promote the progression of glioma. Artificial Cells, Nanomedicine, and Biotechnology 2019;47:2882-90. [DOI: 10.1080/21691401.2019.1638795] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 469 |
Adeniji EA, Olotu FA, Soliman MES. Exploring the Lapse in Druggability: Sequence Analysis, Structural Dynamics and Binding Site Characterization of K-RasG12C Variant, a Feasible Oncotherapeutics Target. Anticancer Agents Med Chem 2018;18:1540-50. [PMID: 30019652 DOI: 10.2174/1871520618666180718110231] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 470 |
Yokoyama N, Kim YJ, Hirabayashi Y, Tabe Y, Takamori K, Ogawa H, Iwabuchi K. Kras promotes myeloid differentiation through Wnt/β-catenin signaling. FASEB Bioadv 2019;1:435-49. [PMID: 32123842 DOI: 10.1096/fba.2019-00004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 471 |
Shen GQ, Aleassa EM, Walsh RM, Morris-Stiff G. Next-Generation Sequencing in Pancreatic Cancer. Pancreas 2019;48:739-48. [PMID: 31206465 DOI: 10.1097/MPA.0000000000001324] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 472 |
Petersen CH, Mahmood B, Badsted C, Dahlby T, Rasmussen HB, Hansen MB, Bindslev N. Possible predisposition for colorectal carcinogenesis due to altered gene expressions in normal appearing mucosa from patients with colorectal neoplasia. BMC Cancer 2019;19:643. [PMID: 31253108 DOI: 10.1186/s12885-019-5833-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 473 |
Rao H, Li X, Liu M, Liu J, Li X, Xu J, Li L, Gao W. Di-Ras2 Promotes Renal Cell Carcinoma Formation by Activating the MAPK Pathway in the Absence of VHL.. [DOI: 10.1101/683821] [Reference Citation Analysis]
|
| 474 |
Xu W, Deng B, Lin P, Liu C, Li B, Huang Q, Zhou H, Yang J, Qu L. Ribosome profiling analysis identified a KRAS-interacting microprotein that represses oncogenic signaling in hepatocellular carcinoma cells. Sci China Life Sci 2020;63:529-42. [DOI: 10.1007/s11427-019-9580-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 475 |
Kawaguchi Y, Kopetz S, Newhook TE, De Bellis M, Chun YS, Tzeng CD, Aloia TA, Vauthey JN. Mutation Status of RAS, TP53, and SMAD4 is Superior to Mutation Status of RAS Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases. Clin Cancer Res. 2019;25:5843-5851. [PMID: 31221662 DOI: 10.1158/1078-0432.ccr-19-0863] [Cited by in Crossref: 75] [Cited by in F6Publishing: 79] [Article Influence: 18.8] [Reference Citation Analysis]
|
| 476 |
Maisel SA, Broka D, Atwell B, Bunch T, Kupp R, Singh SK, Mehta S, Schroeder J. Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer. J Transl Med 2019;17:201. [PMID: 31215437 DOI: 10.1186/s12967-019-1939-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 477 |
Liu H, Ertay A, Peng P, Li J, Liu D, Xiong H, Zou Y, Qiu H, Hancock D, Yuan X, Huang WC, Ewing RM, Downward J, Wang Y. SGLT1 is required for the survival of triple-negative breast cancer cells via potentiation of EGFR activity. Mol Oncol 2019;13:1874-86. [PMID: 31199048 DOI: 10.1002/1878-0261.12530] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 478 |
Tan AHY, Tu W, McCuaig R, Hardy K, Donovan T, Tsimbalyuk S, Forwood JK, Rao S. Lysine-Specific Histone Demethylase 1A Regulates Macrophage Polarization and Checkpoint Molecules in the Tumor Microenvironment of Triple-Negative Breast Cancer. Front Immunol 2019;10:1351. [PMID: 31249575 DOI: 10.3389/fimmu.2019.01351] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 479 |
Sonkar K, Ayyappan V, Tressler CM, Adelaja O, Cai R, Cheng M, Glunde K. Focus on the glycerophosphocholine pathway in choline phospholipid metabolism of cancer. NMR Biomed 2019;32:e4112. [PMID: 31184789 DOI: 10.1002/nbm.4112] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 11.3] [Reference Citation Analysis]
|
| 480 |
Londhe P, Gutwillig M, London C. Targeted Therapies in Veterinary Oncology. Vet Clin North Am Small Anim Pract 2019;49:917-31. [PMID: 31186124 DOI: 10.1016/j.cvsm.2019.04.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 481 |
Revathidevi S, Munirajan AK. Akt in cancer: Mediator and more. Semin Cancer Biol 2019;59:80-91. [PMID: 31173856 DOI: 10.1016/j.semcancer.2019.06.002] [Cited by in Crossref: 182] [Cited by in F6Publishing: 205] [Article Influence: 45.5] [Reference Citation Analysis]
|
| 482 |
Duarte-Medrano G, Lopez-Méndez I, Ramírez-Luna MÁ, Valdovinos-Andraca F, Cruz-Martínez R, Medina-Vera I, Pérez-Monter C, Téllez-Ávila FI. Analysis of circulating blood and tissue biopsy PDX1 and MSX2 gene expression in patients with pancreatic cancer: A case-control experimental study. Medicine (Baltimore) 2019;98:e15954. [PMID: 31261501 DOI: 10.1097/MD.0000000000015954] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 483 |
Nooridaloii MR, , Department of Medical Genetics, Faculty of Medicine Tehran of Medical Sciences, Tehran, Iran, Boustanipour E, MSc Student, Department of Medical Genetics, Faculty of Medicine Tehran of Medical Sciences, Tehran, Iran. The molecular genetics of neurofibromatosis type 1 and its future prospective. MEDICAL SCIENCES 2019;29:101-116. [DOI: 10.29252/iau.29.2.101] [Reference Citation Analysis]
|
| 484 |
Kim HS, Kim KM, Lee SB, Kim GR, Han YD, Cho MS, Hur H, Lee KY, Kim NK, Min BS. Clinicopathological and biomolecular characteristics of stage IIB/IIC and stage IIIA colon cancer: Insight into the survival paradox. J Surg Oncol 2019;120:423-30. [PMID: 31134644 DOI: 10.1002/jso.25515] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 485 |
Kostrhunova H, Zajac J, Novohradsky V, Kasparkova J, Malina J, Aldrich-Wright JR, Petruzzella E, Sirota R, Gibson D, Brabec V. A Subset of New Platinum Antitumor Agents Kills Cells by a Multimodal Mechanism of Action Also Involving Changes in the Organization of the Microtubule Cytoskeleton. J Med Chem 2019;62:5176-90. [PMID: 31030506 DOI: 10.1021/acs.jmedchem.9b00489] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 486 |
Ansaryan S, Khayamian MA, Saghafi M, Shalileh S, Nikshoar MS, Abbasvandi F, Mahmoudi M, Bahrami F, Abdolahad M. Stretch Induces Invasive Phenotypes in Breast Cells Due to Activation of Aerobic-Glycolysis-Related Pathways. Adv Biosyst 2019;3:e1800294. [PMID: 32648669 DOI: 10.1002/adbi.201800294] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 487 |
Arendt KA, Ntaliarda G, Armenis V, Kati D, Henning C, Giotopoulou GA, Pepe MA, Klotz LV, Lamort A, Hatz RA, Kobold S, Stathopoulos GT. An in vivo inflammatory loop potentiates KRAS blockade.. [DOI: 10.1101/629139] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 488 |
Zappavigna S, Vanacore D, Lama S, Potenza N, Russo A, Ferranti P, Dallio M, Federico A, Loguercio C, Sperlongano P, Caraglia M, Stiuso P. Silybin-Induced Apoptosis Occurs in Parallel to the Increase of Ceramides Synthesis and miRNAs Secretion in Human Hepatocarcinoma Cells. Int J Mol Sci 2019;20:E2190. [PMID: 31058823 DOI: 10.3390/ijms20092190] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 489 |
Soleimani A, Amirinejad M, Rahsepar S, Vazirian F, Bahrami A, Ferns GA, Khazaei M, Avan A, Hassanian SM. Therapeutic potential of RAS prenylation pharmacological inhibitors in the treatment of breast cancer, recent progress, and prospective. J Cell Biochem 2019;120:6860-7. [PMID: 30378159 DOI: 10.1002/jcb.27992] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 490 |
Mancera N, Smalley KS, Margo CE. Melanoma of the eyelid and periocular skin: Histopathologic classification and molecular pathology. Survey of Ophthalmology 2019;64:272-88. [DOI: 10.1016/j.survophthal.2018.12.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 491 |
Hussain W, Khan YD, Rasool N, Khan SA, Chou K. SPrenylC-PseAAC: A sequence-based model developed via Chou's 5-steps rule and general PseAAC for identifying S-prenylation sites in proteins. Journal of Theoretical Biology 2019;468:1-11. [DOI: 10.1016/j.jtbi.2019.02.007] [Cited by in Crossref: 70] [Cited by in F6Publishing: 98] [Article Influence: 17.5] [Reference Citation Analysis]
|
| 492 |
Sakanashi F, Shintani M, Tsuneyoshi M, Ohsaki H, Kamoshida S. Apoptosis, necroptosis and autophagy in colorectal cancer: Associations with tumor aggressiveness and p53 status. Pathol Res Pract 2019;215:152425. [PMID: 31097354 DOI: 10.1016/j.prp.2019.04.017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 493 |
Lim JKM, Delaidelli A, Minaker SW, Zhang HF, Colovic M, Yang H, Negri GL, von Karstedt S, Lockwood WW, Schaffer P, Leprivier G, Sorensen PH. Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance. Proc Natl Acad Sci U S A 2019;116:9433-42. [PMID: 31000598 DOI: 10.1073/pnas.1821323116] [Cited by in Crossref: 116] [Cited by in F6Publishing: 125] [Article Influence: 29.0] [Reference Citation Analysis]
|
| 494 |
Cho W, Jin X, Pang J, Wang Y, Mivechi NF, Moskophidis D. The Molecular Chaperone Heat Shock Protein 70 Controls Liver Cancer Initiation and Progression by Regulating Adaptive DNA Damage and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Signaling Pathways. Mol Cell Biol 2019;39:e00391-18. [PMID: 30745413 DOI: 10.1128/MCB.00391-18] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 495 |
Xu K, Park D, Magis AT, Zhang J, Zhou W, Sica GL, Ramalingam SS, Curran WJ, Deng X. Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy. Mol Cancer 2019;18:85. [PMID: 30971271 DOI: 10.1186/s12943-019-1012-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 496 |
Nussinov R, Jang H, Tsai CJ, Cheng F. Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers. PLoS Comput Biol 2019;15:e1006658. [PMID: 30921324 DOI: 10.1371/journal.pcbi.1006658] [Cited by in Crossref: 52] [Cited by in F6Publishing: 58] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 497 |
Ghosh AK, Samanta I, Mondal A, Liu WR. Covalent Inhibition in Drug Discovery. ChemMedChem 2019;14:889-906. [PMID: 30816012 DOI: 10.1002/cmdc.201900107] [Cited by in Crossref: 116] [Cited by in F6Publishing: 120] [Article Influence: 29.0] [Reference Citation Analysis]
|
| 498 |
Grassinger JM, Merz S, Aupperle-Lellbach H, Erhard H, Klopfleisch R. Correlation of BRAF Variant V595E, Breed, Histological Grade and Cyclooxygenase-2 Expression in Canine Transitional Cell Carcinomas. Vet Sci 2019;6:E31. [PMID: 30893857 DOI: 10.3390/vetsci6010031] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 499 |
Shimomura I, Yokoi A, Kohama I, Kumazaki M, Tada Y, Tatsumi K, Ochiya T, Yamamoto Y. Drug library screen reveals benzimidazole derivatives as selective cytotoxic agents for KRAS-mutant lung cancer. Cancer Lett 2019;451:11-22. [PMID: 30862488 DOI: 10.1016/j.canlet.2019.03.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 500 |
Zhao G, Guo S, Jiang K, Zhang T, Wu H, Qiu C, Deng G. MiRNA profiling of plasma-derived exosomes from dairy cows during gestation. Theriogenology 2019;130:89-98. [PMID: 30878693 DOI: 10.1016/j.theriogenology.2019.03.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 501 |
Adderley H, Blackhall FH, Lindsay CR. KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition. EBioMedicine 2019;41:711-6. [PMID: 30852159 DOI: 10.1016/j.ebiom.2019.02.049] [Cited by in Crossref: 80] [Cited by in F6Publishing: 85] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 502 |
Cimino PJ, Huang L, Du L, Wu Y, Bishop J, Dalsing-Hernandez J, Kotlarczyk K, Gonzales P, Carew J, Nawrocki S, Jordan MA, Wilson L, Lloyd GK, Wirsching HG. Plinabulin, an inhibitor of tubulin polymerization, targets KRAS signaling through disruption of endosomal recycling. Biomed Rep 2019;10:218-24. [PMID: 30972217 DOI: 10.3892/br.2019.1196] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 503 |
Zhang Y, Wang Z, Ma X, Yang S, Hu X, Tao J, Hou Y, Bai G. Glycyrrhetinic acid binds to the conserved P-loop region and interferes with the interaction of RAS-effector proteins. Acta Pharm Sin B 2019;9:294-303. [PMID: 30976491 DOI: 10.1016/j.apsb.2018.11.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 504 |
Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, Dinardo CD, Cortes JE, Jabbour EJ, Garcia-manero G, Kantarjian HM, Ravandi F. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 2019;19:142-148.e1. [DOI: 10.1016/j.clml.2018.12.009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 505 |
Kawiak A, Domachowska A, Lojkowska E. Plumbagin Increases Paclitaxel-Induced Cell Death and Overcomes Paclitaxel Resistance in Breast Cancer Cells through ERK-Mediated Apoptosis Induction. J Nat Prod 2019;82:878-85. [DOI: 10.1021/acs.jnatprod.8b00964] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 506 |
van Montfort T, van der Sluis R, Darcis G, Beaty D, Groen K, Pasternak AO, Pollakis G, Vink M, Westerhout EM, Hamdi M, Bakker M, van der Putten B, Jurriaans S, Prins JH, Jeeninga R, Thomas AAM, Speijer D, Berkhout B. Dendritic cells potently purge latent HIV-1 beyond TCR-stimulation, activating the PI3K-Akt-mTOR pathway. EBioMedicine 2019;42:97-108. [PMID: 30824386 DOI: 10.1016/j.ebiom.2019.02.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 507 |
Chan ASL, Narita M. Short-term gain, long-term pain: the senescence life cycle and cancer. Genes Dev 2019;33:127-43. [PMID: 30709901 DOI: 10.1101/gad.320937.118] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 11.3] [Reference Citation Analysis]
|
| 508 |
Sharma AK, Lee SJ, Zhou M, Rigby AC, Townson SA. NMR 1H,13C, 15N resonance assignment of the G12C mutant of human K-Ras bound to GppNHp. Biomol NMR Assign 2019;13:227-31. [PMID: 30798456 DOI: 10.1007/s12104-019-09882-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 509 |
Wang Y, Xiong H, Liu D, Hill C, Ertay A, Li J, Zou Y, Miller P, White E, Downward J, Goldin RD, Yuan X, Lu X. Autophagy inhibition specifically promotes epithelial-mesenchymal transition and invasion in RAS-mutated cancer cells. Autophagy 2019;15:886-99. [PMID: 30782064 DOI: 10.1080/15548627.2019.1569912] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 15.5] [Reference Citation Analysis]
|
| 510 |
Wang Z, Tao H, Ma Y, Tang T, Zhang Q, Jiang Q, Qi S, Li J, Qi Z. [Aloin induces apoptosis via regulating the activation of MAPKs signaling pathway in human gastric cancer cells in vitro]. Nan Fang Yi Ke Da Xue Xue Bao 2018;38:1025-31. [PMID: 30377097 DOI: 10.12122/j.issn.1673-4254.2018.09.01] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
|
| 511 |
Hatzidaki E, Parsonidis P, Apostolou P, Daikopoulou V, Papasotiriou I. Novel small molecule decreases cell proliferation, migration, clone formation, and gene expression through ERK inhibition in MCF-7 and MDA-MB-231 breast cancer cell lines. Anticancer Drugs 2019;30:618-27. [PMID: 30741723 DOI: 10.1097/CAD.0000000000000766] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 512 |
Yin C, Zhu B, Zhang T, Liu T, Chen S, Liu Y, Li X, Miao X, Li S, Mi X, Zhang J, Li L, Wei G, Xu Z, Gao X, Huang C, Wei Z, Goding CR, Wang P, Deng X, Cui R. Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis. Cell 2019;176:1113-1127.e16. [DOI: 10.1016/j.cell.2019.01.002] [Cited by in Crossref: 38] [Cited by in F6Publishing: 45] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 513 |
Hillig RC, Sautier B, Schroeder J, Moosmayer D, Hilpmann A, Stegmann CM, Werbeck ND, Briem H, Boemer U, Weiske J, Badock V, Mastouri J, Petersen K, Siemeister G, Kahmann JD, Wegener D, Böhnke N, Eis K, Graham K, Wortmann L, von Nussbaum F, Bader B. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction. Proc Natl Acad Sci U S A 2019;116:2551-60. [PMID: 30683722 DOI: 10.1073/pnas.1812963116] [Cited by in Crossref: 156] [Cited by in F6Publishing: 164] [Article Influence: 39.0] [Reference Citation Analysis]
|
| 514 |
Park J, Cho YH, Shin WJ, Lee SK, Lee J, Kim T, Cha PH, Yang JS, Cho J, Min DS, Han G, Lee HY, Choi KY. A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer. Sci Rep 2019;9:648. [PMID: 30679620 DOI: 10.1038/s41598-018-37059-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 515 |
Tomiyama A, Ichimura K. Signal transduction pathways and resistance to targeted therapies in glioma. Semin Cancer Biol 2019;58:118-29. [PMID: 30685341 DOI: 10.1016/j.semcancer.2019.01.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
|
| 516 |
Jeong WJ, Park JC, Kim WS, Ro EJ, Jeon SH, Lee SK, Park YN, Min DS, Choi KY. WDR76 is a RAS binding protein that functions as a tumor suppressor via RAS degradation. Nat Commun 2019;10:295. [PMID: 30655611 DOI: 10.1038/s41467-018-08230-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 517 |
Shahjahani M, Hadad EH, Azizidoost S, Nezhad KC, Shahrabi S. Complex karyotype in myelodysplastic syndromes: Diagnostic procedure and prognostic susceptibility. Oncol Rev 2019;13:389. [PMID: 30858933 DOI: 10.4081/oncol.2019.389] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 518 |
Budko AA, Khesina PA, Diakov LM, Lazarevich NL. Small GTPase Rab3B: biological properties and possible role in carcinogenesis. Usp mol onkol 2019;5:78-85. [DOI: 10.17650/2313-805x-2018-5-4-78-85] [Reference Citation Analysis]
|
| 519 |
Tsang C, Lo K, Nicholls JM, Huang S, Tsao S. Pathogenesis of Nasopharyngeal Carcinoma. Nasopharyngeal Carcinoma 2019. [DOI: 10.1016/b978-0-12-814936-2.00003-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 520 |
Hou W, Duensing S. Biomarkers for Anti-angiogenic Therapy. Tumor Angiogenesis 2019. [DOI: 10.1007/978-3-319-33673-2_32] [Reference Citation Analysis]
|
| 521 |
Wit EC. Introduction to Network Inference in Genomics. Network Science 2019. [DOI: 10.1007/978-3-030-26814-5_7] [Reference Citation Analysis]
|
| 522 |
Li N, Zhao X, You S. Identification of key regulators of pancreatic ductal adenocarcinoma using bioinformatics analysis of microarray data. Medicine (Baltimore) 2019;98:e14074. [PMID: 30633213 DOI: 10.1097/MD.0000000000014074] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 523 |
Nguyen R, Dyer MA. Neuroblastoma. Neuroblastoma 2019. [DOI: 10.1016/b978-0-12-812005-7.00003-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 524 |
Vail DM, Thamm DH, Liptak JM. Molecular/Targeted Therapy of Cancer. Withrow and MacEwen's Small Animal Clinical Oncology 2019. [DOI: 10.1016/b978-0-323-59496-7.00015-3] [Reference Citation Analysis]
|
| 525 |
Damodaran S, Willis J, Roychowdhury S. Precision Cancer Medicine and Clinical Trial Design. Precision Cancer Medicine 2019. [DOI: 10.1007/978-3-030-23637-3_4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 526 |
Malik P, Ameta RK. Recent Advances in the au NP Treatment Strategies of Lung Cancers. Biomedical Engineering and its Applications in Healthcare 2019. [DOI: 10.1007/978-981-13-3705-5_29] [Reference Citation Analysis]
|
| 527 |
Bhatia DR, Rath S, Gupta S. New Emerging Molecules in Cancer Research Which Hold Promise in Current Era. Unravelling Cancer Signaling Pathways: A Multidisciplinary Approach 2019. [DOI: 10.1007/978-981-32-9816-3_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 528 |
Yang T, Wen Y, Li J, Tan T, Yang J, Pan J, Hu C, Yao Y, Zhang J, Xin Y, Li S, Xia H, He J, Zou Y. NRAS and KRAS polymorphisms are not associated with hepatoblastoma susceptibility in Chinese children. Exp Hematol Oncol 2019;8:11. [PMID: 31086727 DOI: 10.1186/s40164-019-0135-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 148] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 529 |
Huang H, Li K, Liu Q, Zhao Y, Xu H, Wu W, Sun K, Ni J, Lin J. Dual-response CuS@MnO 2 nanoparticles with activatable CT/MR-enhanced in vivo imaging guided photothermal therapy. RSC Adv 2019;9:2718-30. [DOI: 10.1039/c8ra08637k] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 530 |
Lonetti A, Pession A, Masetti R. Targeted Therapies for Pediatric AML: Gaps and Perspective. Front Pediatr 2019;7:463. [PMID: 31803695 DOI: 10.3389/fped.2019.00463] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 9.8] [Reference Citation Analysis]
|
| 531 |
Lee WJ, Moon J, Jeon D, Kim TJ, Yoo JS, Park DK, Lee ST, Jung KH, Park KI, Jung KY, Kim M, Lee SK, Chu K. Possible epigenetic regulatory effect of dysregulated circular RNAs in epilepsy. PLoS One 2018;13:e0209829. [PMID: 30592747 DOI: 10.1371/journal.pone.0209829] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 532 |
de Weger VA, de Jonge M, Langenberg MHG, Schellens JHM, Lolkema M, Varga A, Demers B, Thomas K, Hsu K, Tuffal G, Goodstal S, Macé S, Deutsch E. A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours. Br J Cancer 2019;120:286-93. [PMID: 30585255 DOI: 10.1038/s41416-018-0355-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 533 |
Zhao S, Chen H, Ding B, Li J, Lv F, Han K, Zhou D, Yu B, Yu Y, Zhang W. Construction of a transcription factor‑long non‑coding RNA‑microRNA network for the identification of key regulators in lung adenocarcinoma and lung squamous cell carcinoma. Mol Med Rep 2019;19:1101-9. [PMID: 30569133 DOI: 10.3892/mmr.2018.9769] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 534 |
Horio Y. Blocking KRAS Signaling for the Treatment of Lung Cancer: Mission Possible? JJLC 2018;58:953-958. [DOI: 10.2482/haigan.58.953] [Reference Citation Analysis]
|
| 535 |
Turbat-Herrera EA, Kilpatrick MJ, Chen J, Meram AT, Cotelingam J, Ghali G, Kevil CG, Coppola D, Shackelford RE. Cystathione β-Synthase Is Increased in Thyroid Malignancies. Anticancer Res 2018;38:6085-90. [PMID: 30396922 DOI: 10.21873/anticanres.12958] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 536 |
Barclay SF, Inman KW, Luks VL, McIntyre JB, Al-Ibraheemi A, Church AJ, Perez-Atayde AR, Mangray S, Jeng M, Kreimer SR, Walker L, Fishman SJ, Alomari AI, Chaudry G, Trenor Iii CC, Adams D, Kozakewich HPW, Kurek KC. A somatic activating NRAS variant associated with kaposiform lymphangiomatosis. Genet Med 2019;21:1517-24. [PMID: 30542204 DOI: 10.1038/s41436-018-0390-0] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 10.8] [Reference Citation Analysis]
|
| 537 |
Hasan MS, Wu X, Zhang L. Uncovering missed indels by leveraging unmapped reads.. [DOI: 10.1101/488601] [Reference Citation Analysis]
|
| 538 |
Shi Y, Yang M, Liu L, Pang Y, Long Y, Zheng H. GTP as a peroxidase-mimic to mediate enzymatic cascade reaction for alkaline phosphatase detection and alkaline phosphatase-linked immunoassay. Sensors and Actuators B: Chemical 2018;275:43-9. [DOI: 10.1016/j.snb.2018.08.038] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 539 |
Anguiano-Sevilla LA, Lugo-Cervantes E, Ordaz-Pichardo C, Rosas-Trigueros JL, Jaramillo-Flores ME. Apoptosis Induction of Agave lechuguilla Torrey Extract on Human Lung Adenocarcinoma Cells (SK-LU-1). Int J Mol Sci 2018;19:E3765. [PMID: 30486412 DOI: 10.3390/ijms19123765] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 540 |
Yang L, Ahn DJ, Koo E. An Ultrasensitive FRET-based DNA Sensor via the Accumulated QD System Derivatized in the Nano-beads. BioChip J 2018;12:340-7. [DOI: 10.1007/s13206-018-2406-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 541 |
Zhang Z, Du J, Wang S, Shao L, Jin K, Li F, Wei B, Ding W, Fu P, van Dam H, Wang A, Jin J, Ding C, Yang B, Zheng M, Feng XH, Guan KL, Zhang L. OTUB2 Promotes Cancer Metastasis via Hippo-Independent Activation of YAP and TAZ. Mol Cell 2019;73:7-21.e7. [PMID: 30472188 DOI: 10.1016/j.molcel.2018.10.030] [Cited by in Crossref: 60] [Cited by in F6Publishing: 68] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 542 |
Zhang G, Yu Z, Fu S, Lv C, Dong Q, Fu C, Kong C, Zeng Y. ERCC6L that is up-regulated in high grade of renal cell carcinoma enhances cell viability in vitro and promotes tumor growth in vivo potentially through modulating MAPK signalling pathway. Cancer Gene Ther 2019;26:323-33. [PMID: 30459398 DOI: 10.1038/s41417-018-0064-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 543 |
Lee SK, Cho YH, Cha PH, Yoon JS, Ro EJ, Jeong WJ, Park J, Kim H, Il Kim T, Min DS, Han G, Choi KY. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab. Exp Mol Med 2018;50:1-12. [PMID: 30459318 DOI: 10.1038/s12276-018-0182-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 544 |
Choi KM, Cho E, Kim E, Shin JH, Kang M, Kim B, Han EH, Chung YH, Kim JY. Prolonged MEK inhibition leads to acquired resistance and increased invasiveness in KRAS mutant gastric cancer. Biochem Biophys Res Commun. 2018;507:311-318. [PMID: 30466782 DOI: 10.1016/j.bbrc.2018.11.030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 545 |
López-Cortés A, Paz-Y-Miño C, Cabrera-Andrade A, Barigye SJ, Munteanu CR, González-Díaz H, Pazos A, Pérez-Castillo Y, Tejera E. Gene prioritization, communality analysis, networking and metabolic integrated pathway to better understand breast cancer pathogenesis. Sci Rep 2018;8:16679. [PMID: 30420728 DOI: 10.1038/s41598-018-35149-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 546 |
Lee SK, Jeong WJ, Cho YH, Cha PH, Yoon JS, Ro EJ, Choi S, Oh JM, Heo Y, Kim H, Min DS, Han G, Lee W, Choi KY. β-Catenin-RAS interaction serves as a molecular switch for RAS degradation via GSK3β. EMBO Rep 2018;19:e46060. [PMID: 30413483 DOI: 10.15252/embr.201846060] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 547 |
Yang JM, Bhattacharya S, West-Foyle H, Hung CF, Wu TC, Iglesias PA, Huang CH. Integrating chemical and mechanical signals through dynamic coupling between cellular protrusions and pulsed ERK activation. Nat Commun 2018;9:4673. [PMID: 30405112 DOI: 10.1038/s41467-018-07150-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 548 |
Iarrobino NA, Gill B, Bernard ME, Mishra MV, Champ CE. Targeting Tumor Metabolism With Statins During Treatment for Advanced-stage Pancreatic Cancer. Am J Clin Oncol. 2018;41:1125-1131. [PMID: 29509593 DOI: 10.1097/coc.0000000000000433] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 549 |
Cruz-Nova P, Schnoor M, Correa-Basurto J, Bello M, Briseño-Diaz P, Rojo-Domínguez A, Ortiz-Mendoza CM, Guerrero-Aguirre J, García-Vázquez FJ, Hernández-Rivas R, Thompson-Bonilla MDR, Vargas M. The small organic molecule C19 binds and strengthens the KRAS4b-PDEδ complex and inhibits growth of colorectal cancer cells in vitro and in vivo. BMC Cancer 2018;18:1056. [PMID: 30382908 DOI: 10.1186/s12885-018-4968-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 550 |
Knowles EEM, Mathias SR, Mollon J, Rodrigue A, Koenis MMG, Dyer TD, Goring HHH, Curran JE, Olvera RL, Duggirala R, Almasy L, Blangero J, Glahn DC. A QTL on chromosome 3q23 influences processing speed in humans. Genes Brain Behav 2019;18:e12530. [PMID: 30379395 DOI: 10.1111/gbb.12530] [Reference Citation Analysis]
|
| 551 |
Mishra A, Jaiswal R, Amita P, Mishra SC. Molecular interactions in juvenile nasopharyngeal angiofibroma: preliminary signature and relevant review. Eur Arch Otorhinolaryngol 2019;276:93-100. [DOI: 10.1007/s00405-018-5178-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 552 |
Rezaei Adariani S, Buchholzer M, Akbarzadeh M, Nakhaei-Rad S, Dvorsky R, Ahmadian MR. Structural snapshots of RAF kinase interactions. Biochem Soc Trans 2018;46:1393-406. [PMID: 30381334 DOI: 10.1042/BST20170528] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 553 |
Novelli ET, First JT, Webb LJ. Quantitative Measurement of Intrinsic GTP Hydrolysis for Carcinogenic Glutamine 61 Mutants in H-Ras. Biochemistry 2018;57:6356-66. [PMID: 30339365 DOI: 10.1021/acs.biochem.8b00878] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 554 |
Gao XJ, Chong LS, Kim MS, Elowitz MB. Programmable protein circuits in living cells. Science 2018;361:1252-8. [PMID: 30237357 DOI: 10.1126/science.aat5062] [Cited by in Crossref: 174] [Cited by in F6Publishing: 173] [Article Influence: 34.8] [Reference Citation Analysis]
|
| 555 |
Iezzi A, Caiola E, Scagliotti A, Broggini M. Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cells. BMC Cancer 2018;18:1028. [PMID: 30352565 DOI: 10.1186/s12885-018-4949-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 556 |
Theodosakis N, Langdon CG, Micevic G, Krykbaeva I, Means RE, Stern DF, Bosenberg MW. Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment-resistant melanoma, colorectal, and lung cancer. Pigment Cell Melanoma Res. 2019;32:292-302. [PMID: 30281931 DOI: 10.1111/pcmr.12742] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 557 |
Méndez-García LA, Nava-Castro KE, Ochoa-Mercado TL, Palacios-Arreola MI, Ruiz-Manzano RA, Segovia-Mendoza M, Solleiro-Villavicencio H, Cázarez-Martínez C, Morales-Montor J. Breast Cancer Metastasis: Are Cytokines Important Players During Its Development and Progression? J Interferon Cytokine Res 2019;39:39-55. [PMID: 30321090 DOI: 10.1089/jir.2018.0024] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 558 |
El-ghamry H, El-wakiel N, Khamis A. Synthesis, structure, antiproliferative activity and molecular docking of divalent and trivalent metal complexes of 4 H -3,5-diamino-1,2,4-triazole and α-hydroxynaphthaldehyde Schiff base ligand: Triazole Schiff base complexes and antiproliferative activity. Appl Organometal Chem 2018;32:e4583. [DOI: 10.1002/aoc.4583] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 559 |
Tian Y, Ma Y, Wu S, Zhang T, Li Z, Wang G, Zhang J. Understand the acquired resistance of RTK inhibitors by computational receptor tyrosine kinases network. Computational Biology and Chemistry 2018;76:275-282. [DOI: 10.1016/j.compbiolchem.2018.07.017] [Reference Citation Analysis]
|
| 560 |
Giménez N, Martínez-Trillos A, Montraveta A, Lopez-Guerra M, Rosich L, Nadeu F, Valero JG, Aymerich M, Magnano L, Rozman M, Matutes E, Delgado J, Baumann T, Gine E, González M, Alcoceba M, Terol MJ, Navarro B, Colado E, Payer AR, Puente XS, López-Otín C, Lopez-Guillermo A, Campo E, Colomer D, Villamor N. Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia. Haematologica 2019;104:576-86. [PMID: 30262568 DOI: 10.3324/haematol.2018.196931] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 561 |
Portale F, Cricrì G, Bresolin S, Lupi M, Gaspari S, Silvestri D, Russo B, Marino N, Ubezio P, Pagni F, Vergani P, Kronnie GT, Valsecchi MG, Locatelli F, Rizzari C, Biondi A, Dander E, D'Amico G. ActivinA: a new leukemia-promoting factor conferring migratory advantage to B-cell precursor-acute lymphoblastic leukemic cells. Haematologica 2019;104:533-45. [PMID: 30262563 DOI: 10.3324/haematol.2018.188664] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 562 |
Magalhães M, Alvarez-Lorenzo C, Concheiro A, Figueiras A, Santos AC, Veiga F. RNAi-based therapeutics for lung cancer: biomarkers, microRNAs, and nanocarriers. Expert Opin Drug Deliv 2018;15:965-82. [PMID: 30232915 DOI: 10.1080/17425247.2018.1517744] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 563 |
Phelps MP, Yang H, Patel S, Rahman MM, McFadden G, Chen E. Oncolytic Virus-Mediated RAS Targeting in Rhabdomyosarcoma. Mol Ther Oncolytics 2018;11:52-61. [PMID: 30364635 DOI: 10.1016/j.omto.2018.09.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 564 |
Geeleher P, Nath A, Wang F, Zhang Z, Barbeira AN, Fessler J, Grossman RL, Seoighe C, Stephanie Huang R. Cancer expression quantitative trait loci (eQTLs) can be determined from heterogeneous tumor gene expression data by modeling variation in tumor purity. Genome Biol 2018;19:130. [PMID: 30205839 DOI: 10.1186/s13059-018-1507-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 565 |
Wong KY, Yao Q, Yuan LQ, Li Z, Ma ESK, Chim CS. Frequent functional activation of RAS signalling not explained by RAS/RAF mutations in relapsed/refractory multiple myeloma. Sci Rep 2018;8:13522. [PMID: 30201956 DOI: 10.1038/s41598-018-31820-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 566 |
Adhikari H, Counter CM. Interrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability. Nat Commun 2018;9:3646. [PMID: 30194290 DOI: 10.1038/s41467-018-05692-6] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 8.6] [Reference Citation Analysis]
|
| 567 |
Zeng Y, Xiao D, He H, He J, Pan H, Yang W, Chen Y, He J. SERINC2-knockdown inhibits proliferation, migration and invasion in lung adenocarcinoma. Oncol Lett 2018;16:5916-22. [PMID: 30405754 DOI: 10.3892/ol.2018.9403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 568 |
Ramos MC, Genilloud O, Reyes F, Vicente F. Drug Discovery from Natural Products for Pancreatic Cancer. Advances in Pancreatic Cancer 2018. [DOI: 10.5772/intechopen.76399] [Reference Citation Analysis]
|
| 569 |
Tang R, Jia Y, Zheng W, Feng Q, Zheng W, Jiang X. Nanocatalyst Complex Can Dephosphorylate Key Proteins in MAPK Pathway for Cancer Therapy. Adv Healthc Mater 2018;7:e1800533. [PMID: 30019396 DOI: 10.1002/adhm.201800533] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 570 |
Ibe I, Haynes M, Koo A, Lindskog D, Friedlaender GE, Lee FY. Molecular Targeted Therapy Approach to Musculoskeletal Tumors. Techniques in Orthopaedics 2018;33:135-9. [DOI: 10.1097/bto.0000000000000298] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 571 |
Mazhar S, Taylor SE, Sangodkar J, Narla G. Targeting PP2A in cancer: Combination therapies. Biochim Biophys Acta Mol Cell Res 2019;1866:51-63. [PMID: 30401535 DOI: 10.1016/j.bbamcr.2018.08.020] [Cited by in Crossref: 66] [Cited by in F6Publishing: 71] [Article Influence: 13.2] [Reference Citation Analysis]
|
| 572 |
Sánchez-Danés A, Blanpain C. Deciphering the cells of origin of squamous cell carcinomas. Nat Rev Cancer 2018;18:549-61. [PMID: 29849070 DOI: 10.1038/s41568-018-0024-5] [Cited by in Crossref: 121] [Cited by in F6Publishing: 124] [Article Influence: 24.2] [Reference Citation Analysis]
|
| 573 |
Mishra A, Mishra SC, Tripathi AM, Pandey A. Clinical correlation of molecular (VEGF, FGF, PDGF, c-Myc, c-Kit, Ras, p53) expression in juvenile nasopharyngeal angiofibroma. Eur Arch Otorhinolaryngol 2018;275:2719-26. [DOI: 10.1007/s00405-018-5110-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 574 |
Burclaff J, Mills JC. Plasticity of differentiated cells in wound repair and tumorigenesis, part II: skin and intestine. Dis Model Mech 2018;11:dmm035071. [PMID: 30171151 DOI: 10.1242/dmm.035071] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 575 |
T D, Venkatraman P, Vemparala S. Phosphorylation promotes binding affinity of Rap-Raf complex by allosteric modulation of switch loop dynamics. Sci Rep 2018;8:12976. [PMID: 30154518 DOI: 10.1038/s41598-018-31234-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 576 |
Tian D, Li Y, Li X, Tian Z. Aloperine inhibits proliferation, migration and invasion and induces apoptosis by blocking the Ras signaling pathway in human breast cancer cells. Mol Med Rep 2018;18:3699-710. [PMID: 30132540 DOI: 10.3892/mmr.2018.9419] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 577 |
Diana A, Franzese E, Centonze S, Carlino F, Della Corte CM, Ventriglia J, Petrillo A, De Vita F, Alfano R, Ciardiello F, Orditura M. Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs. Curr Oncol Rep 2018;20:76. [PMID: 30128845 DOI: 10.1007/s11912-018-0726-6] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 10.4] [Reference Citation Analysis]
|
| 578 |
Li X, Wang J, Zhang C, Lin C, Zhang J, Zhang W, Zhang W, Lu Y, Zheng L, Li X. Circular RNA circITGA7 inhibits colorectal cancer growth and metastasis by modulating the Ras pathway and upregulating transcription of its host gene ITGA7: CircITGA7 inhibits CRC growth and metastasis. J Pathol 2018;246:166-79. [DOI: 10.1002/path.5125] [Cited by in Crossref: 135] [Cited by in F6Publishing: 154] [Article Influence: 27.0] [Reference Citation Analysis]
|
| 579 |
Tosi D, Pérez-Gracia E, Atis S, Vié N, Combès E, Gabanou M, Larbouret C, Jarlier M, Mollevi C, Torro A, Del Rio M, Martineau P, Gongora C. Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment. BMC Cancer 2018;18:812. [PMID: 30103709 DOI: 10.1186/s12885-018-4712-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 580 |
Bourhill T, Mori Y, Rancourt DE, Shmulevitz M, Johnston RN. Going (Reo)Viral: Factors Promoting Successful Reoviral Oncolytic Infection. Viruses 2018;10:E421. [PMID: 30103501 DOI: 10.3390/v10080421] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 581 |
Lo JH, Hao L, Muzumdar MD, Raghavan S, Kwon EJ, Pulver EM, Hsu F, Aguirre AJ, Wolpin BM, Fuchs CS, Hahn WC, Jacks T, Bhatia SN. iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer. Mol Cancer Ther 2018;17:2377-88. [PMID: 30097486 DOI: 10.1158/1535-7163.MCT-17-1090] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
|
| 582 |
Heiden BT, Patel N, Nancarrow DJ, Hermann M, Brown RKJ, Orringer MB, Lin J, Chang AC, Carrott PW, Lynch WR, Zhao L, Beer DG, Reddy RM. Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake Correlates with KRAS and EMT Gene Signatures in Operable Esophageal Adenocarcinoma. J Surg Res 2018;232:621-8. [PMID: 30463782 DOI: 10.1016/j.jss.2018.06.046] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 583 |
Alon M, Arafeh R, Lee JS, Madan S, Kalaora S, Nagler A, Abgarian T, Greenberg P, Ruppin E, Samuels Y. CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma. Oncotarget 2018;9:31264-77. [PMID: 30131853 DOI: 10.18632/oncotarget.25805] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 584 |
Yao L, Conforti F, Hill C, Bell J, Drawater L, Li J, Liu D, Xiong H, Alzetani A, Chee SJ, Marshall BG, Fletcher SV, Hancock D, Coldwell M, Yuan X, Ottensmeier CH, Downward J, Collins JE, Ewing RM, Richeldi L, Skipp P, Jones MG, Davies DE, Wang Y. Paracrine signalling during ZEB1-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in lung fibrosis. Cell Death Differ 2019;26:943-57. [PMID: 30050057 DOI: 10.1038/s41418-018-0175-7] [Cited by in Crossref: 58] [Cited by in F6Publishing: 64] [Article Influence: 11.6] [Reference Citation Analysis]
|
| 585 |
Burclaff J, Mills JC. Plasticity of differentiated cells in wound repair and tumorigenesis, part I: stomach and pancreas. Dis Model Mech 2018;11:dmm033373. [PMID: 30037967 DOI: 10.1242/dmm.033373] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 586 |
Janostiak R, Rauniyar N, Lam TT, Ou J, Zhu LJ, Green MR, Wajapeyee N. MELK Promotes Melanoma Growth by Stimulating the NF-κB Pathway. Cell Rep 2017;21:2829-41. [PMID: 29212029 DOI: 10.1016/j.celrep.2017.11.033] [Cited by in Crossref: 42] [Cited by in F6Publishing: 49] [Article Influence: 8.4] [Reference Citation Analysis]
|
| 587 |
Shallis RM, Ahmad R, Zeidan AM. The genetic and molecular pathogenesis of myelodysplastic syndromes. Eur J Haematol 2018;101:260-71. [PMID: 29742289 DOI: 10.1111/ejh.13092] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 8.2] [Reference Citation Analysis]
|
| 588 |
Bery N, Cruz-Migoni A, Bataille CJ, Quevedo CE, Tulmin H, Miller A, Russell A, Phillips SE, Carr SB, Rabbitts TH. BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions. Elife 2018;7:e37122. [PMID: 29989546 DOI: 10.7554/eLife.37122] [Cited by in Crossref: 25] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 589 |
Urasaki Y, Fiscus RR, Le TT. Detection of the Cell Cycle-Regulated Negative Feedback Phosphorylation of Mitogen-Activated Protein Kinases in Breast Carcinoma using Nanofluidic Proteomics. Sci Rep 2018;8:9991. [PMID: 29968772 DOI: 10.1038/s41598-018-28335-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 590 |
Counihan JL, Grossman EA, Nomura DK. Cancer Metabolism: Current Understanding and Therapies. Chem Rev 2018;118:6893-923. [DOI: 10.1021/acs.chemrev.7b00775] [Cited by in Crossref: 106] [Cited by in F6Publishing: 113] [Article Influence: 21.2] [Reference Citation Analysis]
|
| 591 |
Zhou Z, Wang Y, Li J, Hu B, Lin X, Chen Y, Wang R, Liu J, Liu H. Design, synthesis, and biological evaluation of Cyclobentinib (CB1107) as a potential anti-CML agent. Med Chem Res 2018;27:1863-75. [DOI: 10.1007/s00044-018-2198-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 592 |
Lee H, Kim N, Yoo YJ, Kim H, Jeong E, Choi S, Moon SU, Oh SH, Mills GB, Yoon S, Kim WY. β-catenin/TCF activity regulates IGF-1R tyrosine kinase inhibitor sensitivity in colon cancer. Oncogene 2018;37:5466-75. [PMID: 29895971 DOI: 10.1038/s41388-018-0362-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 593 |
Peng X, Liu Y, Peng X, Wang Z, Zhang Z, Qiu Y, Jin M, Wang R, Kong D. Clinical features and the molecular biomarkers of olfactory neuroblastoma. Pathol Res Pract 2018;214:1123-9. [PMID: 29921494 DOI: 10.1016/j.prp.2018.06.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 594 |
Lindsay CR, Jamal-Hanjani M, Forster M, Blackhall F. KRAS: Reasons for optimism in lung cancer. Eur J Cancer 2018;99:20-7. [PMID: 29894909 DOI: 10.1016/j.ejca.2018.05.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 7.4] [Reference Citation Analysis]
|
| 595 |
Ray K, Ujvari B, Ramana V, Donald J. Cross-talk between EGFR and IL-6 drives oncogenic signaling and offers therapeutic opportunities in cancer. Cytokine & Growth Factor Reviews 2018;41:18-27. [DOI: 10.1016/j.cytogfr.2018.04.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 596 |
Krygowska AA, Castellano E. PI3K: A Crucial Piece in the RAS Signaling Puzzle. Cold Spring Harb Perspect Med 2018;8:a031450. [PMID: 28847905 DOI: 10.1101/cshperspect.a031450] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 597 |
Tape CJ. The Heterocellular Emergence of Colorectal Cancer. Trends Cancer 2017;3:79-88. [PMID: 28239669 DOI: 10.1016/j.trecan.2016.12.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 598 |
Lin H, Fan X, He L, Zhou D. Methylation patterns of RASA3 associated with clinicopathological factors in hepatocellular carcinoma. J Cancer 2018;9:2116-22. [PMID: 29937930 DOI: 10.7150/jca.24567] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 599 |
Song K, Zhao W, Wang W, Zhang N, Wang K, Chang Z. Individualized predictive signatures for 5-fluorouracil-based chemotherapy in right- and left-sided colon cancer. Cancer Sci 2018;109:1939-48. [PMID: 29700901 DOI: 10.1111/cas.13622] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 600 |
Fuentes NR, Mlih M, Barhoumi R, Fan YY, Hardin P, Steele TJ, Behmer S, Prior IA, Karpac J, Chapkin RS. Long-Chain n-3 Fatty Acids Attenuate Oncogenic KRas-Driven Proliferation by Altering Plasma Membrane Nanoscale Proteolipid Composition. Cancer Res 2018;78:3899-912. [PMID: 29769200 DOI: 10.1158/0008-5472.CAN-18-0324] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 601 |
Wang H, Zhang Y, Yun H, Chen S, Chen Y, Liu Z. ERK expression and its correlation with STAT1 in esophageal squamous cell carcinoma. Oncotarget 2017;8:45249-58. [PMID: 28431406 DOI: 10.18632/oncotarget.16902] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 602 |
Van Sciver RE, Lee MP, Lee CD, Lafever AC, Svyatova E, Kanda K, Colliver AL, Siewertsz van Reesema LL, Tang-Tan AM, Zheleva V, Bwayi MN, Bian M, Schmidt RL, Matrisian LM, Petersen GM, Tang AH. A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology. Cancers (Basel) 2018;10:E142. [PMID: 29757973 DOI: 10.3390/cancers10050142] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 603 |
Hansen R, Peters U, Babbar A, Chen Y, Feng J, Janes MR, Li L, Ren P, Liu Y, Zarrinkar PP. The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors. Nat Struct Mol Biol 2018;25:454-62. [DOI: 10.1038/s41594-018-0061-5] [Cited by in Crossref: 81] [Cited by in F6Publishing: 82] [Article Influence: 16.2] [Reference Citation Analysis]
|
| 604 |
Ni G, Liang D, Cummins SF, Walton SF, Chen S, Wang Y, Mounsey K, Wei MQ, Yuan J, Pan X, Liu X, Wang T. Comparative Proteomic Study of the Antiproliferative Activity of Frog Host-Defence Peptide Caerin 1.9 and Its Additive Effect with Caerin 1.1 on TC-1 Cells Transformed with HPV16 E6 and E7. Biomed Res Int 2018;2018:7382351. [PMID: 29862288 DOI: 10.1155/2018/7382351] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 605 |
Kota S, Hou S, Guerrant W, Madoux F, Troutman S, Fernandez-Vega V, Alekseeva N, Madala N, Scampavia L, Kissil J, Spicer TP. A novel three-dimensional high-throughput screening approach identifies inducers of a mutant KRAS selective lethal phenotype. Oncogene 2018;37:4372-84. [PMID: 29743592 DOI: 10.1038/s41388-018-0257-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 606 |
Nguyen HT, Duong HQ. The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy (review). Oncol Lett. 2018;16:9-18. [PMID: 29928381 DOI: 10.3892/ol.2018.8679] [Cited by in Crossref: 68] [Cited by in F6Publishing: 93] [Article Influence: 13.6] [Reference Citation Analysis]
|
| 607 |
Park YR, Kim YM, Lee SW, Lee HY, Lee GE, Lee JE, Kim YT. Optimization to detect TP53 mutations in circulating cell-free tumor DNA from patients with serous epithelial ovarian cancer. Obstet Gynecol Sci 2018;61:328-36. [PMID: 29780774 DOI: 10.5468/ogs.2018.61.3.328] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 608 |
Banys-Paluchowski M, Fehm T, Janni W, Aktas B, Fasching PA, Kasimir-Bauer S, Milde-Langosch K, Pantel K, Rack B, Riethdorf S, Solomayer EF, Witzel I, Müller V. Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer. BMC Cancer 2018;18:541. [PMID: 29739347 DOI: 10.1186/s12885-018-4282-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 609 |
Narla G, Sangodkar J, Ryder CB. The impact of phosphatases on proliferative and survival signaling in cancer. Cell Mol Life Sci 2018;75:2695-718. [PMID: 29725697 DOI: 10.1007/s00018-018-2826-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 610 |
Sharma AK, Lee SJ, Rigby AC, Townson SA. NMR 1H,13C, 15N backbone and 13C side chain resonance assignment of the G12C mutant of human K-Ras bound to GDP. Biomol NMR Assign 2018;12:269-72. [PMID: 29721757 DOI: 10.1007/s12104-018-9821-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 611 |
Bratt JM, Chang KY, Rabowsky M, Franzi LM, Ott SP, Filosto S, Goldkorn T, Arif M, Last JA, Kenyon NJ, Zeki AA. Farnesyltransferase Inhibition Exacerbates Eosinophilic Inflammation and Airway Hyperreactivity in Mice with Experimental Asthma: The Complex Roles of Ras GTPase and Farnesylpyrophosphate in Type 2 Allergic Inflammation. J Immunol 2018;200:3840-56. [PMID: 29703864 DOI: 10.4049/jimmunol.1601317] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 612 |
Allaway RJ, Gosline SJC, La Rosa S, Knight P, Bakker A, Guinney J, Le LQ. Cutaneous neurofibromas in the genomics era: current understanding and open questions. Br J Cancer 2018;118:1539-48. [PMID: 29695767 DOI: 10.1038/s41416-018-0073-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 613 |
Huxley N, Crathorne L, Varley-Campbell J, Tikhonova I, Snowsill T, Briscoe S, Peters J, Bond M, Napier M, Hoyle M. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation. Health Technol Assess 2017;21:1-294. [PMID: 28682222 DOI: 10.3310/hta21380] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 614 |
Jang JW, Kim MK, Bae SC. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway. Small GTPases 2020;11:280-8. [PMID: 29457552 DOI: 10.1080/21541248.2018.1435986] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 615 |
Li C, Liu L, Dinu V. Pathways of topological rank analysis (PoTRA): a novel method to detect pathways involved in hepatocellular carcinoma. PeerJ 2018;6:e4571. [PMID: 29666752 DOI: 10.7717/peerj.4571] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 616 |
Akao Y, Kumazaki M, Shinohara H, Sugito N, Kuranaga Y, Tsujino T, Yoshikawa Y, Kitade Y. Impairment of K-Ras signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miR-143. Cancer Sci 2018;109:1455-67. [PMID: 29498789 DOI: 10.1111/cas.13559] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 617 |
Tuladhar A, Rein KS. Manumycin A Is a Potent Inhibitor of Mammalian Thioredoxin Reductase-1 (TrxR-1). ACS Med Chem Lett 2018;9:318-22. [PMID: 29670693 DOI: 10.1021/acsmedchemlett.7b00489] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 618 |
Ikeno Y, Seo S, Iwaisako K, Yoh T, Nakamoto Y, Fuji H, Taura K, Okajima H, Kaido T, Sakaguchi S, Uemoto S. Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by 18F-FDG-PET is associated with the KRAS mutation status and prognosis. J Transl Med. 2018;16:95. [PMID: 29642912 DOI: 10.1186/s12967-018-1475-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 619 |
Morciano G, Marchi S, Morganti C, Sbano L, Bittremieux M, Kerkhofs M, Corricelli M, Danese A, Karkucinska-Wieckowska A, Wieckowski MR, Bultynck G, Giorgi C, Pinton P. Role of Mitochondria-Associated ER Membranes in Calcium Regulation in Cancer-Specific Settings. Neoplasia 2018;20:510-23. [PMID: 29626751 DOI: 10.1016/j.neo.2018.03.005] [Cited by in Crossref: 81] [Cited by in F6Publishing: 85] [Article Influence: 16.2] [Reference Citation Analysis]
|
| 620 |
Doherty RE, Academic Unit of Ophthalmology & Orthoptics, Department of Oncology & Metabolism, The Medical School, The University of Sheffield, Sheffield, UK, Alfawaz M, Francis J, Lijka-jones B, Sisley K, Department of Clinical Laboratories, College of Applied Medical Sciences, Northern Borders University, Arar, Saudi Arabia, Metabolism, The Medical School, The University of Sheffield, Sheffield, UK, Academic Unit of Ophthalmology & Orthoptics, Department of Oncology & Metabolism, The Medical School, The University of Sheffield, Sheffield, UK, Department of Clinical Laboratories, College of Applied Medical Sciences, Northern Borders University, Arar, Saudi Arabia, Academic Unit of Ophthalmology & Orthoptics, Department of Oncology & Metabolism, The Medical School, The University of Sheffield, Sheffield, UK, Academic Unit of Ophthalmology & Orthoptics, Department of Oncology & Metabolism, The Medical School, The University of Sheffield, Sheffield, UK, Academic Unit of Ophthalmology & Orthoptics, Department of Oncology & Metabolism, The Medical School, The University of Sheffield, Sheffield, UK. Genetics of Uveal Melanoma. Noncutaneous Melanoma 2018. [DOI: 10.15586/codon.noncutaneousmelanoma.2018.ch2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 621 |
Ahn SY, Yang JH, Kim NH, Lee K, Cha YH, Yun JS, Kang HE, Lee Y, Choi J, Kim HS, Yook JI. Anti-helminthic niclosamide inhibits Ras-driven oncogenic transformation via activation of GSK-3. Oncotarget 2017;8:31856-63. [PMID: 28418865 DOI: 10.18632/oncotarget.16255] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 622 |
Ganapathy S, Peng B, Shen L, Yu T, Lafontant J, Li P, Xiong R, Makriyannis A, Chen C. Suppression of PKC causes oncogenic stress for triggering apoptosis in cancer cells. Oncotarget 2017;8:30992-1002. [PMID: 28415683 DOI: 10.18632/oncotarget.16047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 623 |
Coelho RG, Fortunato RS, Carvalho DP. Metabolic Reprogramming in Thyroid Carcinoma. Front Oncol 2018;8:82. [PMID: 29629339 DOI: 10.3389/fonc.2018.00082] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 624 |
Wang PN, Huang J, Duan YH, Zhou JM, Huang PZ, Fan XJ, Huang Y, Wang L, Liu HL, Wang JP, Huang MJ. Downregulation of phosphorylated MKK4 is associated with a poor prognosis in colorectal cancer patients. Oncotarget 2017;8:34352-61. [PMID: 28423721 DOI: 10.18632/oncotarget.16128] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 625 |
Erinjeri NJ, Nicolson NG, Deyholos C, Korah R, Carling T. Whole-Exome Sequencing Identifies Two Discrete Druggable Signaling Pathways in Follicular Thyroid Cancer. J Am Coll Surg 2018;226:950-959.e5. [PMID: 29571661 DOI: 10.1016/j.jamcollsurg.2018.01.059] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 626 |
Liu J, Zeng W, Huang C, Wang J, Xu L, Ma D. Upregulation of c-mesenchymal epithelial transition expression and RAS mutations are associated with late lung metastasis and poor prognosis in colorectal carcinoma. Exp Ther Med 2018;15:4229-42. [PMID: 29725370 DOI: 10.3892/etm.2018.5966] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 627 |
Han CW, Jeong MS, Jang SB. Structure, signaling and the drug discovery of the Ras oncogene protein. BMB Rep 2017;50:355-60. [PMID: 28571593 DOI: 10.5483/bmbrep.2017.50.7.062] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 628 |
Pierro C, Zhang X, Kankeu C, Trebak M, Bootman MD, Roderick HL. Oncogenic KRAS suppresses store-operated Ca2+ entry and ICRAC through ERK pathway-dependent remodelling of STIM expression in colorectal cancer cell lines. Cell Calcium 2018;72:70-80. [PMID: 29748135 DOI: 10.1016/j.ceca.2018.03.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 629 |
Bennani B, Gilles S, Fina F, Nanni I, Ibrahimi SA, Riffi AA, Nejjari C, Benajeh D, Abkari ME, Martin P, Ouafik L. Mutation Analysis of Braf Exon 15 and Kras Codons 12 and 13 in Moroccan Patients with Colorectal Cancer. Int J Biol Markers 2010;25:179-84. [DOI: 10.5301/jbm.2010.6091] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 630 |
Liu S, Iaria J, Simpson RJ, Zhu HJ. Ras enhances TGF-β signaling by decreasing cellular protein levels of its type II receptor negative regulator SPSB1. Cell Commun Signal 2018;16:10. [PMID: 29534718 DOI: 10.1186/s12964-018-0223-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 631 |
Segges P, Corrêa S, Du Rocher B, Vera-Lozada G, Krsticevic F, Arce D, Sternberg C, Abdelhay E, Hassan R. Targeting Hodgkin and Reed-Sternberg Cells with an Inhibitor of Heat-Shock Protein 90: Molecular Pathways of Response and Potential Mechanisms of Resistance. Int J Mol Sci 2018;19:E836. [PMID: 29534015 DOI: 10.3390/ijms19030836] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 632 |
Christodoulou EG, Yang H, Lademann F, Pilarsky C, Beyer A, Schroeder M. Detection of COPB2 as a KRAS synthetic lethal partner through integration of functional genomics screens. Oncotarget 2017;8:34283-97. [PMID: 28415695 DOI: 10.18632/oncotarget.16079] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 633 |
Yoshioka E, Chelakkot VS, Licursi M, Rutihinda SG, Som J, Derwish L, King JJ, Pongnopparat T, Mearow K, Larijani M, Dorward AM, Hirasawa K. Enhancement of Cancer-Specific Protoporphyrin IX Fluorescence by Targeting Oncogenic Ras/MEK Pathway. Theranostics 2018;8:2134-46. [PMID: 29721068 DOI: 10.7150/thno.22641] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 634 |
Khan AQ, Kuttikrishnan S, Siveen KS, Prabhu KS, Shanmugakonar M, Al-Naemi HA, Haris M, Dermime S, Uddin S. RAS-mediated oncogenic signaling pathways in human malignancies. Semin Cancer Biol 2019;54:1-13. [PMID: 29524560 DOI: 10.1016/j.semcancer.2018.03.001] [Cited by in Crossref: 73] [Cited by in F6Publishing: 82] [Article Influence: 14.6] [Reference Citation Analysis]
|
| 635 |
Yang W, Qu Y, Tan B, Jia Y, Wang N, Hu P, Wang J. Prognostic significance of preoperative IKBKE expression in esophageal squamous cell carcinoma. Onco Targets Ther 2018;11:1305-14. [PMID: 29563809 DOI: 10.2147/OTT.S156818] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 636 |
Ganapathy S, Fagman JB, Shen L, Yu T, Zhou X, Dai W, Makriyannis A, Chen C. Ral A, via activating the mitotic checkpoint, sensitizes cells lacking a functional Nf1 to apoptosis in the absence of protein kinase C. Oncotarget 2016;7:84326-37. [PMID: 27741517 DOI: 10.18632/oncotarget.12607] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 637 |
Modica TME, Maiorani O, Sartori G, Pivetta E, Doliana R, Capuano A, Colombatti A, Spessotto P. The extracellular matrix protein EMILIN1 silences the RAS-ERK pathway via α4β1 integrin and decreases tumor cell growth. Oncotarget 2017;8:27034-46. [PMID: 28177903 DOI: 10.18632/oncotarget.15067] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 638 |
Rodenak-Kladniew B, Castro A, Stärkel P, De Saeger C, García de Bravo M, Crespo R. Linalool induces cell cycle arrest and apoptosis in HepG2 cells through oxidative stress generation and modulation of Ras/MAPK and Akt/mTOR pathways. Life Sci 2018;199:48-59. [PMID: 29510199 DOI: 10.1016/j.lfs.2018.03.006] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 639 |
Asik A, Kayabasi C, Ozmen Yelken B, Yılmaz Susluer S, Dogan Sigva ZO, Balcı Okcanoglu T, Saydam G, Biray Avci C, Gunduz C. Antileukemic effect of paclitaxel in combination with metformin in HL-60 cell line. Gene 2018;647:213-20. [DOI: 10.1016/j.gene.2018.01.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 640 |
Sarnowski MP, Pedretty KP, Giddings N, Woodcock HL, Del Valle JR. Synthesis and β-sheet propensity of constrained N-amino peptides. Bioorganic & Medicinal Chemistry 2018;26:1162-6. [DOI: 10.1016/j.bmc.2017.08.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 641 |
Tikhonova IA, Huxley N, Snowsill T, Crathorne L, Varley-campbell J, Napier M, Hoyle M. Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England. PharmacoEconomics 2018;36:837-51. [DOI: 10.1007/s40273-018-0630-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 642 |
Pan T, Zhang Y, Zhou N, He X, Chen C, Liang L, Duan X, Lin Y, Wu K, Zhang H. A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth. Oncotarget 2016;7:44299-309. [PMID: 27322423 DOI: 10.18632/oncotarget.9996] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 643 |
Eckfeldt CE, Pomeroy EJ, Lee RD, Hazen KS, Lee LA, Moriarity BS, Largaespada DA. RALB provides critical survival signals downstream of Ras in acute myeloid leukemia. Oncotarget 2016;7:65147-56. [PMID: 27556501 DOI: 10.18632/oncotarget.11431] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 644 |
He F, Chen H, Yang P, Wu Q, Zhang T, Wang C, Wei J, Chen Z, Hu H, Li W, Cao J. Gankyrin sustains PI3K/GSK-3β/β-catenin signal activation and promotes colorectal cancer aggressiveness and progression. Oncotarget 2016;7:81156-71. [PMID: 27835604 DOI: 10.18632/oncotarget.13215] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 645 |
Bartel K, Winzi M, Ulrich M, Koeberle A, Menche D, Werz O, Müller R, Guck J, Vollmar AM, von Schwarzenberg K. V-ATPase inhibition increases cancer cell stiffness and blocks membrane related Ras signaling - a new option for HCC therapy. Oncotarget 2017;8:9476-87. [PMID: 28036299 DOI: 10.18632/oncotarget.14339] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 646 |
Jeong WJ, Ro EJ, Choi KY. Interaction between Wnt/β-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of β-catenin and RAS by targeting the Wnt/β-catenin pathway. NPJ Precis Oncol 2018;2:5. [PMID: 29872723 DOI: 10.1038/s41698-018-0049-y] [Cited by in Crossref: 93] [Cited by in F6Publishing: 105] [Article Influence: 18.6] [Reference Citation Analysis]
|
| 647 |
Massimino M, Stella S, Tirrò E, Romano C, Pennisi MS, Puma A, Manzella L, Zanghì A, Stagno F, Di Raimondo F, Vigneri P. Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia. Mol Cancer 2018;17:56. [PMID: 29455672 DOI: 10.1186/s12943-018-0805-1] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 648 |
Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer 2018;17:53. [PMID: 29455669 DOI: 10.1186/s12943-018-0793-1] [Cited by in Crossref: 116] [Cited by in F6Publishing: 135] [Article Influence: 23.2] [Reference Citation Analysis]
|
| 649 |
Cazzanelli G, Pereira F, Alves S, Francisco R, Azevedo L, Dias Carvalho P, Almeida A, Côrte-Real M, Oliveira MJ, Lucas C, Sousa MJ, Preto A. The Yeast Saccharomyces cerevisiae as a Model for Understanding RAS Proteins and their Role in Human Tumorigenesis. Cells 2018;7:E14. [PMID: 29463063 DOI: 10.3390/cells7020014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 650 |
Cannataro VL, Gaffney SG, Stender C, Zhao ZM, Philips M, Greenstein AE, Townsend JP. Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C. Oncogene 2018;37:2444-55. [PMID: 29453361 DOI: 10.1038/s41388-017-0105-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 651 |
Wang Q, Acharya N, Liu Z, Zhou X, Cromie M, Zhu J, Gao W. Enhanced anticancer effects of Scutellaria barbata D. Don in combination with traditional Chinese medicine components on non-small cell lung cancer cells. J Ethnopharmacol 2018;217:140-51. [PMID: 29458146 DOI: 10.1016/j.jep.2018.02.020] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 652 |
Xu Y, Xu Q, Sun H, Liu T, Shi K, Wang W. Could IVIM and ADC help in predicting the KRAS status in patients with rectal cancer? Eur Radiol. 2018;28:3059-3065. [PMID: 29450716 DOI: 10.1007/s00330-018-5329-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 653 |
Yeh YW, Cheng CC, Yang ST, Tseng CF, Chang TY, Tsai SY, Fu E, Chiang CP, Liao LC, Tsai PW, Yu YL, Su JL. Targeting the VEGF-C/VEGFR3 axis suppresses Slug-mediated cancer metastasis and stemness via inhibition of KRAS/YAP1 signaling. Oncotarget 2017;8:5603-18. [PMID: 27901498 DOI: 10.18632/oncotarget.13629] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 654 |
Wolff RA, Wang-Gillam A, Alvarez H, Tiriac H, Engle D, Hou S, Groff AF, San Lucas A, Bernard V, Allenson K, Castillo J, Kim D, Mulu F, Huang J, Stephens B, Wistuba II, Katz M, Varadhachary G, Park Y, Hicks J, Chinnaiyan A, Scampavia L, Spicer T, Gerhardinger C, Maitra A, Tuveson D, Rinn J, Lizee G, Yee C, Levine AJ. Dynamic changes during the treatment of pancreatic cancer. Oncotarget 2018;9:14764-90. [PMID: 29599906 DOI: 10.18632/oncotarget.24483] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 655 |
Chen H, Gao J, Du Z, Zhang X, Yang F, Gao W. Expression of factors and key components associated with the PI3K signaling pathway in colon cancer. Oncol Lett 2018;15:5465-72. [PMID: 29552187 DOI: 10.3892/ol.2018.8044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 656 |
Leoncini PP, Bertaina A, Papaioannou D, Flotho C, Masetti R, Bresolin S, Menna G, Santoro N, Zecca M, Basso G, Nigita G, Veneziano D, Pagotto S, D'Ovidio K, Rota R, Dorrance A, Croce CM, Niemeyer C, Locatelli F, Garzon R. MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment. Oncotarget 2016;7:55395-408. [PMID: 27447965 DOI: 10.18632/oncotarget.10577] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 657 |
Pelleieux S, Picard C, Lamarre-Théroux L, Dea D, Leduc V, Tsantrizos YS, Poirier J. Isoprenoids and tau pathology in sporadic Alzheimer's disease. Neurobiol Aging 2018;65:132-9. [PMID: 29476987 DOI: 10.1016/j.neurobiolaging.2018.01.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 658 |
Liu J, Zeng W, Huang C, Wang J, Yang D, Ma D. Predictive and Prognostic Implications of Mutation Profiling and Microsatellite Instability Status in Patients with Metastatic Colorectal Carcinoma. Gastroenterol Res Pract 2018;2018:4585802. [PMID: 29643917 DOI: 10.1155/2018/4585802] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 659 |
Ho JY, Hsu RJ, Wu CH, Liao GS, Gao HW, Wang TH, Yu CP. Reduced miR-550a-3p leads to breast cancer initiation, growth, and metastasis by increasing levels of ERK1 and 2. Oncotarget 2016;7:53853-68. [PMID: 27462780 DOI: 10.18632/oncotarget.10793] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 660 |
Li H, Yu X, Liu X, Hu P, Shen L, Zhou Y, Zhu Y, Li Z, Hui H, Guo Q, Xu J. Wogonoside induces depalmitoylation and translocation of PLSCR1 and N-RAS in primary acute myeloid leukaemia cells. J Cell Mol Med 2018;22:2117-30. [PMID: 29377576 DOI: 10.1111/jcmm.13481] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 661 |
Ross KC, Chin KF, Kim D, Marion CD, Yen TJ, Bhattacharjee V. Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib. Oncotarget 2018;9:13324-36. [PMID: 29568360 DOI: 10.18632/oncotarget.24341] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 662 |
Feng A, Tu Z, Yin B. The effect of HMGB1 on the clinicopathological and prognostic features of non-small cell lung cancer. Oncotarget 2016;7:20507-19. [PMID: 26840258 DOI: 10.18632/oncotarget.7050] [Cited by in Crossref: 27] [Cited by in F6Publishing: 41] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 663 |
Martinko AJ, Truillet C, Julien O, Diaz JE, Horlbeck MA, Whiteley G, Blonder J, Weissman JS, Bandyopadhyay S, Evans MJ, Wells JA. Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins. Elife 2018;7:e31098. [PMID: 29359686 DOI: 10.7554/eLife.31098] [Cited by in Crossref: 57] [Cited by in F6Publishing: 61] [Article Influence: 11.4] [Reference Citation Analysis]
|
| 664 |
Masliah-Planchon J, Garinet S, Pasmant E. RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action. Oncotarget 2016;7:38892-907. [PMID: 26646588 DOI: 10.18632/oncotarget.6476] [Cited by in Crossref: 83] [Cited by in F6Publishing: 89] [Article Influence: 16.6] [Reference Citation Analysis]
|
| 665 |
Liu Y, Chen X, Cheng R, Yang F, Yu M, Wang C, Cui S, Hong Y, Liang H, Liu M, Zhao C, Ding M, Sun W, Liu Z, Sun F, Zhang C, Zhou Z, Jiang X, Chen X. The Jun/miR-22/HuR regulatory axis contributes to tumourigenesis in colorectal cancer. Mol Cancer 2018;17:11. [PMID: 29351796 DOI: 10.1186/s12943-017-0751-3] [Cited by in Crossref: 61] [Cited by in F6Publishing: 67] [Article Influence: 12.2] [Reference Citation Analysis]
|
| 666 |
van der Hoeven D, Cho KJ, Zhou Y, Ma X, Chen W, Naji A, Montufar-Solis D, Zuo Y, Kovar SE, Levental KR, Frost JA, van der Hoeven R, Hancock JF. Sphingomyelin Metabolism Is a Regulator of K-Ras Function. Mol Cell Biol 2018;38:e00373-17. [PMID: 29158292 DOI: 10.1128/MCB.00373-17] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 667 |
Radojicic J, Zaravinos A, Spandidos DA. HPV, KRAS mutations, alcohol consumption and tobacco smoking effects on esophageal squamous-cell carcinoma carcinogenesis. Int J Biol Markers 2012;27:1-12. [DOI: 10.5301/jbm.2011.8737] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 668 |
Herrero A, Reis-Cardoso M, Jiménez-Gómez I, Doherty C, Agudo-Ibañez L, Pinto A, Calvo F, Kolch W, Crespo P, Matallanas D. Characterisation of HRas local signal transduction networks using engineered site-specific exchange factors. Small GTPases 2020;11:371-83. [PMID: 29172991 DOI: 10.1080/21541248.2017.1406434] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 669 |
Zhou Y, Hancock JF. A novel prenyl-polybasic domain code determines lipid-binding specificity of the K-Ras membrane anchor. Small GTPases 2020;11:220-4. [PMID: 29239694 DOI: 10.1080/21541248.2017.1379583] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 670 |
Li X, Liang L, De Vivo I, Tang JY, Han J. Pathway analysis of expression-related SNPs on genome-wide association study of basal cell carcinoma. Oncotarget 2016;7:36885-95. [PMID: 27367190 DOI: 10.18632/oncotarget.9212] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 671 |
Lee SK, Hwang JH, Choi KY. Interaction of the Wnt/β-catenin and RAS-ERK pathways involving co-stabilization of both β-catenin and RAS plays important roles in the colorectal tumorigenesis. Adv Biol Regul 2018;68:46-54. [PMID: 29449169 DOI: 10.1016/j.jbior.2018.01.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 672 |
Smigiel JM, Parameswaran N, Jackson MW. Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics. Cancers (Basel) 2018;10:E14. [PMID: 29320425 DOI: 10.3390/cancers10010014] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 673 |
Bo X, Chen Y, Sheng W, Gong Y, Wang H, Gao W, Zhang B. The regulation and function of microRNA-377/RASSF8 signaling axis in gastric cancer. Oncol Lett 2018;15:3630-8. [PMID: 29456730 DOI: 10.3892/ol.2018.7740] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 674 |
Momenzadeh H, Mirzai M, Jowkar Z, Geramizadeh B. Frequency of NRAS Gene Mutation in Wild Type KRAS and BRAF Colorectal Cancers; a Single Center Study. Middle East J Dig Dis 2018;10:18-23. [PMID: 29682243 DOI: 10.15171/mejdd.2017.85] [Reference Citation Analysis]
|
| 675 |
Varin J, Poulain L, Hivelin M, Nusbaum P, Hubas A, Laurendeau I, Lantieri L, Wolkenstein P, Vidaud M, Pasmant E, Chapuis N, Parfait B. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells. Oncotarget 2016;7:35753-67. [PMID: 26840085 DOI: 10.18632/oncotarget.7099] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
|
| 676 |
Ni D, Liu D, Zhang J, Lu S. Computational Insights into the Interactions between Calmodulin and the c/nSH2 Domains of p85α Regulatory Subunit of PI3Kα: Implication for PI3Kα Activation by Calmodulin. Int J Mol Sci 2018;19:E151. [PMID: 29300353 DOI: 10.3390/ijms19010151] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 677 |
Locatelli F, Algeri M, Merli P, Strocchio L. Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia. Expert Review of Hematology 2018;11:129-43. [DOI: 10.1080/17474086.2018.1421937] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 678 |
Rad E, Murray JT, Tee AR. Oncogenic Signalling through Mechanistic Target of Rapamycin (mTOR): A Driver of Metabolic Transformation and Cancer Progression. Cancers (Basel) 2018;10:E5. [PMID: 29301334 DOI: 10.3390/cancers10010005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 679 |
Malik N, Macartney T, Hornberger A, Anderson KE, Tovell H, Prescott AR, Alessi DR. Mechanism of activation of SGK3 by growth factors via the Class 1 and Class 3 PI3Ks. Biochem J 2018;475:117-35. [PMID: 29150437 DOI: 10.1042/BCJ20170650] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 680 |
Yang J, Yang T, Yan W, Li D, Wang F, Wang Z, Guo Y, Bai P, Tan N, Chen L. TAK1 inhibition by natural cyclopeptide RA-V promotes apoptosis and inhibits protective autophagy in Kras-dependent non-small-cell lung carcinoma cells. RSC Adv 2018;8:23451-8. [DOI: 10.1039/c8ra04241a] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 681 |
Park JK, Coffey NJ, Limoges A, Le A. The Heterogeneity of Lipid Metabolism in Cancer. The Heterogeneity of Cancer Metabolism 2018. [DOI: 10.1007/978-3-319-77736-8_3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 682 |
Hauptman N, Jevšinek Skok D, Glavač D. Noncoding RNA Alterations in Cancer Molecular Pathways. Cancer and Noncoding RNAs 2018. [DOI: 10.1016/b978-0-12-811022-5.00014-0] [Reference Citation Analysis]
|
| 683 |
Samuel MS. Ras (H-, K-, N-Ras). Encyclopedia of Signaling Molecules 2018. [DOI: 10.1007/978-3-319-67199-4_67] [Reference Citation Analysis]
|
| 684 |
González-pérez PP, Cárdenas-garcía M. Inspecting the Role of PI3K/AKT Signaling Pathway in Cancer Development Using an In Silico Modeling and Simulation Approach. Bioinformatics and Biomedical Engineering 2018. [DOI: 10.1007/978-3-319-78723-7_7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 685 |
Nolan C, Deangelis LM. Overview of metastatic disease of the central nervous system. Handbook of Clinical Neurology 2018. [DOI: 10.1016/b978-0-12-811161-1.00001-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 686 |
Pérez-mancera PA. Mouse Models of Pancreatic Exocrine Cancer. Pancreatic Cancer 2018. [DOI: 10.1007/978-1-4939-7193-0_77] [Reference Citation Analysis]
|
| 687 |
Haraguchi M, Takahashi K. EGFR: How Important Is EGFR Mutation Status in the Management of Lung Cancer? Respiratory Disease Series: Diagnostic Tools and Disease Managements 2018. [DOI: 10.1007/978-981-10-8144-6_15] [Reference Citation Analysis]
|
| 688 |
Tsirulnikov K, Duarte S, Ray A, Datta N, Zarrinpar A, Hwang L, Faull K, Pushkin A, Kurtz I. Aminoacylase 3 Is a New Potential Marker and Therapeutic Target in Hepatocellular Carcinoma. J Cancer 2018;9:1-12. [PMID: 29290764 DOI: 10.7150/jca.21747] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 689 |
Janes MR, Zhang J, Li L, Hansen R, Peters U, Guo X, Chen Y, Babbar A, Firdaus SJ, Darjania L, Feng J, Chen JH, Li S, Li S, Long YO, Thach C, Liu Y, Zarieh A, Ely T, Kucharski JM, Kessler LV, Wu T, Yu K, Wang Y, Yao Y, Deng X, Zarrinkar PP, Brehmer D, Dhanak D, Lorenzi MV, Hu-lowe D, Patricelli MP, Ren P, Liu Y. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Cell 2018;172:578-589.e17. [DOI: 10.1016/j.cell.2018.01.006] [Cited by in Crossref: 589] [Cited by in F6Publishing: 615] [Article Influence: 117.8] [Reference Citation Analysis]
|
| 690 |
Berger S, Martens UM, Bochum S. Larotrectinib (LOXO-101). Recent Results Cancer Res 2018;211:141-51. [PMID: 30069765 DOI: 10.1007/978-3-319-91442-8_10] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 691 |
Buckles TC, Ziemba BP, Masson GR, Williams RL, Falke JJ. Single-Molecule Study Reveals How Receptor and Ras Synergistically Activate PI3Kα and PIP3 Signaling. Biophys J 2017;113:2396-405. [PMID: 29211993 DOI: 10.1016/j.bpj.2017.09.018] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 7.2] [Reference Citation Analysis]
|
| 692 |
Spencer-Smith R, Li L, Prasad S, Koide A, Koide S, O'Bryan JP. Targeting the α4-α5 interface of RAS results in multiple levels of inhibition. Small GTPases 2019;10:378-87. [PMID: 28692342 DOI: 10.1080/21541248.2017.1333188] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 693 |
Lau HY, Wang M. Small change, big effect: Taking RAS by the tail through suppression of post-prenylation carboxylmethylation. Small GTPases 2020;11:271-9. [PMID: 29261009 DOI: 10.1080/21541248.2017.1415637] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 694 |
Cantini L, Calzone L, Martignetti L, Rydenfelt M, Blüthgen N, Barillot E, Zinovyev A. Classification of gene signatures for their information value and functional redundancy. NPJ Syst Biol Appl 2018;4:2. [PMID: 29263798 DOI: 10.1038/s41540-017-0038-8] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 695 |
González Pérez PP, Omicini A, Sbaraglia M. A biochemically inspired coordination-based model for simulating intracellular signalling pathways. Journal of Simulation 2017;7:216-26. [DOI: 10.1057/jos.2012.28] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 696 |
Kessler E, Brittain P, Davis SL, Leong S, Eckhardt SG, Lieu CH. Targeted Therapies. The American Cancer Society's Principles of Oncology 2017. [DOI: 10.1002/9781119468868.ch21] [Reference Citation Analysis]
|
| 697 |
Montesion M, Bhardwaj N, Williams ZH, Kuperwasser C, Coffin JM. Mechanisms of HERV-K (HML-2) Transcription during Human Mammary Epithelial Cell Transformation. J Virol 2018;92:e01258-17. [PMID: 29046454 DOI: 10.1128/JVI.01258-17] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 698 |
Spencer-Smith R, O'Bryan JP. Direct inhibition of RAS: Quest for the Holy Grail? Semin Cancer Biol 2019;54:138-48. [PMID: 29248537 DOI: 10.1016/j.semcancer.2017.12.005] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 699 |
Li ZZ, Wang F, Zhang ZC, Wang F, Zhao Q, Zhang DS, Wang FH, Wang ZQ, Luo HY, He MM, Wang DS, Jin Y, Ren C, Qiu MZ, Ren J, Pan ZZ, Li YH, Shao JY, Xu RH. Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response. Oncotarget 2016;7:28356-68. [PMID: 27050078 DOI: 10.18632/oncotarget.8541] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 700 |
Duran CL, Howell DW, Dave JM, Smith RL, Torrie ME, Essner JJ, Bayless KJ. Molecular Regulation of Sprouting Angiogenesis. Compr Physiol 2017;8:153-235. [PMID: 29357127 DOI: 10.1002/cphy.c160048] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 701 |
Cuellar J, Valpuesta JM, Wittinghofer A, Sot B. Domain topology of human Rasal. Biol Chem 2017;399:63-72. [PMID: 28885980 DOI: 10.1515/hsz-2017-0159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 702 |
Zhou Y, Hancock JF. Deciphering lipid codes: K-Ras as a paradigm. Traffic 2018;19:157-65. [PMID: 29120102 DOI: 10.1111/tra.12541] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 703 |
Morikawa T, Inada R, Nagasaka T, Mori Y, Kishimoto H, Kawai T, Umeda Y, Mishima H, Goel A, Fujiwara T. BRAF V600E mutation is a predictive indicator of upfront chemotherapy for stage IV colorectal cancer. Oncol Lett 2018;15:2195-201. [PMID: 29434925 DOI: 10.3892/ol.2017.7553] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 704 |
Shojaee S, Nana-Sinkam P. Recent advances in the management of non-small cell lung cancer. F1000Res 2017;6:2110. [PMID: 29259780 DOI: 10.12688/f1000research.11471.1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 705 |
Michael JV, Goldfinger LE. Concepts and advances in cancer therapeutic vulnerabilities in RAS membrane targeting.Semin Cancer Biol. 2019;54:121-130. [PMID: 29203271 DOI: 10.1016/j.semcancer.2017.11.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 706 |
Hou H, Liu D, Zhang C, Jiang Y, Lu G, Zhou N, Yang X, Zhang X, Li Z, Zhu H, Qian Z, Zhang X. Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine. Oncotarget 2017;8:105072-80. [PMID: 29285234 DOI: 10.18632/oncotarget.21349] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 707 |
Eso Y, Uza N, Yamagishi H, Imada K, Kimura Y, Masui T, Kodama Y, Seno H. Utility of KRAS mutational analysis in the preoperative diagnosis of synchronous pancreatic cancer and intrahepatic cholangiocarcinoma: A case report. Medicine (Baltimore) 2017;96:e9217. [PMID: 29390348 DOI: 10.1097/MD.0000000000009217] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 708 |
Herranz H, Cohen SM. Drosophila as a Model to Study the Link between Metabolism and Cancer. J Dev Biol 2017;5:E15. [PMID: 29615570 DOI: 10.3390/jdb5040015] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 709 |
Umapathy G, Guan J, Gustafsson DE, Javanmardi N, Cervantes-Madrid D, Djos A, Martinsson T, Palmer RH, Hallberg B. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas. Sci Signal 2017;10:eaam7550. [PMID: 29184034 DOI: 10.1126/scisignal.aam7550] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 710 |
Ishige T, Itoga S, Matsushita K. Locked Nucleic Acid Technology for Highly Sensitive Detection of Somatic Mutations in Cancer. Adv Clin Chem 2018;83:53-72. [PMID: 29304903 DOI: 10.1016/bs.acc.2017.10.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 711 |
Imperial R, Toor OM, Hussain A, Subramanian J, Masood A. Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications. Semin Cancer Biol 2019;54:14-28. [PMID: 29175106 DOI: 10.1016/j.semcancer.2017.11.016] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 712 |
Choi M, Bien H, Mofunanya A, Powers S. Challenges in Ras therapeutics in pancreatic cancer. Semin Cancer Biol 2019;54:101-8. [PMID: 29170065 DOI: 10.1016/j.semcancer.2017.11.015] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 713 |
Falco M, Palma G, Rea D, De Biase D, Scala S, D'Aiuto M, Facchini G, Perdonà S, Barbieri A, Arra C. Tumour biomarkers: homeostasis as a novel prognostic indicator. Open Biol 2016;6:160254. [PMID: 27927793 DOI: 10.1098/rsob.160254] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 714 |
Xie C, Li Y, Li LL, Fan XX, Wang YW, Wei CL, Liu L, Leung EL, Yao XJ. Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells. Front Pharmacol 2017;8:823. [PMID: 29184501 DOI: 10.3389/fphar.2017.00823] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 715 |
Takahashi H, Takahashi M, Ohnuma S, Unno M, Yoshino Y, Ouchi K, Takahashi S, Yamada Y, Shimodaira H, Ishioka C. microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer. BMC Cancer 2017;17:723. [PMID: 29115941 DOI: 10.1186/s12885-017-3739-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 716 |
N B, K R C. Tetrandrine and cancer - An overview on the molecular approach. Biomed Pharmacother 2018;97:624-32. [PMID: 29101806 DOI: 10.1016/j.biopha.2017.10.116] [Cited by in Crossref: 59] [Cited by in F6Publishing: 62] [Article Influence: 9.8] [Reference Citation Analysis]
|
| 717 |
Goemann IM, Romitti M, Meyer ELS, Wajner SM, Maia AL. Role of thyroid hormones in the neoplastic process: an overview. Endocr Relat Cancer 2017;24:R367-85. [PMID: 28928142 DOI: 10.1530/ERC-17-0192] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 718 |
Dimakakos EP, Vathiotis I, Syrigos K. The Role of Tinzaparin in Oncology. Clin Appl Thromb Hemost 2018;24:697-707. [PMID: 29088922 DOI: 10.1177/1076029617729215] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 719 |
Carné Trécesson S, Souazé F, Basseville A, Bernard AC, Pécot J, Lopez J, Bessou M, Sarosiek KA, Letai A, Barillé-Nion S, Valo I, Coqueret O, Guette C, Campone M, Gautier F, Juin PP. BCL-XL directly modulates RAS signalling to favour cancer cell stemness. Nat Commun 2017;8:1123. [PMID: 29066722 DOI: 10.1038/s41467-017-01079-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 720 |
Wang L. Screening and Biosensor-Based Approaches for Lung Cancer Detection. Sensors (Basel) 2017;17:E2420. [PMID: 29065541 DOI: 10.3390/s17102420] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 721 |
Deeter A, Dalman M, Haddad J, Duan ZH. Inferring gene and protein interactions using PubMed citations and consensus Bayesian networks. PLoS One 2017;12:e0186004. [PMID: 29049295 DOI: 10.1371/journal.pone.0186004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 722 |
Wang J, Leng X, Wang G, Wan X, Cao H. The construction of intrahepatic cholangiocarcinoma model in zebrafish. Sci Rep 2017;7:13419. [PMID: 29042681 DOI: 10.1038/s41598-017-13815-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 723 |
Hentze JL, Høgdall C, Kjær SK, Blaakær J, Høgdall E. Searching for new biomarkers in ovarian cancer patients: Rationale and design of a retrospective study under the Mermaid III project. Contemp Clin Trials Commun 2017;8:167-74. [PMID: 29696206 DOI: 10.1016/j.conctc.2017.10.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 724 |
Garg A, Bansal M, Gotoh N, Feng GS, Zhong J, Wang F, Kariminejad A, Brooks S, Zhang X. Alx4 relays sequential FGF signaling to induce lacrimal gland morphogenesis. PLoS Genet 2017;13:e1007047. [PMID: 29028795 DOI: 10.1371/journal.pgen.1007047] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 725 |
Nogueira A, Vala H, Vasconcelos-Nóbrega C, Faustino-Rocha AI, Pires CA, Colaço A, Oliveira PA, Pires MJ. Long-term treatment with chaethomellic acid A reduces glomerulosclerosis and arteriolosclerosis in a rat model of chronic kidney disease. Biomed Pharmacother 2017;96:489-96. [PMID: 29032332 DOI: 10.1016/j.biopha.2017.09.137] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 726 |
Stapleton CP, Conlon PJ, Phelan PJ. Using omics to explore complications of kidney transplantation. Transpl Int 2018;31:251-62. [PMID: 28892567 DOI: 10.1111/tri.13067] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 727 |
Vivekanandhan S, Yang L, Cao Y, Wang E, Dutta SK, Sharma AK, Mukhopadhyay D. Genetic status of KRAS modulates the role of Neuropilin-1 in tumorigenesis. Sci Rep 2017;7:12877. [PMID: 29018205 DOI: 10.1038/s41598-017-12992-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 728 |
Liang L, Zeng JH, Wang JY, He RQ, Ma J, Chen G, Cai XY, Hu XH. Down-regulation of miR-26a-5p in hepatocellular carcinoma: A qRT-PCR and bioinformatics study. Pathol Res Pract 2017;213:1494-509. [PMID: 29113686 DOI: 10.1016/j.prp.2017.10.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 729 |
Lin G, Keshari KR, Park JM. Cancer Metabolism and Tumor Heterogeneity: Imaging Perspectives Using MR Imaging and Spectroscopy. Contrast Media Mol Imaging 2017;2017:6053879. [PMID: 29114178 DOI: 10.1155/2017/6053879] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 730 |
Gooding AJ, Zhang B, Jahanbani FK, Gilmore HL, Chang JC, Valadkhan S, Schiemann WP. The lncRNA BORG Drives Breast Cancer Metastasis and Disease Recurrence. Sci Rep 2017;7:12698. [PMID: 28983112 DOI: 10.1038/s41598-017-12716-6] [Cited by in Crossref: 49] [Cited by in F6Publishing: 60] [Article Influence: 8.2] [Reference Citation Analysis]
|
| 731 |
Merchant M, Moffat J, Schaefer G, Chan J, Wang X, Orr C, Cheng J, Hunsaker T, Shao L, Wang SJ, Wagle MC, Lin E, Haverty PM, Shahidi-Latham S, Ngu H, Solon M, Eastham-Anderson J, Koeppen H, Huang SA, Schwarz J, Belvin M, Kirouac D, Junttila MR. Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors. PLoS One 2017;12:e0185862. [PMID: 28982154 DOI: 10.1371/journal.pone.0185862] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 732 |
Jiang Y, Zhuang C, Chen L, Lu J, Dong G, Miao Z, Zhang W, Li J, Sheng C. Structural Biology-Inspired Discovery of Novel KRAS–PDEδ Inhibitors. J Med Chem 2017;60:9400-6. [DOI: 10.1021/acs.jmedchem.7b01243] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 733 |
Zhao J, Stains CI. Identification of a Fragmented Small GTPase Capable of Conditional Effector Binding. RSC Adv 2017;7:12265-8. [PMID: 28966788 DOI: 10.1039/C6RA25575B] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 734 |
Zheng T, Ni Y, Li J, Chow BKC, Panagiotou G. Designing Dietary Recommendations Using System Level Interactomics Analysis and Network-Based Inference. Front Physiol 2017;8:753. [PMID: 29033850 DOI: 10.3389/fphys.2017.00753] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 735 |
Kuhlmann N, Chollet C, Baldus L, Neundorf I, Lammers M. Development of Substrate-Derived Sirtuin Inhibitors with Potential Anticancer Activity. ChemMedChem 2017;12:1703-14. [DOI: 10.1002/cmdc.201700414] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 736 |
Tewari D, Nabavi SF, Nabavi SM, Sureda A, Farooqi AA, Atanasov AG, Vacca RA, Sethi G, Bishayee A. Targeting activator protein 1 signaling pathway by bioactive natural agents: Possible therapeutic strategy for cancer prevention and intervention. Pharmacol Res 2018;128:366-75. [PMID: 28951297 DOI: 10.1016/j.phrs.2017.09.014] [Cited by in Crossref: 141] [Cited by in F6Publishing: 145] [Article Influence: 23.5] [Reference Citation Analysis]
|
| 737 |
Hasanpourghadi M, Pandurangan AK, Mustafa MR. Modulation of oncogenic transcription factors by bioactive natural products in breast cancer. Pharmacol Res 2018;128:376-88. [PMID: 28923544 DOI: 10.1016/j.phrs.2017.09.009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 738 |
Pereira ASP, Bester MJ, Apostolides Z. Exploring the anti-proliferative activity of Pelargonium sidoides DC with in silico target identification and network pharmacology. Mol Divers 2017;21:809-20. [PMID: 28924942 DOI: 10.1007/s11030-017-9769-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 739 |
Birkner K, Wasser B, Loos J, Plotnikov A, Seger R, Zipp F, Witsch E, Bittner S. The Role of ERK Signaling in Experimental Autoimmune Encephalomyelitis. Int J Mol Sci 2017;18:E1990. [PMID: 28914804 DOI: 10.3390/ijms18091990] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 740 |
Roy J, Wycislo KL, Pondenis H, Fan TM, Das A. Comparative proteomic investigation of metastatic and non-metastatic osteosarcoma cells of human and canine origin. PLoS One 2017;12:e0183930. [PMID: 28910304 DOI: 10.1371/journal.pone.0183930] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 741 |
Tsuboi M, Taniuchi K, Shimizu T, Saito M, Saibara T. The transcription factor HOXB7 regulates ERK kinase activity and thereby stimulates the motility and invasiveness of pancreatic cancer cells. J Biol Chem 2017;292:17681-702. [PMID: 28912272 DOI: 10.1074/jbc.M116.772780] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 742 |
Takahashi M, Li Y, Dillon TJ, Kariya Y, Stork PJS. Phosphorylation of the C-Raf N Region Promotes Raf Dimerization. Mol Cell Biol 2017;37:e00132-17. [PMID: 28694330 DOI: 10.1128/MCB.00132-17] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 743 |
Grant TJ, Mehta AK, Gupta A, Sharif AAD, Arora KS, Deshpande V, Ting DT, Bardeesy N, Ganem NJ, Hergovich A, Singh A. STK38L kinase ablation promotes loss of cell viability in a subset of KRAS-dependent pancreatic cancer cell lines. Oncotarget 2017;8:78556-72. [PMID: 29108249 DOI: 10.18632/oncotarget.20833] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 744 |
Budha NR, Ji T, Musib L, Eppler S, Dresser M, Chen Y, Jin JY. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation. Clin Pharmacokinet. 2016;55:1435-1445. [PMID: 27225997 DOI: 10.1007/s40262-016-0412-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 745 |
Plotnik JP, Hollenhorst PC. Interaction with ZMYND11 mediates opposing roles of Ras-responsive transcription factors ETS1 and ETS2. Nucleic Acids Res 2017;45:4452-62. [PMID: 28119415 DOI: 10.1093/nar/gkx039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 746 |
Ai J, Lv M, Li X, Chen Z, Hu G, Li Q. Synthesis, anti-lung cancer activity and molecular docking study of 3-methylene-2-oxoindoline-5-carboxamide derivatives. Med Chem Res 2018;27:161-70. [DOI: 10.1007/s00044-017-2050-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 747 |
Bianchi-Smiraglia A, Rana MS, Foley CE, Paul LM, Lipchick BC, Moparthy S, Moparthy K, Fink EE, Bagati A, Hurley E, Affronti HC, Bakin AV, Kandel ES, Smiraglia DJ, Feltri ML, Sousa R, Nikiforov MA. Internally ratiometric fluorescent sensors for evaluation of intracellular GTP levels and distribution. Nat Methods 2017;14:1003-9. [PMID: 28869758 DOI: 10.1038/nmeth.4404] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 748 |
Richtig G, Hoeller C, Kashofer K, Aigelsreiter A, Heinemann A, Kwong L, Pichler M, Richtig E. Beyond the BRAFV600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients. Br J Dermatol 2017;177:936-44. [DOI: 10.1111/bjd.15436] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 749 |
Hashikawa KI, Katamune C, Kusunose N, Matsunaga N, Koyanagi S, Ohdo S. Dysfunction of the circadian transcriptional factor CLOCK in mice resists chemical carcinogen-induced tumorigenesis. Sci Rep 2017;7:9995. [PMID: 28855649 DOI: 10.1038/s41598-017-10599-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 750 |
Patsoukis N, Bardhan K, Weaver JD, Sari D, Torres-gomez A, Li L, Strauss L, Lafuente EM, Boussiotis VA. The adaptor molecule RIAM integrates signaling events critical for integrin-mediated control of immune function and cancer progression. Sci Signal 2017;10:eaam8298. [DOI: 10.1126/scisignal.aam8298] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 751 |
Vatansever S, Erman B, Gümüş ZH. Oncogenic G12D mutation alters local conformations and dynamics of K-Ras.. [DOI: 10.1101/178483] [Reference Citation Analysis]
|
| 752 |
Pandey MK, Gupta SC, Nabavizadeh A, Aggarwal BB. Regulation of cell signaling pathways by dietary agents for cancer prevention and treatment. Semin Cancer Biol 2017;46:158-81. [PMID: 28823533 DOI: 10.1016/j.semcancer.2017.07.002] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 753 |
Hill SY, Rompala G, Homanics GE, Zezza N. Cross-generational effects of alcohol dependence in humans on HRAS and TP53 methylation in offspring. Epigenomics 2017;9:1189-203. [PMID: 28799801 DOI: 10.2217/epi-2017-0052] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 754 |
Park HJ, Park JB, Lee SJ, Song M. Phellinus linteus Grown on Germinated Brown Rice Increases Cetuximab Sensitivity of KRAS-Mutated Colon Cancer. Int J Mol Sci 2017;18:E1746. [PMID: 28800074 DOI: 10.3390/ijms18081746] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 755 |
Oliva S, Gambella M, Boccadoro M, Bringhen S. Systemic virotherapy for multiple myeloma. Expert Opin Biol Ther 2017;17:1375-87. [PMID: 28796556 DOI: 10.1080/14712598.2017.1364359] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 756 |
Schuhmacher AJ, Hernández-porras I, García-medina R, Guerra C. Noonan syndrome: lessons learned from genetically modified mouse models. Expert Review of Endocrinology & Metabolism 2017;12:367-78. [DOI: 10.1080/17446651.2017.1361821] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 757 |
Pepper IJ, Van Sciver RE, Tang AH. Phylogenetic analysis of the SINA/SIAH ubiquitin E3 ligase family in Metazoa. BMC Evol Biol 2017;17:182. [PMID: 28784114 DOI: 10.1186/s12862-017-1024-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 758 |
Zeng M, Lu J, Li L, Feru F, Quan C, Gero TW, Ficarro SB, Xiong Y, Ambrogio C, Paranal RM, Catalano M, Shao J, Wong KK, Marto JA, Fischer ES, Jänne PA, Scott DA, Westover KD, Gray NS. Potent and Selective Covalent Quinazoline Inhibitors of KRAS |
